|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2015/12/30 ¤U¤È 05:03:19
|
Y¥H¤¤¸Îªº®Éµ{±À¦ô¡G 3¤ëªì ¼f¬d 3¤ë¤U¦¯ ¸³¨Æ·|³q¹L¤WÂd¤é´Á 4¤ëªì Âd¶R¦P·N¤WÂd«´¬ù¤é´Á ³Ì§Ö 6¤ëÀ³¥iIPO |
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2023/2/6 ¤W¤È 06:15:45²Ä 123 ½g¦^À³
|
¨S·Q¨ìÂ÷§Ú´£¥X¥Í§Þ²£·~ªº¡§¤j¥ß¥ú¡¨³oµü³£¤w¸g¨¬¨¬7¦~¤F, ®¥³ß¹Î¶¤±o¨ì쥻´N¹w´Á±o¨ì¦¨´N, ³o¤@¸ô¨«¨Ó¯uªº¬Oªi§é«Ü¤j, Â÷¶}¥Í§Þ·~§ë¸ê´X¦~ ªñ´Á¦^¨Óµo²{¥xÆWÀu½èªº¤½¥q¯uªº¦h, ´Á³\ÃĵØÃĪº¦¨¥\¯à±a°Ê¾ãӥͧ޲£·~ªº§ë¸ê¤º²[ ÃĵØÃĸô¤Wªº®À§é¤]¯àÅý«á´Á¤½¥qÉÃè |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/3/19 ¤U¤È 11:06:31²Ä 122 ½g¦^À³
|
http://www.aoporphan.com/en.html ¦b³Ì¥kÃäProducts and Therapies¥i¥H§ä¨ìproducts |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/3/19 ¤U¤È 10:52:17²Ä 121 ½g¦^À³
|
1¥¦¬O¼Ú¬wºû¤]¯Ç20¦~¤½¥q¡A¦³¦¨¥\5ºØÃĪº¬ö¿ý¡C¤Ñ¤Ñ¦b¾Þ§L¡A¾ÔªG½÷·×¡C 2PV¹êÅç¯à¦b³Ìµu®É¶¡¤º¦b¼Ú¬w14°ê±Ð¾Ç¤jÂå°|§¹¦¨¡C 3¼Ú·ù¤Î¬ü°ê³£¦P·N¦bopen label¤U¶i¦æ¡C 4¨C¦¸¬ã°Q·|¤Îµoªí·|¡A¨C¦¸Â\¥X¨Óªº¥d¥q¡A³£¬O¥@¬É¯ÅA©@¡A "¤@¸s¡¨±M®a¡BÂå®v¡C |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/3/19 ¤U¤È 09:41:32²Ä 120 ½g¦^À³
|
¨p¤H¤½¥q ¤£¹L¢Ô¢Ò¢Ï¬Ý¹L¥L̪º¢Þ2 data«áÄ@·N±µ¨ü¥L̪ºPhase 3 ¸ê®Æ¨ì¬ü°ê¥Ó½ÐÃĬF´N¥iª¾¨ä¹ê¤O www.aoporphan.com/en/news-media/press-release.html |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/3/19 ¤U¤È 08:38:17²Ä 119 ½g¦^À³
|
½Ð°Ýºô¤Í¡AÃĵØÃĦ³¹Ù¦ñ¤½¥q AOP Orphan¡A¤½¥q¦³¤W¥«¶Ü?ªÑ»ù¦h¤Ö? |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2016/3/19 ¤U¤È 03:21:35²Ä 118 ½g¦^À³
|
·sÃĬãµo¤½¥q¦n¹³µLªk§¹¥þ·ÓµÛ¤½¥qì¹w´Á¶i«×¨«ªº,¦ý³o¬O¥¿±`ªº~ |
|
|
·|û¡Gwu701610136601 µoªí®É¶¡:2016/3/17 ¤U¤È 02:58:41²Ä 117 ½g¦^À³
|
¤w¸g¼fij³q¹L¨Ã¤½§i ¯Á¤Þ ªÑ²¼¥N¸¹ ¤½¥q¦WºÙ ¥Ó½Ð¤é´Á ¸³¨Æªø ªÑ¥»(¥Ó½Ð®É) ¤WÂd¼fij©eû·|¼fij¤é´Á Âd¶R¸³¨Æ·|³q¹L¤WÂd¤é´Á Âd¶R¦P·N¤WÂd«´¬ù¤é´Á ªÑ²¼¤WÂd¶R½æ¤é´Á ¥D¿ì©Ó¾P°Ó ©Ó¾P»ù ³Æµù 1 6446 ÃĵØÃÄ 104/12/30 ¸â«C¬h 1,904,582,590 105/03/17 ³Í°ò ¬ì§Þ¨Æ·~ http://www.tpex.org.tw/web/regular_emerging/apply_schedule/applicant/applicant_companies.php?l=zh-tw |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/3/17 ¤U¤È 01:51:39²Ä 116 ½g¦^À³
|
®¥³ß¤j®a¡I |
|
|
·|û¡Gadigo10135839 µoªí®É¶¡:2016/3/17 ¤U¤È 12:10:45²Ä 115 ½g¦^À³
|
¤@±i¤~»{ÁÊ23ªÑ¡I·sªÑ´«Âªѯà¼vÅT¦h¤Ö¡H |
|
|
·|û¡G±¶10141423 µoªí®É¶¡:2016/3/17 ¤W¤È 11:07:04²Ä 114 ½g¦^À³
|
©ú¤Ñ²{¼W³Ì«áú´Ú¤é¡A¬OÅ@½L结§ô¡AÁÙ¬O¦ÑªÑ½æÀ£结§ô¡H |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/3/17 ¤W¤È 07:54:27²Ä 113 ½g¦^À³
|
³æ¯Âªº¤WÂd¼fij,À³¤£P¦³¬Q¤Ñªº¿E±¡ À³¸Ó¬O°ò¥»±¦³¹ê½è§Q¦h |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/3/16 ¤U¤È 07:03:25²Ä 112 ½g¦^À³
|
ÃĵØÃÄ©ú¤WÂd¼fij-¿³Âd¥ý¼yº¦ http://udn.com/news/story/7254/1567288 |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/3/16 ¤U¤È 03:53:53²Ä 111 ½g¦^À³
|
ÁÂÁÂDesert¤j¤j¡C¤S¼Wªø¤Fª¾ÃÑ¡A·PÁ¡C |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/3/16 ¤U¤È 02:43:30²Ä 110 ½g¦^À³
|
AML(Acute Myeloid Leukemia) »PCML( Chronic Myeloid Leukimia)¬O¤£¦Pªº¯f¯g»P¾÷Âà¡C https://zh.m.wikipedia.org/zh-tw/¥Õ¦å¯f |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/3/16 ¤U¤È 12:49:53²Ä 109 ½g¦^À³
|
ÃĵØÃÄ6446©Ò¬ãµoªººC©Ê°©Åè²ÓM©Ê¥Õ¦å¯f(Chronic myeloid leukemia¡ACML)¡B¦b¼Ú¬w¶iÁ{§É²Ä¤G´Á¶i¦æ¤¤¡C |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/3/16 ¤U¤È 12:36:37²Ä 108 ½g¦^À³
|
¥»¤é6446ÃĵØÃĤ¤º¦¡A¬O§_»PCelator Pharmaceuticals Inc (CPXX) ¥»¤é¤jº¦$ 8.94 7.26 (+432.14%) ¦³Ãö«Y? Celator Announces Phase 3 Trial for VYXEOS™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival ¡C ½Ð°Ý¥Lªº¦åÀùÃÄ¡A·|¤£·|¹ï«Â¯ÙÃĵØÃÄ? |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/3/15 ¤U¤È 05:06:10²Ä 107 ½g¦^À³
|
©êºp, §Ú§ë¸êÃĵØ3¦~¦h,¥u«µø¤½¥qÃĪ«µo®iÁͶլO§_«ö·Ó¤½¥q³W¹º¤è¦Vpµe¶i¦æ, ²£«~Ävª§¤O, ¤Î¤½¥qªv²z¡I µu´Áªº¤@¨ÇÃĪ«¶}µoªº½T¤Á®Éµ{§Ú³q±`¤£·|°l°Ý, §Ú·Q¤½¥q¤]µLªk«OÃÒ¦ó®É¤@©w¦p¦ó (´N¦p¤¤¸Î¶i¿³¤¤¤p«¬3´Á¤w¸g¤ñìp¹º±ß¤F5~6Ó¤ë¡^ ¤£¹L§ÚÓ¤H¦ôp2©u©³©Î3©u¤¤PV1101 Phase 3ªº¸ê®ÆÀ³¸Ó¥X¨Ó, ¦pµL·N¥~¹F¼Ð, ¦ó®É°eÃÄÃÒ¥u¬O®É¶¡°ÝÃD, ¥Ø«ePV¥«³õ¤@½u¥ÎÃĨõL¹ï¤â, òÏÃ¥´¶¶§Q¤W¥«¤~¬O¤ý¹D. |
|
|
·|û¡G±¶10141423 µoªí®É¶¡:2016/3/15 ¤W¤È 11:34:09²Ä 106 ½g¦^À³
|
·Æ½ü¤j¤j±z¦n¡G½Ð±Ð¤@¤U¦³³Ì·sªº药µý¶i«×¶Ü¡H¤µ¦~¦~©³¤½¥q¬O§_©ú½T·|°eFDA¼f¬d¡AÁÂÁ¡I |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/3/14 ¤U¤È 08:11:48²Ä 105 ½g¦^À³
|
³q±`¤£·|¹Lªº³£·|¨Æ¥ý¦Û¦æºM¾P¥Ó½Ð(¥i¥H¥h¤U±³sµ²¬Ý¬Ý,¥h¦~¦n´X®a¡¨¦ÛºM¡§¡^ ÁöµM¤£n»¡ªº¤Óº¡, ¦ý¬OFDA¯à§K°£PV1101ªº3´ÁÁ{§Éª½±µ¥Î¼Ú¬w¼Æ¾Ú°eÃÄÃÒªº¤½¥q, À³¸Ó¬Onª§¨ú§Ö§Ö±¾µPªº§a! http://www.tpex.org.tw/web/regular_emerging/apply_schedule/applicant/applicant_companies.php?l=zh-tw |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/3/14 ¤U¤È 08:11:36²Ä 104 ½g¦^À³
|
¬Ý¨ä¥L®a¤½¥q¦n¹³³£¬O¯à«ö®É¶¡ªí¶¶§Q¤W¥«Âdªº¡I ¨º´N¹³¨ä¥L®a¤@¼Ë´N¥i¥H¤F |
|
|
·|û¡G¦V¿ú¨«10137837 µoªí®É¶¡:2016/3/14 ¤U¤È 07:52:45²Ä 103 ½g¦^À³
|
½Ð°Ý¦U¦ì«e½úÌ¡G 3/17Âd¶R¤¤¤ß¼fij¤@©w´N·|³q¹L¶Ü¡HÁÙ¬O·|¦³·N®Æ¥~ªº¼@±¡¡H ¬Ý¨ä¥L®a¤½¥q¦n¹³³£¬O¯à«ö®É¶¡ªí¶¶§Q¤W¥«Âdªº¡I |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/3/11 ¤U¤È 06:46:17²Ä 102 ½g¦^À³
|
¼f¬d«eÁÙ¬O¥¥Ãæa¸û¦n¡I |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/3/11 ¤U¤È 03:41:34²Ä 101 ½g¦^À³
|
©_©Ç¡A¥»¤éÃĵØÃÄ6446¡A¦³¤WÂd¥Ó½Ð¼fij¡AC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬¤§²Ä¤T´ÁÁ{§É¸ÕÅç¥xÁú±Ò°Ê¡B AOPInternational Hematology Expert Meeting Agenda When: 29.04 - 1.05.2016 Where: Nice, France µ¥§Q¦h®ø®§¡C´N¬O¤£º¦¡C ¨ä¤¤·|ij°Q½×ÃD¥Ø¡GFirst-Line treatment of PV: From hydroxyurea to pegylated IFN¡C Can we cure PV with IFN-alfa? Drug: Peg-P-IFN-alpha-2b (AOP2014) ¡AOther Names:•AOP2014•P1101 Estimated Enrollment: 256 Study Start Date: September 2013 Estimated Study Completion Date: March 2016 Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure) ¥i¯àÁÙ¬O¦hÂI@¤ß¡A¦Aµ¥«Ý¤@¨âÓ¤ë¡A§Æ±æ¦¤é¬ð¯}«eªi°ªÂI199¤¸¡CÃĵØÃÄ¥[ªo¡C |
|
|
·|û¡Gwu701610136601 µoªí®É¶¡:2016/3/11 ¤U¤È 01:14:45²Ä 100 ½g¦^À³
|
¸gÀ˵ø105¦~1¤ë~104¦~9¤ëÂd¶R¸³¨Æ·|³q¹L¤WÂdªº¤é´Á§¡¬O·í¤ë²Ä¥|Ó¬P´Á¤(°£104¦~11¤ë¨Ò¥~(¬O·í¤ë²Ä¤TÓ¬P´Á¤))¡A ¦pÃĵØ3/17³q¹L¤WÂd¼fij©eû·|¼fij¡A«hÀ³©ó3/25¤éÂd¶R¸³¨Æ·|³q¹L¡C5~6¤ë¤WÂdÀ³¥i´Á«Ý!!!! |
|
|
·|û¡Gwu701610136601 µoªí®É¶¡:2016/3/11 ¤U¤È 01:03:28²Ä 99 ½g¦^À³
|
ÃĵØÃĤWÂd®× Âd¶R17¤é¼fij ¤¤¥¡ªÀ¤¤¥¡ªÀ ¡V 2016¦~3¤ë11¤é ¤U¤È12:05 ¡]¤¤¥¡ªÀ°OªÌÁú´@´@¥x¥_11¤é¹q¡^Âd¶R¤¤¤ßq3¤ë17¤é¼fij¿³Âd¥Í§Þ·sÃĤ½¥qÃĵØÂåÃĤWÂd¥Ó½Ð®×¡A¥Ñ©ó¸Ó¤½¥q·sÃÄP1101¥Î©óªvÀøC¨x¯f¬r°ò¦]Åé²Ä¤G«¬¤§²Ä¤T´ÁÁ{§É¸ÕÅç¥Ó½Ð¡A»á¨ü¥«³õÆf¥Ø¡C ÃĵØÂåÃĥӽЮɸꥻÃB19.04»õ¤¸¡A¸³¨Æªø¬°¸â«C¬h¡A±ÀÂËÃÒ¨é°Ó¬°³Í°ò¡B¤¸¤j¡B´I¨¹¤Î²Î¤@ÃÒ¨é¡Cªk¤H¹w´Á¡A³Ì§Ö¤µ¦~²Ä2©u¥i±¾µP¤WÂd¡C ÃĵØÂåÃÄ103¦~¦X¨ÖÀç·~¦¬¤J·s¥x¹ô1335¸U¤¸¡Aµ|«á²b·l¬°8.53»õ¤¸¡A¨CªÑÁ«·l4.54¤¸¡C104¦~«e3©u¦X¨ÖÀç·~¦¬¤J816¸U¤¸¡Aµ|«á²b·l5.68»õ¤¸¡A¨CªÑÁ«·l3¤¸¡C ÃĵØÃĪº·sÃÄP1101¥Î©óªvÀøC¨x¯f¬r°ò¦]Åé²Ä¤G«¬¤§²Ä¤T´ÁÁ{§É¸ÕÅç¥Ó½Ð¡A¤wÀòÁú°ê¹«~ÃĪ«ºÞ²z¸p(MFDS)¦P·N¶i¦æ¡AÃĵØÃĪí¥Ü¡A¸ÓÁ{§É¸ÕÅ笰¦h°ê¦h¤¤¤ß²Ä¤T´ÁÁ{§É¸ÕÅç¡A±N¦b¥xÆW¤ÎÁú°ê¦P®É¶i¦æ¡A¹wp¦¬®×240¤H¡A2017¦~§¹¦¨¸ÕÅç¡C P1101¬O·s¤@¥NPEGªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(Ropeginterferon alfa-2b)¡A¦bªvÀøC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬²Ä¤G´ÁÁ{§É¸ÕÅç¤w§¹¦¨¡A¥tC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤@«¬¡B¯u©Ê¬õ¦å²y¼W¥Í¯g¡B¦´Áìµo©Ê°©ÅèÅÖºû¤Æµ¥Á{§É¸ÕÅç¡A¥¿«ùÄò¶i¦æ¤¤¡C ¦Ü©óPV·sÃÄ¡uBESREMi¡v¡A©ó¥h¦~2¤ë©³§¹¦¨¦¬®×¡A³Ì²×¦¬®×¤H¼Æ¬°260¦W¡A¨äÀøµ{¬°¤G¶gª`®g¤@¦¸¡A¤µ¦~2¤ë©³¨ü¸ÕªÌªvÀø¤w¥þ³¡©¡º¡¤@¦~¡A«Ý¹êÅç¼Æ¾Ú¾ã²z§¹´N·|¦V¼Ú·ù¡B¬ü°êFDA»¼¥æ·sÃĤW¥«¦æ¾P³\¥i¡A®É¶¡¥i¯à¸¨¦b¤U¥b¦~¡C¥Ø«e¼Ú¬wªºPV¯f±w¬ù10¦h¸U¤H¡A¬ü°ê¤]¦³¬ù10¸U¦WªºPV¯f±w¡C1050311 |
|
|
·|û¡Gªüºµ10136469 µoªí®É¶¡:2016/3/11 ¤W¤È 09:07:45²Ä 98 ½g¦^À³
|
Agendaªº®æ¦¡¶Ã±¼¤F¡A¦³¿³½ìªº¤j¤j½Ð¨ì¥H¤Uºô§}¤U¸ü: http://www.aoporphan.com/en/news-media/press-release/sales-marketing/international-hematology-expert-meeting-agenda.html |
|
|
·|û¡Gªüºµ10136469 µoªí®É¶¡:2016/3/11 ¤W¤È 09:00:09²Ä 97 ½g¦^À³
|
Scientific Program Friday, April 29th 08:50 Welcome H. Gisslinger, R. Widmann 09:00?2:00 MPN I Chair: H. Gisslinger, T. Barbui 09:00?9:30 Update on transformation from MPN R. Kralovics to AML 09:30-10:00 Biomarkers in MPNs: their influence T. Barbui in clinical practice 10:00-10:30 Mutations in patients with myelofibrosis: R. Kušec which patient to test, when and why 10:30?1:00 Coffee break 11:30?1:30 How to treat an ET patient P. Petrides 11:30?2:00 Current treatment options R.A. Mesa for PV patients 12:00-12:30 Different guidelines in the management J. Schwarz of MPNs in Europe - Is there a consensus? 12:30-14:30 Lunch break 14:30?6:00 MPN II Chair: F. Keil, P. Petrides 14:30?5:00 Case report on patients with myelofibrosis I. Hus 15:00?5:30 State of the art in the treatment of F. Cervantes patients with myelofibrosis 15:30-16:00 Transplantation in myelofibrosis: N. Kröger which patient, when and why Saturday, April 30th 09:00?1:30 CML I and MPN III Chair: M. Griesshammer, M.Penka 09:00-09:30 First and second line options A. Petzer in the treatment of CML patients 09:30-10:00 Safety and efficacy of addition of pegylated IFN H. Hjorthto standard dose dasatinib in newly diagnosed Hansen chronic phase CML patients 10:00-10:30 Long-term toxicity and perspectives A. Burchert of a cure in routine practice in CML 10:30-11:00 Coffee break 11:00-11:30 Potential toxicities of novel drugs in D. Wolf the management of MPN 11:30-12:00 Impact of platelet (WBC) counts on V. Buxhofer-Ausch thromboembolic events 12:00-14:00 Lunch break 14:00?6:30 The Future Chair: G. Gastl, H. Hasselbalch 14:00?4:30 First-Line treatment of PV: S. Burgstaller From hydroxyurea to pegylated IFN 14:30-15:00 Long acting interferons and anagrelide in patients with MPNs H. Gisslinger 15:00?5:30 Coffee Break 15:30-16:00 Perspectives of IFN-treatment in patients H. Hasselbalch with MPNs ?Where will we stand in the year 2020? - 16:00-16:30 Can we cure PV with IFN-alfa? R. T. Silver |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/3/11 ¤W¤È 08:18:30²Ä 96 ½g¦^À³
|
½Ð°Ýºµ¤j: AOP¦bªk°êÁ|¿ì¦å²G±M®a·|ijªºAgenda¥hþ§ä±o¨ì¡H ÁÙ¬O¥i¥Hpo¤W¨Ó°Ñ¦Ò¤@¤U¡H Á|¿ì¦¹·|ij¬O§_¥Nªí, 3´ÁÁ{§Éµ²ªG©¡®É·|µoªí¡H ÁÂÁ |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/3/11 ¤W¤È 12:03:33²Ä 95 ½g¦^À³
|
¥xÆW¤§¥ú ¥t¥~¡A¯à±N¥xÆW¤Hµo©úªºªv¨x·sÃÄ¡A¥´¨ìÁú°ê¤H¨¤W¡A ³o¬O¤£Â²³æªº¡C ±qµo©ú¨ì¦Û¤v³J¥Õ½èÃļt»s³y¡A³£¬OÃĵؤ@¤â¥]¿ì¡C ¦pªG³o¤£¬O¥xÆW¤§¥ú¡A¤°»ò¤~¥s¥xÆW¤§¥ú¡C |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/3/10 ¤U¤È 11:40:36²Ä 94 ½g¦^À³
|
ºµô¡G ¨Æ¹ê¤W¡A±q2013¡B14¡B15³sÄò¤T¦~¡A¤w¸g¦bASH¬ü°ê¦å²G¸~½F¦~·|¡A ¥þ²y³Ì¤jªº¦å²G¬ÛÃö¯e¯f²±·|¡AµoªíP1101ªvÀø¬õ¦å²y¼W¦h¯g¡]PV), ¥O¤H®¶¾Äªº®ø®§! ªk°êªºµoªí¡A§ó¬OÀA¤W²Kªá |
|
|
·|û¡Gªüºµ10136469 µoªí®É¶¡:2016/3/10 ¤U¤È 09:40:16²Ä 93 ½g¦^À³
|
AOP±N©ó4¤ë©³¡B5¤ëªì¦bªk°êÁ|¿ì¤@³õ°ê»Ú¦å²G±M®a·|ij¡C±q¨äAgenda¬Ý¥XAOP¦ü¥G¹ïP1101¨ú±oªvÀøPVªº¤@¥ÎÃĸê®æ«H¤ßº¡º¡¡A¤×¨ä·|ijªº®É¶¡ÂI¦bÁ{§É¼Æ¾Ú¤w¸g§¹¥þ¨ú±o¤§«á¡C¨ä¤¤ªº¤@Ó³ø§iÃD¥Ø¬O¡GFirst-Line treatment of PV: From hydroxyurea to pegylated IFN |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/3/10 ¤U¤È 05:23:11²Ä 92 ½g¦^À³
|
¡i®É³ø-¥x¥_¹q¡jÃĵØÂåÃÄ(6446)ªí¥Ü¡A¸Ó¤½¥q·sÃÄP1101¥Î©óªvÀøC«¬¨xª¢¯f¬r°ò¦]Åé²Ä ¤G«¬¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¶ÉÀòÁú°ê¹«~ÃĪ«ºÞ²z¸p(Ministry of Food and Drug Safety ²ºÙMFDS)®Öã¦P·N¶i¦æ¡C²Ä¤T´ÁÁ{§É¸ÕÅç¤w¥i¥¿¦¡©ó¥xÆW¤ÎÁú°ê¨â¦a¦P®É¶i¦æ¤HÅé¸ÕÅç ¡C P1101«Y·s¤@¥NPEGªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(Ropeginterferon alfa-2b)¡A¦bªvÀøC«¬¨xª¢¯f ¬r°ò¦]Åé²Ä¤G«¬²Ä¤G´ÁÁ{§É¸ÕÅç¤w§¹¦¨¡A¥tC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤@«¬¡B¯u©Ê¬õ¦å²y¼W¥Í ¯g¡B¦´Áìµo©Ê°©ÅèÅÖºû¤Æµ¥Á{§É¸ÕÅ祿«ùÄò¶i¦æ¤¤¡C ¸Ó²Ä¤T´Á¤HÅéÁ{§É¸ÕÅ祿¦¡©ó¥xÆW¤ÎÁú°ê¨â¦a¦P¨B¶i¦æ¡A¹w¦ô¥i«öìpµe®Éµ{§¹¦¨¦¬®× ¥Ø¼Ð«á¡A¸g¸ê®Æ²Îp¤ÀªR¸ÕÅçµ²ªG³ø§i«á¡A¦V¥xÆWTFDA¤ÎÁú°êMFDS¥Ó½Ð·sÃĬdÅçµn°O¡A¨Ï ¤½¥q³yºÖ¨â¦a¨xª¢¯f±w¤§¥Ø¼Ð±N§ó¶i¤@¨B¡C ¥Ø«e¤½¥q²Ö¿n¤w§ë¤J¸ÓÁ{§É¸ÕÅ礧¬ÛÃö¶O¥Î¬ù6598¸U7¤d¤¸¡A¥»Á{§É¸ÕÅ笰¦h°ê¦h¤¤¤ß ²Ä¤T´ÁÁ{§É¸ÕÅç¡A±N©ó¥xÆW¤ÎÁú°ê¨â¦a¦P¨B¶i¦æ¦¬®×¡AÁ`¦¬®×¤H¼Æ¦Ü¤Ö240¤H¡A¹w¦ô©ó201 7¦~§¹¦¨¸ÕÅç¡C(½s¿è¾ã²z¡G²ø¶®¬Ã) |
|
|
·|û¡G¤Óºò±i10135421 µoªí®É¶¡:2016/3/10 ¤U¤È 05:15:04²Ä 91 ½g¦^À³
|
²Ä¤T´ÁÁ{§É¸ÕÅçÁ`¦¬®×¤H¼Æ¦Ü¤Ö240¤H¡A¹w¦ô©ó2017¦~§¹¦¨¸ÕÅç¡C ¤½§i¥»¤½¥q·sÃÄP1101¥Î©óªvÀøC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬¤§²Ä¤T´ÁÁ{§É¸ÕÅç¥Ó½Ð¡A¤wÀòÁú°ê¹«~ÃĪ«ºÞ²z¸p(MFDS)¦P·N¶i¦æ 1.¨Æ¹êµo¥Í¤é:105/03/10 2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¨Ì¥»¤½¥q·sÃÄP1101¥Î©óªvÀøC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A ¶ÉÀòÁú°ê¹«~ÃĪ«ºÞ²z¸p(Ministry of Food and Drug Safety²ºÙMFDS)®Ö ã¦P·N¶i¦æ¡C¥»²Ä¤T´ÁÁ{§É¸ÕÅç¤w¥i¥¿¦¡©ó¥xÆW¤ÎÁú°ê¨â¦a¦P®É¶i¦æ¤HÅé¸Õ Åç¡C 6.¦]À³±¹¬I:µo§G«¤j°T®§¤½§i©ó¤½¶}¸ê°TÆ[´ú¯¸ 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¬ãµo·sÃÄ¥N¸¹©Î¦WºÙ¡GP1101(INN: Ropeginterferon alfa-2b) (2)¥Î³~¡GP1101«Y·s¤@¥NPEGªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(Ropeginterferon alfa-2b)¡A ¦bªvÀøC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬²Ä¤G´ÁÁ{§É¸ÕÅç¤w§¹¦¨¡A¥tC«¬¨xª¢¯f¬r°ò ¦]Åé²Ä¤@«¬¡B¯u©Ê¬õ¦å²y¼W¥Í¯g¡B¦´Áìµo©Ê°©ÅèÅÖºû¤Æµ¥Á{§É¸ÕÅ祿«ùÄò ¶i¦æ¤¤¡C (3)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¥»²Ä¤T´Á¤HÅéÁ{§É¸ÕÅ祿¦¡©ó¥xÆW¤ÎÁú°ê¨â¦a¦P ¨B¶i¦æ¡A¹w¦ô¥i«öìpµe®Éµ{§¹¦¨¦¬®×¥Ø¼Ð«á¡A¸g¸ê®Æ²Îp¤ÀªR¸ÕÅçµ²ªG³ø §i«á¡A¦V¥xÆWTFDA¤ÎÁú°êMFDS¥Ó½Ð·sÃĬdÅçµn°O¡A¨Ï¤½¥q³yºÖ¨â¦a¨xª¢¯f±w ¤§¥Ø¼Ð±N§ó¶i¤@¨B¡C (4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G (¤@)´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G²Ä¤T´ÁÁ{§É¸ÕÅç¥Ó½ÐÀòÁú°ê¹«~ÃĪ« ºÞ²z¸p(MFDS)®Öã¶i¦æ¡C (¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î (¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î (¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¥»¤½¥q²Ö¿n¤w§ë¤J¸ÓÁ{§É¸ÕÅ礧¬ÛÃö¶O¥Î¬ù 65,987¤d¤¸ (5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G A.¹wp§¹¦¨®É¶¡¡G¥»Á{§É¸ÕÅ笰¦h°ê¦h¤¤¤ß²Ä¤T´ÁÁ{§É¸ÕÅç¡A±N©ó¥xÆW¤ÎÁú°ê ¨â¦a¦P¨B¶i¦æ¦¬®×¡AÁ`¦¬®×¤H¼Æ¦Ü¤Ö240¤H¡A¹w¦ô©ó2017¦~§¹¦¨¸ÕÅç¡C B.¹wpÀ³t¾á¤§¸q°È¡G¥»¤½¥q±N¤ä¥I°õ¦æÁ{§É¸ÕÅç¤Î¥Ó½Ð·sÃĬdÅçµn°O¤§¬ÛÃö ¶O¥Î¡C (6)·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{· ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/3/10 ¤U¤È 04:25:58²Ä 90 ½g¦^À³
|
ÁÂÁ·Ƥj¤jªº»¡©ú ·Ç³Æ¿ú¼W¸ê¥h~~ |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/3/10 ¤U¤È 03:53:55²Ä 89 ½g¦^À³
|
Á¾¨õ Á¾¨õ ¦AÁ¾¨õ ¦pªG¦³¾÷·|³Q¥«³õ»EµJ Ãĵؤ@©wn¤@¨B¤@¸}¦L §ó¥[½ñ¹ê |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/3/10 ¤U¤È 03:27:07²Ä 88 ½g¦^À³
|
Ó¤H»{¬°À³¸Ó±Æ¦b3¤ë©³©Î4¤ëªì ¦]¬°¥Ø«eú´Ú¤¤ªº¤p«¬¼W¸ê18¤éºI¤î, ¨ä¥Øªº¬°ºû«ù¼fij®É¤½¥q²bȦb5¤¸¥H¤W ©Ò¥HÀ³¸Ó±Æ¦b¼W¸ê§¹¦¨¤§«á§a |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/3/10 ¤W¤È 10:33:24²Ä 87 ½g¦^À³
|
¦ý¤£ª¾¬°¦ó¤WÂd¼fij©eû·|¤§¼fij¤é´Á³£ÁÙ¨S¦³½T©w? ¤j¤j̲M·¡¶Ü? |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/3/10 ¤W¤È 09:34:57²Ä 86 ½g¦^À³
|
¨q¤£¨qˬO¨ä¦¸ ¦³¯u¥\¤Ò¤~¬O³Ì«nªº ±N¨Ó¥Í§ÞªÑªº¥Ø¥ú±N¥þ»EµJ¦bÃĵب¤W ¥ú·Q¨ì´N«Ü²n |
|
|
·|û¡GAlan10136952 µoªí®É¶¡:2016/3/10 ¤W¤È 09:30:02²Ä 85 ½g¦^À³
|
¬O¸Ó½ü¨ì«¥Ì¤W³õ¨q¤@¨qÅo¡I¡I |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/3/10 ¤W¤È 09:23:55²Ä 84 ½g¦^À³
|
Æg!! ·U¬Ý·U³ßÅw!! |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/3/4 ¤U¤È 08:40:31²Ä 83 ½g¦^À³
|
¦N§Q¼w¤SÅQÉa¤F¡I§Ü¦ã´þ·s药Odefsey获FDA§åã 来·½¡G¥Íª«±´¯Á 2016-3-3 3¤ë1¤é¡A¦N§Q¼w¬ì学¤½¥q¡]GILD¡^«Å¥¬¡A¨ä§Ü¦ã´þ·s药Odefsey 获FDA§åã¤W¥«¡COdefsey ¬O¤@Ïú¤T¦X¤@Î`¦X剂¡]R/F/TAF¡^¡A¥]¬A200 mg®¦¦±¥L滨¡]emtricitabine¡^¡B25 mg§Q¤Ç韦ªL¡]rilpivirine¡^©M25 mg´À诺ºÖ韦¦ã©Ô×ôÓi´I马»Ä¡]TAF¡^¡C¨ä¤¤¡A®¦¦±¥L滨©MTAF属¤_¦N§Q¼w¦Û¨ªº两´Ú药ª«¡A¦Ó§Q¤Ç韦ªL¬O强¥ÍºX¤U产«~¡C Odefsey¬O¦N§Q¼w±À¥Xªº²Ä¤G´Ú¥HTAF§@为®Ö苷类°f转录酶§í¨î剂ªº§Ü¦ã´þ药ª«¡A¨ã备§C剂¶q强药®ÄªºÉ¬势¡C¦Ó¦N§Q¼wº个¥]§tTAFªº§Ü¦ã´þ¥|¦X¤@Î`¦X¨î剂¬OGenvoya¡A¤_¥h¦~11¤ë¥÷获±oFDA§åã¡C Odefseyɬ势 Odefsey«eÊ^药ª«¬OTAF¡CTAF¬O¤@Ïú·s«¬®Ö苷类°f转录酶§í¨î剂¡]NRTI¡^¡A¬O¦N§Q¼w¤w¤W¥«药ª«Viread¡]´À诺ºÖ韦à¡ATDF¡^ªº¤É级ª©¡C临§É试验证实¡ATAF进¤J细M®Ä²v©ú显°ª¤_TDF¡A¦Ó¥B¥i¥H¦b§C¤_TDF¤Q¤À¤§¤@剂¶q时¡A´N¨ã¦³«D±`°ªªº§Ü¯f¬r疗®Ä¡A从¦Ó°§C药ª«°Æ§@¥Î¡A减轻肾损伤©M°©质²¨ªQ¡C Óì¥Î±wªÌ¤Îª`·N¨Æ项 Odefsey Óì¥Î¤_12岁¥H¤W¥B¥¼±µ¨ü过§Ü¯f¬rªv疗¡]¯f¬r载¶q¶W100,000«þ贝/ml¡^ªºHIV-1·P¬VªÌ¡COdefsey还¥i¥H§@为稳©wªº§Ü¯f¬r药ª«¡A给¥X现6个¤ë¥H¤W¯f¬r§í¨îªº·P¬VªÌ¡]¯f¬r载¶q§C¤_50«þ贝/ml¡^¥B没¦³¥X现过药ª«ªv疗¥¢败ªº±wªÌ长´ÁªA¥Î¡C Odefsey药ª«会¤Þ发¦å²G¤¤¨Å»Ä积²Ö¡Aĵ±§¥X现¨Å»Ä»Ä¤¤¬r©M严«ªº¨x脏问题¡C¥B¡AOdefsey¤£Óì¥Î¤_¤A«¬¨xª¢±wªÌ¡C Éq实¦N§Q¼wªºÅQ¥D¦a¦ì 虽µM¶ZÖîڪv¤´µM¦³«Ü¦hªº¬D战n¸ó¶V¡A¦ý¬O随着¥Íª«医学ªº发®i¡B¨î药¤u艺ªº±À进¡A¬ì学®a¤w经¦¨¥\¬ã发¥X¶W过30Ïú°f转²v¯f¬r药ª«¡A¥B¥H¦N§Q¼w为ºªº医药¥ø业¥ý¦Z±À¥X¦h´ÚARTÎ`¦X剂¡A让¦ã´þ¯f¥¿从绝¯gºCºC´Â着ºC©Ê¯f转变¡C ¦]¦¹¡A¶V¦h¶V¦hªº¬ì学®a©M¨î药¥ø业¥¿¦b从长´Á¥Î药ªº±wªÌ¨¤«×¥X发¡A寻¨D·sªºªv疗药ª«¡A¯à够¼W强药®Äªº¦P时°§C@药©Ê¡A¦}简¤ÆªA药¬yµ{¡C¦N§Q¼wº®u执¦æ©xݸ³¨Æ长John C. Martin³Õ¤hªí¥Ü¡AOdefsey¦b¦w¥þ©Ê¡B疗®Ä¥H¤Î@药©Ê¤W³£¨ã备Ìå¤jªºÉ¬势¡A为¦ã´þ¯f±wªÌ´£¨Ñ¤F·sªºªv疗选择¡C该药¬O¦N§Q¼w¦b¦ã´þ¯f领°ìªÃ©Ó创·s²z©Àªº¦¨ªG¡C |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/3/2 ¤W¤È 08:13:34²Ä 82 ½g¦^À³
|
¥»¶gÀ³¥i±Æ¤J¤WÂd¼fij 5¤ë±¾µPÀ³¸ÓÆZ¼ÖÆ[ªº |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/3/1 ¤U¤È 02:41:56²Ä 81 ½g¦^À³
|
¼Ú·ùÆ~¼o¦º §ÚÌ©IÆ~¼Ú·ù¥ý¦w¸m¦n¤j§åÃø¦W ¤£nÅý¥L̤j¶qªP¦º¦b°kÃø¹Lµ{¤¤ ³o¨ÇÃø¥Á¤j¦h¼Æ¬O¦n¤H ¦Ó¼Ú·ù©Úµ´¥L̪ºì¦]¥u¦]¤Ö¼Æ¤H³Q©Ê«I Åý³\³\¦h¦h¦n¤HÃø¥Á¤p«ÄªP¦º «o¥´µÛ¤HÅv¤jºX¥s§O¤H¼o¦º ¯u¬O¿Ø¨ë°Ú |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/2/25 ¤U¤È 05:27:15²Ä 80 ½g¦^À³
|
·sÃĦ¨±Ñn¤¤©Ê¬Ý«Ý ¨C1¤ä·sÃĪº¬ãµo³£¥«È±o¹ªÀyªº Romo¤T´Á临§É显¥Ü积Ìå疗®Ä¡A¦w进¸yªO§óµw¤F 来·½¡G¬ü¤¤药·½ 2016-2-23 ¡i·s闻¨Æ¥ó¡j¡G¤µ¤Ñ¦w进«Å¥¬©MUCB¦X§@开发ªº°©质²¨ªQ药ª«romosozumab¡]Romo¡^¦b¤@个¤T´Á临§É试验¤¤达¨ì¤@个¤@级终点©M¤@个¤G级终点¡A¦ý错过¤@个¤G级终点¡C¦b这个¥s°µFRAMEªº¤T´Á临§É试验¤¤¡A±w¦³°©质²¨ªQ¡B绝经¦Z妇¤k¨C¤ëª`®g¤@¦¸Romo¤ñ¦w¼¢剂ú£¤Ö73%¯á¬W°©µõ¡Bú£¤Ö36%©Ò¦³类«¬°©µõ¡A¦ý¥t¤@个¤G级终点§Y«D¯á¬W°©µõ没¦³达¨ì¡C¦w进说¤µ¦~将¦VFDA¥Ó请¤W¥«¡C¦ý¦]为¤µ¤Ñªº数Õu¤ñ竞争对¤âRadiusªº¥Ò状®Ç¸¢¯À¬Û关³J¥Õ类¦üª«药ª«²¤®t¡A¦w进ªÑ²¼¤U·Æ1.5%¡A¦ÓRadius¤W扬25%¡C ¡i药·½¸ÑªR¡j¡GRomosozumab¬O¦w进¦b¬ãºÞ线¤¤³Ì³Q关ª`ªº产«~¡A¦pªG¤W¥«¥i¯à¦¨为«½S药ª«¡CRomo¬O¤@个§ÜÊ^药ª«¡A¤¤©M¤@个¥s°µsclerostinªº«H号³J¥Õ¡CSclerostin¥u¦³°©细M¤Àªc¡A专门±±¨î°©细M¼W´Þªº«H号传导¡C这Ïú组织¯SÉÝ©Ê«H号³J¥Õ对药ª«开发¦³«Ü¤j§l¤Þ¤O¡A¦]为针对这类³J¥Õªº药ª«¨t统¬r©Ên¤p¤_§í¨î©Ò¦³组织³£ªí达ªº³J¥Õ¡C这¬Û当¤_Êð乱¤@¤èªº¦a头³D¡A°£±¼¥¦们§Y¨Ï¤£¤Óºëã损¥¢¤]¥u¤_¤pS围¡A¦Ó¥þªÀ会S围ªº¬Fµ¦变¤Æ¦ZªG§óÎ`杂¡C ¤T¦~«eRomo´¿§@为¥[§Ö°©§é«ìÎ`药ª«¡A¦ý¥Ñ¤_¤G´Á临§É®ÄªG¤£¨Î¥[¤W审§å环¹Òªº变¤Æ¦w进©ñ弃¤F这个Óì应¯g¡CRomo¥h¦~´¿经¦b¤@个¤T´Á临§É试验¤¤显¥Ü¤ñþ÷来ªº«½S°©质²¨ªQ药ª«Forteo¦b¦P¤@¤H¸s§ó¦³®Ä¦a¼W¥[°©±K«×¡A¦ý¬O现¦bªº药监环¹Ò¤U¥u§ïµ½°©±K«×这Ïúsurrogate¡]©M°§CLDL类¦ü¡^¤w经ÆÓªk获±o¤W¥«资®æ¡C¦w进«Å称¥un¤ñ¦w¼¢剂§ó¦n§ïµ½°©µõ频²v§Y¥i达¨ì¤W¥«标ã¡A¦ý现¦b¤w¦³¤@个©M¤fªA双êé»Ä°©质²¨ªQ药ª«头对头ªº¤T´Á临§É¥¿¦b进¦æ¡C§Y¨ÏFDA¨ÌÕu¤µ¤Ñªº试验结ªG§åãRomo¤W¥«¡A¤]¤@©w会n¨D©M标ã疗ªk¦boutcomeªº头对头¤ñ较数Õu§@为Romo«O¯d¦b¥«场¤Wªº¨ÌÕu¡C °©质²¨ªQ¬O«Â胁¦Ñ¦~¤Hªº±`见¯f¡A约¦³30-40%妇¤k绝经¦Z会¦³°©质²¨ªQ¡CRomo¤£仅§í¨î°©组织¦A§l¦¬¡A¦Ó¥B¥[§Ö°©组织§Î¦¨¡C虽µMRadiusªº¥Ò状®Ç¸¢¯À¬Û关³J¥Õ类¦üª«abaloparatideú£¤Ö86%ªº¯á¬W°©µõ频²v¡A¦ý这个产«~n¨C¤Ñª`®g¡C¥t¥~¥Ò状®Ç¸¢¯À¬Û关³J¥Õ类¦üª«¦³动ª«PÀù风险¡A疗®Ä¤]§ó§½¤_¯á¬W¡C¦ý¬O¤µ¤ÑRomo¤]¥¼¯àú£¤Ö¯á¬W¥H¥~°©组织损伤风险¡A这¬O§ë资ªÌ¿E¯P¤Ï应ªº¥Dnì¦]¡C¦ý¦P试验¤§间¤ñ较¦³«Ü¦h¤zÊð¦]¯À¡A³Ì¦Z©M标ã疗ªk¤ñ较¨ì©³谁³Ì¦ZÐ`¥X还¤£¦n说¡C ¦w进«e¤L¦~¬ã发®Ä²v¿¨ü质ºÃ¡A¦ý³Ìªñ两¦~³J¥Õ组§í¨î剂¡BBiTE§ÜÊ^¡BT-Vec¡B¤×¨ä¬OPSCK9§ÜÊ^ªº¥ý¦Z¤W¥«§Î¶H¤j¦³§ï观¡CRomo©M¥t¤@个¥Dn¦b¬ã药ª«CGRP§ÜÊ^AMG334³£¬O©MPSCK9§í¨î剂¤@ý©®ÚÕu¤HÊ^°ò¦]学ªºÉ¬质数Õu¥ß项¡A¥R¤À§Q¥Î¤F§ÜÊ^药ª«ªº°ª选择©Ê¡C¦Ó¥B针对³£¬O¤p¤À¤l难¥H调±±ªº³J¥Õ¬Û¤¬§@¥Î¡AÁקK¤F¤fªA药ª«ªº竞争¡C¦Ò虑¨ì³ÌªñPD-1§ÜÊ^ªº¦¨¥\¦ü¥G°ª选择单¹v点¼Ò¦¡进¤J¤@个黄ª÷时¥N¡C |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/2/24 ¤W¤È 11:19:21²Ä 79 ½g¦^À³
|
³Í°ò§ëÅU¤]¿î¿ï¤F¬ÛÃö·§©ÀªÑ:1.¬Fµ¦¨ü´fªÑ¡G°êºÓ(2406)¡BZ}(6244)¡BÃĵØÂå (6446)¡BÁp¦X(4129)¡Bº~µ¾(2634)¡C2.²£·~¯à¨£«×°ª:¥úïú¬ì(3428)¡BÁp¨È(3081)¡B«H÷~¬ì(5274)¡Bºô®a(80 44)¡B¥x¶ì¤Æ(6505)¡BF-à±»ô(9802)¡B±o¤O(1464)¡BF-¼sµØ(1338)¡B®ð¥ß(4555)¡B¾ìº~(6414)¡B¥þ®a(5903)¡C 3.°ª´Þ§Q²v¡þ§C¥»¯q¤ñ±Ú¸s¡G¥x°p(6269)¡B©MºÓ(4938)¡B¤¤¹©(9933)¡BF-ñZ³Ó(5264)µ¥¡C ÃĵØÂå¥Ø«e°£¤F¦³5´Ú·sÃij°Äò¶i¤J¤T´ÁÁ{§É¥~¡A¶i«×³Ì§ÖªºªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)ªºP1101¡A¤]¤O©é ¤µ¦~©³«e¥Ó½ÐÃÄÃÒ¡A¨ÃÀÀ¦b¬ü°ê¦Û²Õ¦æ¾P¹Î¶¤¾P°â¡C |
|
|
·|û¡G¤p¨Æ10135609 µoªí®É¶¡:2016/2/22 ¤U¤È 08:28:17²Ä 78 ½g¦^À³
|
1 µo¨¥¤é´Á 105/02/22 µo¨¥®É¶¡ 19:18:52 µo¨¥¤H ¶À¥¿¨¦ µo¨¥¤H¾ºÙ Á`¸g²z µo¨¥¤H¹q¸Ü 02-26557688 ¥D¦® C«¬¨xª¢°ò¦]Åé²Ä¤@«¬»PC«¬¨xª¢°ò¦]Åé²Ä¤G«¬ªºÁ{§É ¬ã¨s¦¨ªG¡A©ó¨È¤Ó¨xŦ¬ã¨s¨ó·|APASLµoªí¨â³õ¤fÀYºtÁ¿ ²Å¦X±ø´Ú ²Ä 42 ´Ú ¨Æ¹êµo¥Í¤é 105/02/22 »¡©ú 1.¨Æ¹êµo¥Í¤é:105/02/22 2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î 5.µo¥Í½t¥Ñ: ÃĵØÂåÃĦ¹¦¸¨üÁܦb¨È¤Ó¨xŦ¬ã¨s¨ó·|APASL (Asian Pacific Association for the Study of the Liver)©ó¤é¥»ªF¨ÊÁ|¦æ²Ä25©¡¦~·|¤Wµoªí¨â³õ¤fÀY ºtÁ¿(2¤ë22¤é¤Î2¤ë23¤é)¡A¤À§O¬°C«¬¨xª¢°ò¦]Åé²Ä¤@«¬(HCV GT1)¤HÅé¸ÕÅç ²Ä¤G´Á»PC«¬¨xª¢°ò¦]Åé²Ä¤G«¬(HCV GT2)¤HÅé¸ÕÅç²Ä¤G´ÁªºÁ{§É¬ã¨s¦¨ªG¡A ¨Ã¥Ñ°ê¤º¨xŦ¯e¯fÅv«Âº[Á{§Épµe¥D«ù¤H¥x¤jÂå°|³¯°öõ±Ð±Â»P°ªÂå¤jÂå¾Ç °|²ø¸UÀs±Ð±Â¥Nªí³ø§i¡C¸Ó¬ã¨s¦¨ªGÅã¥ÜP1101ÄÝ©ó·s¤@¥Nªºªø®Ä«¬¤zÂZ¯À¡A ¦b¯Â«×¤W¨ã¦³«D±`Àu²§ªºªí²{¡A¤£¦ý±wªÌªº@¨ü«×°ª¡A°Æ§@¥Î¤j´T´î§C¡A¥B¯à ¨ÏªvÀø©P´Á¥Ñ¥H©¹¶Ç²Î¤zÂZ¯ÀªvÀøªº2¤Ñ1°w¡A©µªø¨ì¥«±¤Wªø®Ä«¬¤zÂZ¯À1©P1°w ¬Æ¦Ü¨ì¥Ø«e¥»¤½¥qP1101¤§2©P1°w(¥tÀ³¥Î©óPVªºªvÀø¤w¥i¥H©µªø¨ì4©P1°w)¡C 6.¦]À³±¹¬I:µo§G«¤j°T®§¤½§i©ó¤½¶}¸ê°TÆ[´ú¯¸ 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/2/22 ¤U¤È 12:17:17²Ä 77 ½g¦^À³
|
6446ÃĵØÃįE¹©¼vÅT¡A³Ì§C¨ÓÓ154¤¸¡A¥B¤U¶^¶q¼W¡A¥Ø«e¤w¦¨¥æ1606±i¡C·Q¥²150¤¸À³¸Ó¦³±j¤O¤ä¼µ(¤]³\¤£¤@©w)¡G 1¡B2¤ë23¤é¤p^¥Í§Þ¤§®È°Ñ»P®y½Íªº¥Í§Þ¤½¥q¥]¬AÁÞ°ò¡B¯E¹©¡BÃĵØÂåÃÄ¡B¤¤¤Ñ¥Í§Þ¶°¹Îµ¥¡A¦Ü©ó°Ñ³Xªº¤½¥q¡A¥Á¶iÄÒªí¥Ü ¤£«K³zÅS¡C 2¡B²{¼W»ù¡GÃĵØÃĥثe¤w»¼¥ó¥Ó½Ð¤WÂd¡A²Ä¤G©u§¹¦¨±¾µP¡A¦P®É¹wpµo¦æ5000±i²{¼W·sªÑ¡Aµo¦æ»ù¼Èq150¤¸¡C²{¼Wú´Ú¤é´Á2¤ë18¤é¦Ü3¤ë18¤é¡C 3¡B6482 ¥°·Ô¬ì 104/12/24 ¥Ó½Ð¤WÂd¡A105¦~2¤ë25¤éÂd¶R¼fij¡C6446ÃĵØÃÄ104/12/30¥Ó½Ð¤WÂd®×¡Aªñ´ÁÀ³¥i¼fij¡C 4¡BY6¤ë¥i¤WÂd®É¡A©Ó¾P»ù¼È©w150¤¸¡C¨£ÃĵØÂåÃĪѥ÷¦³¤½¥qªÑ²¼ªì¦¸¤WÂdÃÒ¨é©Ó¾P°Óµû¦ô³ø§i(¥D¿ìÃÒ¨é©Ó¾P°Ó¡G³Í°òÃÒ¨éªÑ¥÷¦³¤½¥q)¶3¡B¶4¡C |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/2/22 ¤W¤È 10:39:57²Ä 76 ½g¦^À³
|
max yao ¤jÁÂÁÂÆg¬ü. §Ú¨ä¹ê¤]»{¦P¯E¹©¤£ºâ¤Ó¥¢±Ñ, ¦ý¬O ¥¿±¨Ó¬Ý¦¹¨Æ¤D¡G - ¥«³õ¥Î¸û²z©Êªº¨¤«×¥hµû¦ô¤½¥q, ¦nªº¤½¥q¦pÃĵتѻù¯à¤Ï¬M¨ä»ùÈ. - ¤]¤£°gÅʦW¤H®ÄÀ³¤F.. - ´Á«ÝÃĵؤɮ欰¥xÆW¥Í§Þ¤@ô¦]¬°¡G US FDA ¦]¬°ÃĵØP1101ªºÀu²§Àø®Ä¦Ó¦P·N§K°£¨ä US phase 3, ª½±µ¥Î¼Ú¬w¼Æ¾Ú, ¦Ó¬Û¤Ïªº¯E¹©ªºUS phase 3¯à¦b2020¦~«e§@§¹´Nºâ¼F®`¤F! |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/2/22 ¤W¤È 08:18:44²Ä 75 ½g¦^À³
|
§Ú¹ï¯E¹©ªºÄ³ÃDªø´ÁÃöª` ²¦³º·sßÓn¦¨¥\¬O«Ü¤£®e©öªº¤@¥ó¨Æ, ³o¤]¬O¬°¦ó¤@¥¹ßÓÃÒ¨ú±o,ªÑ»ù·|º¦¤W¼Æ¤d¤¸ªºì¦] §Ú¿ï¾Ü¤@¸ô¥[½XÃĵØ,¬°¦ó? ¦]¬°¥¦°µ©t¨àßÓ,¦bÁ{¤Wµ¹¤©¥LÀu´f, ©Ò¦³Á{§Éªº¬IßÓ³£¬Oopenªº,µL¶·¸Ñª¼ ¦bÁ{§Éªº¹Lµ{¤¤§ÚÌ´N¥iª¾¹D³o¤äßÓ¬O§_¦¨¥\? ¦p¤µÃĵØßÓÁö¤T´Áªº¼Æ¾Ú¤w§¹¦¨©|¥¼¤½§G... ¦ý¤@ª½¥H¨Ó¦n®ø®§¤£Â_...,¥B¤w¶}©l§G§½¼Ú¬wªº¾P°â... µ²ªG¤£¨¥¥i³ë |
|
|
·|û¡Gmax yao10135972 µoªí®É¶¡:2016/2/22 ¤W¤È 06:56:52²Ä 74 ½g¦^À³
|
·Æ½ü¤j¯u¬O¯«·Ç!4174¥xÆW¤T´Á¸Ñª¼ªGµMÁÙ¬O¥X¥]¤F,²×¨s¬O±oµ¥¨ì½Õ¾ã«á¬ü°ê¤T´Áµ²ªG,ÁÙn3~5¦~,«æ¤£±o°Õ! ¤£¹L,³o¤U¤l©Ò¦³·sÃĪѥ]¬AÃĵØ,¤Sn±½¨ì»ä·§À¤F~ |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/2/16 ¤U¤È 02:45:13²Ä 73 ½g¦^À³
|
1¡B²Ä¤T´Á¹êÅç¦Ü¥»¤ë©³§i¤@¬q¸¨¡A´N¥i±N¬ÛÃö¸ê®Æ¾ã²z¡A¥Ó½ÐÃĵý¡C 2¡B¦Ü©ó©µªø¹êÅç¡A¬On¼W¥[ÃÄ«~»ùÈ¡A³o¥s¡¨¦pªê²KÁl¡¨ |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/2/16 ¤U¤È 02:23:34²Ä 72 ½g¦^À³
|
²Ä¤T´Á¹êÅç´Á¬°12¤ë ¦pªG¤£²M·¡¥i¥H³z¹L¦¹ºô¯¸³s±µ https://www.clinicaltrials.gov/ct2/show/NCT01949805?term=AOP+or |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/2/16 ¤U¤È 02:09:01²Ä 71 ½g¦^À³
|
http://www.proud-pv.com/proud-pv-study.html |
|
|
·|û¡Gªüºµ10136469 µoªí®É¶¡:2016/2/16 ¤W¤È 11:36:29²Ä 70 ½g¦^À³
|
Further study details as provided by AOP Orphan Pharmaceuticals AG: Primary Outcome Measures: •Hct level of 40 - 42% without phlebotomies. [ Time Frame: 1.5 years ] [ Designated as safety issue: No ] Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values. Estimated Enrollment: 130 Study Start Date: November 2014 Estimated Study Completion Date: June 2017 Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure) |
|
|
·|û¡GFLYER10133103 µoªí®É¶¡:2016/2/16 ¤W¤È 11:00:43²Ä 69 ½g¦^À³
|
©µªø¸ÕÅç¹w¦ôn¨ì2017¦~6¤ë? ©Î³\¥iª½¸ò¤½¥q¸ß°Ý¬O§_¦p¦¹? ¥t¥~¡A¤]³\¤[¥¼¨£ª÷¨©¨©¤jªº±M·~¤À¨É¡K |
|
|
·|û¡Gªüºµ10136469 µoªí®É¶¡:2016/2/16 ¤W¤È 10:23:02²Ä 68 ½g¦^À³
|
ÁÂÁÂDesertªº¦^µª¡A½Ð°Ý¬O¦b¤T´ÁÁ{§Éªº©µªø¸ÕÅç°µ§¹¤~·|¥Ó½ÐÃÄÃÒ¶Ü?§_«h«ç»ò¥i¥H¦bÃIJ°¤W¼gªvÀøn¦~ªº®ÄªG?©µªø¸ÕÅç¹w¦ôn¨ì2017¦~6¤ë¤~·|°µ§¹¡C |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/2/16 ¤W¤È 02:15:25²Ä 67 ½g¦^À³
|
Ãĵتº¨C¤@¦¸¬¡°Ê¦³ªÅ§Ú³£°Ñ¥[¡A¹ïªüºµªººÃ°Ý¡AÁ`µ²¦³¤G¡G !,¥h¦~¤G¤ë¦¬®×260¤H§¹¦¨¡A¨ì³o¤ë©³º¡¤@¦~¡A¶}©l¦¬¶°¡]¦n¹³¹M¤Î¥þ¼Ú¬w60¦hÂå¾Ç¤¤¤ß¡^ ¹êÅç¸ê®Æ¨Ã¶i¦æ²Îp¾ã²z¡A¹wp¦~©³«e´N¥i¦V¼Ú·ùEMA,¬ü°êFDA´£¥X¦æ¾PÃÄÃҥӽСC ©Ò¥H¥Ó½ÐÃÄÃÒ¤§®É¶¡¡AEverything is under control. ¦]¬°«Y¦h«ü¼Ð¼Æ¡A¥BÂå¾Ç¤¤¤ß¤À´²¼Ú¬w14°ê¡A¾¨§Ö¾ã¾¨³t´£¥X¡A ³o´Nn¬ÝAOPÃĵتº¦æ¬F¯à¤O¡I©Ò©¯AOP¦h¶µ¦¨¥\¸gÅç¡A¾r»´´N¼ô¤F¡C 2.²Ä¤@¤Î²Ä¤G´Á¹êÅç¤wÀòµý¹ê¥B°ò©óÃĮĤӦn¤F¡]±q³Ì¦²Ä¤@¦ì¹êÅçªÌ¶}©l¤w¶W¹L¤¦~¡^¡A ©Ò¥HEMA¦P·NÅýAOP°w¹ï¦b°Ñ¥[ÖפT´Áªº260¦ì¤¤¶W¹L¬I¥´P1101¤@¦~ªÌ¤¤¤§ 130±wªÌ«ùÄò°Ñ»P¤HÅé¹êÅç¡B³o¬O¬°¤F¶i¤@¨BÁA¸ÑP1101,How far it can go, ¬O§_¦³¦h¤Ö¤ñ²v§¹¥þªv¡PV¡]PV¥»¨´N¬O¤@ºØ«ÜÃøªvªº¦åÀù¡A¤@ºØJAK2°ò¦]¬ðÅÜ¡^¡A ¥H«á´N¥i¥H¦bÃIJ°¤W¼g»¡¡G¥i¥H«ùÄò¥´2¦~3¦~©Î§ó¦h¦~¡A ©Ò¥H³oConti¹êÅç¹ï¤½¥q¥¼¨Ó¦æ¾P¡B¦¬¤J¤W¬O¤@¤F¤£°_ªº§Q¦h¡C 3.ÂåÃĪºªF¦è¤Ó½ÆÂø¡A§Ú̳£¦b¾Ç²ß¡A©Ò¥HConti¡]nuation¡^ ªº¦¹¤@¹êÅç«Çµ´¹ï¥¿±ªº¡C¦pªG¦³ºÃ°Ý¡A¥i¥H¦V¤½¥q¹q¸ß¡A 4.³o´X¦~¨Ó¡A°Ñ»P¬ã°Q¡A·PıAOP ÆZ¦³¥»¨Æªº¡H |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/2/15 ¤W¤È 09:17:22²Ä 66 ½g¦^À³
|
¥h¦~8¤ë¥÷¸ß°Ý¤½¥q¦³Ãö¬O§_PV¦b¼Ú¬wÁ{§É¤T´Á°µ¨ì¤@¥b´N¥i¥ý°e¥X¼Æ¾Ú¤A¨Æ¡A¤½¥q¦^µªªí¥ÜAOPn°µ§¹¤@¦~¼Æ¾Ú«á¦A´£¥XÃÄÃҥӽСA¥i¯à¬O¦]¬°AOP ©ó2015 ¦~6 ¤ë»P¼w°êFDA¶}·|¡A©x¤è«Øij±N²Ä¤GªvÀø«ü¼Ð¬ðÅÜ×´_(functional cure)²¾¬°²Ä¤@ªvÀø«ü¼Ð§a~~ °w¹ï²Ä¤GªvÀø«ü¼Ð¬ðÅÜ×´_(functional cure)²¾¬°²Ä¤@ªvÀø«ü¼Ð¤A¨Æ¡A§Ú·Q¬O¥¿±ªº¡Aªí¥Ü¤@¦~¤§«á©Ò¦³¯f±w§¹¥þµL¶·©ñ¦å¡AªvÀø28 ¬P´Á«á¡AJAK2 °ò¦]¬ðÅܶq¤j´T°§C¡A¦¹¤À¤l¤ÏÀ³³Qµø¬°¬Oªv¡ªº§ïµ½¼x¥ü¡A¬G¥»¤½¥qP1101 ¥¼¨Ó¦³¾÷·|¦¨¬°ªvÀøPV ªº²Ä¤@½u¥ÎÃÄ¡C ¥t°Ñ¦Ò¸gÀÙ¤é³ø105¦~2¤ë1¤éªº³ø¾É(ÃÄµØ ¤Q¦~¿i¤@¼C ´«Â°ê»Ú)´£¨ì¦p¤U¡A§Ú·QÀ³¸Ó¬O°w¹ï¥b¦~(104¦~9¤ë¡A³Ì«á¤@Ó¯f¤H¦¬®×¥b¦~«á)¼Æ¾Úªºµ²ªG°µ°Q½×§a¡C ¡u¥h¦~9¤ë¡AÃĵØÂåÃijпì¤Hº[µ¦²¤ªøªL°êÄÁ¦b¶ø¦a§Qªº®ÈÀ]§zÔ¬ªººÎ¤@ı¡A¹j¤Ñ¤@¤j¦´NÅX¨®«e©¹ºû¤]¯ÇÂå¾Ç°|¡C9¤ëªººû¤]¯Ç¤w¸g¬O²`¬î¡AªL°êÄÁ«o«D±`®¶¾Ä¡A§¹¥þ¨S¦³·P¨ü¨ì¬î²D¡C ¡@¡@ºû¤]¯ÇÂå¾Ç°|ªþÄÝÂå°|¬O¶ø¦a§Q³Ìª¾¦Wªº¤jÂå°|¡AªL°êÄÁ¨Ó¨ì¦å²G¸~½F³¡ªù¡Aªï±¦Ó¨Ó¬O¨¬ï¥Õ³Tªº¤¤¦~Âå®v¡A¨â¤H´H·y«á¡A¶}©lÃĵØÃÄ¥h¦~³ÌÃöÁ䪺·|ij¡C ¡@¡@³oÓ¤¤¦~Âå®v¬O¼Ú¬w¦³¦Wªº¦å²G¸~½F»â°ì±M®a¡B¤]¬Oºû¤]¯ÇÂå¾Ç°|¦å²G¯e¯f¥DªvÂå®v¦ë¤ó©u´µªL®æ¡]Heinz Gisslinger¡^¡A©u´µªL®æ¦b¼Ú¬ü¦å²G¸~½FªvÀø¬ã¨s»â°ì³Æ¨ü´L±R¡C ¡@¡@ºû¤]¯ÇÂå¾Ç°|¬OÃĵØÃĦb¼Ú¬wªºÁ{§É°ò¦a¡A¤]¬OÃĵØÃıÂÅv¹Ù¦ñAOP¶i¦æP1101Á{§É¸ÕÅ窺¥DnÂå°|¡C¦¦b¥h¦~2¤ë¡AP1101¦b¼Ú¬wªºÁ{§É¤T´Á¸ÕÅ禬®×§¹²¦¡A´N®i¶}¤@³s¦êÃöÁ䪺ÃĪ«¸ÕÅç¡A¾AÀ³¯g¬O¡u¬õ¦å²y¼W¥Í¡vªº¦å²G¯e¯f¡C³o¬O¤@ºØ¨u¨£¦å²G¯e¯f¡A±wªÌÅ餺¬õ¦å²y·|¤£Â_¼W¥Í¡A»P«UºÙªº¦åÀù¼Ò¦¡¬Û¦P¡A¥Ø«eµLÃÄ¥iªv¡C ¡@¡@©u´µªL®æ»¡¡AÁ{§Éµ²ªGµo²{P1101¹ï¯f±w¦Ó¨¥¦³¸û¦nªº@¨ü©Ê¡A¥b°I´Á¤]¸ûªø¡A¥L»{¬°³oÓ²£«~¹ï¯f¤HªvÀø¬¡©Ê¡A·|¤ñ¹L¥hªº²£«~§ó¦n¡CªL°êÄÁÅ¥§¹«á¤j¨ü®¶¾Ä¡A¥L·PÁ¦X§@¹Ù¦ñ»P¦P¨Æªº¨¯¶Ô¥I¥X¡A¦h¦~¨Óªº§ë¤J²×©ó¬Ý¨ìÀÆ¥ú¡C¡v |
|
|
·|û¡Gªüºµ10136469 µoªí®É¶¡:2016/2/14 ¤U¤È 11:32:48²Ä 65 ½g¦^À³
|
¤½¶}»¡©ú®ÑP.63 EMA ¬Û·í¤ä«ùAOP ¥H¥b¦~ªº¸ÕÅçµ²ªG¹w¥ý¥Ó½Ð¼Ú¬wªº¤W¥«³\¥i¡A¤§«á¦A¥HªvÀø¤@¦~ªº§¹¾ãµ²ªG§¹¦¨¾ãÓ¤W¥«¥Ó½Ð¡C AOP¨ì©³¦³¨S¦³¥H¥b¦~ªº¸ÕÅçµ²ªG¹w¥ý¥Ó½Ð¼Ú¬wªº¤W¥«³\¥i©O?«ç»ò³£¨S¦³®ø®§? ¥H¤U³oÓ³sµ²Åã¥ÜAOP¥¿¦b°µ¤T´ÁÁ{§Éªº©µªø¸ÕÅç¡A¹w¦ôn¨ì2017¦~6¤ë¤~·|§¹¦¨¡A¤£ª¾ÃÄÃÒªº¥Ó½Ð·|¤£·|©µ¨ì¨º¤§«á?ttps://clinicaltrials.gov/ct2/show/NCT02218047?term=p1101&rank=6 |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/2/14 ¤U¤È 09:15:57²Ä 64 ½g¦^À³
|
PV¨ì©³²Ä2©u©Î²Ä3©u¦VEMA ¥Ó½ÐÃÄÃÒ¡A¤½¶}»¡©ú®Ñ¦³¤£¦P»¡ªk¡G ¼Ú¬w¡G P1101(PV)¡GAOP ªºP1101(PV)²Ä¤T´Á¤HÅé¸ÕÅç¡A¤w¦b2015 ¦~2 ¤ë§¹¦¨¦¬®×¡A¹wp2016 ¦~ ²Ä¤G©u¾ã²zÁ{§É¼Æ¾Ú§¹¦¨«á§Y¥i¦VEMA ¥Ó½ÐÃÄÃÒ¡C ¥t¥~AOP ©ó2015 ¦~6 ¤ë»P¼w°êFDA¶}·|¡A©x¤è«Øij±N²Ä¤GªvÀø«ü¼Ð¬ðÅÜ×´_(functional cure)²¾¬°²Ä¤@ªvÀø«ü¼Ð¡C¦¹«h®ø®§¡A¨ì©³·N¿×¤°»ò? |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/2/14 ¤U¤È 08:49:52²Ä 63 ½g¦^À³
|
¦³ÃöPV¡AÃĵØÃÄ©x¤è»¡©ú¡A¥i°Ñ¦Ò¡G(104¦~12¤ë¥Ó½Ð¤WÂd¤½¶}»¡©ú®Ñ) ¯÷´NP1101 ¥Ø«e¶i®i¤Î¥¼¨Óµo®i©Ê²n»¡©ú¦p¤U: I. ¼Ú¬w²Ä¤G´Á¸ÕÅçµ²ªGÀu²§¡A¹w´Á²£«~³q¹L¤W¥«®Ö㤧¥i¯à©Ê°ª ¥ÑAOP Orphan ¥X¸ê¨Ã¶i¦æ¥HP1101 ªvÀøPV ªº²Ä¤G´ÁÁ{§É¸ÕÅç¤wÀò±o°ªÀø®Ä§C¬r ©Êªº¦¨ªG¡A¨ä¼Æ¾Ú©ó2012¡B2013 ¤Î2014 ¦~¬ü°ê¦å²G¯e¯f¨ó·|(ASH/AJH)µoªí¡Aµ²ªG¬Û ·íÀu²§¡G41 ¦ì¯f±wPV ¯f±wªº¸ê®ÆÅã¥Ü¡A¾ãÅé¯e¯f¤ÏÀ³²v¶W¹L90%¡A45~50%ªº¯f±w¦b¦å ²G¾Ç°Ñ¼Æ¥¿±`¤Æ¤UÅã¥Ü§¹¥þ¤ÏÀ³¡A¥BµÊŦ¤j¤p¥ç¦³¥¿±`¤ÆÁͶաA«nªº¬O¡A¤@¦~¤§«á ©Ò¦³¯f±w§¹¥þµL¶·©ñ¦å¡AªvÀø28 ¬P´Á«á¡AJAK2 °ò¦]¬ðÅܶq¤j´T°§C¡A¦¹¤À¤l¤ÏÀ³³Q µø¬°¬Oªv¡ªº§ïµ½¼x¥ü¡A¬G¥»¤½¥qP1101 ¥¼¨Ó¦³¾÷·|¦¨¬°ªvÀøPV ªº²Ä¤@½u¥ÎÃÄ¡C¨Ì¾Ú Blood,8 October 2015,Volume 126, Number15,P1762¡A¤S¤À¤l¤ÏÀ³³¡¤À¥çµoªí©ó2015 ¦~4 ¤ë¬ü°ê¦å²G´Á¥ZAmerican Journal of Hematology, Vol 90,No 4,April 2015,P288¡F ¦¹Á{§É¤@/¤G´Áµ²ªG¤w©ó104 ¦~10 ¤ëµoªí©ó¦å²G¯e¯f³ÌÅv«Âªº´Á¥ZBlood¡C II. PV ²Ä¤T´Á¼Ú¬w¸ÕÅçµ²ªG±N©ó2016 ¦~²Ä¤T©u¥XÄl AOP Orphan ©ó2013 ¦~9 ¤ë¶}©l¦b¼Ú¬w¶i¦æ²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç(pivotal trial)¡A ¸Ó¸ÕÅç«Y¦b¼Ú¬w14 °ê®a50 Ó¹êÅ礤¤ß¶i¦æ¡A¤w©ó2015 ¦~2 ¤ë§¹¦¨¯f¤HÁ`¼Æ¦¬®×¡A¸Ó ¸ÕÅç°²³]¤@¦~¤§«áP1101 ªº¯e¯f¤ÏÀ³²vÀu©óHydroxyurea(·Rªv½¦Ån/§ÜÀùÃĪ«)¡A¬G¹w p2016 ¦~²Ä¤T©u¾ã²zÁ{§É¼Æ¾Ú§¹¦¨«á§Y¥i¦VEMA ¥Ó½ÐÃÄÃÒ¡AY¶i®i¶¶§Q«h²£«~¥i©ó 2017 ¦~²Ä¤T©u¤W¥«¡C |
|
|
·|û¡Gªüºµ10136469 µoªí®É¶¡:2016/2/13 ¤U¤È 10:29:32²Ä 62 ½g¦^À³
|
Ãĵؤ§«e»¡Ãö©óPV¦b¼Ú¬wÁ{§É¤T´Á°µ¨ì¤@¥b´N¥i¥ý°e¥X¼Æ¾Ú¡A¥H¥[³t¼f¬d¡C¥Ø«eÁ{§É¤T´Á¤w¸g§Öµ²§ô¡A¤£ª¾¬°¦ó³£ÁÙ¥¼Å¥»¡¦³¥ý°e´Á¤¤Á{§É¼Æ¾Ú¥H¥[³tÃÄÃÒ®Öµoªº°T®§? |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/2/11 ¤U¤È 08:21:12²Ä 61 ½g¦^À³
|
Incyte¤½¥q³ø§i2015¦~²Ä¥|©u«×©M¦~²×°]°È³ø§i¡A´£¨Ñ¦³ÃöÃöÁäÁ{§É¶µ¥Ø2016¦~°]°È«ü¾É©M§ó·sªÑªF •±qJakafi®¡]ruxolitinib¡^¡A¸û¥h¦~¦P´Á72¢Hªº¼Wªø©M$±qJakafi 2015¦~¥þ¦~²b²£«~¦¬¤J6.01»õ¡A¸û¥h¦~¦P´Á68¢Hªº¼Wªø$ 2015¦~²Ä¥|©u«×²b§Q¼í²£«~¦¬¤J1.82»õ •2016¦~«ü¾É¦b$ 800¸U¦Ü$ 815»õ¬ü¤¸¤§¶¡Jakafiºô²£«~¦¬¤J¡A¤Ï¬M¦b°©ÅèÅÖºû¤Æ¡]MF¡^ªº¼ç¦b»Ý¨D«ùÄò¼Wªøªº¹w´Á¡A¨Ã±q¯u©Ê¬õ²ÓM¼W¦h¯gªº«ùÄò±À¥X¡]PV¡^ªº¶V¨Ó¶V¤jªº°^Äm •¼sªx©M13¶}µo¤À¤l¦h¤¸¤Æªº§ë¸ê²Õ¦X¥¿¦b¬ã¨s§@¬°³æ¤@Àøªk¥H¤Î¦b¦hÓ¾AÀ³¯g²Õ¦X ¹q¸Ü·|ij©Mºôµ¸ª½¼½¤W¤È10:00 ET©w©ó¤µ¤Ñ ¯S©ÔµØ¦{«Âº¸©ú¹y - ¡]¬ü°ê°Ó·~¸ê°T¡^ - ¤G¤ë11¡A2016-- Incyte¤½¥q¤½¥q¡]Nasdaq¡GINCY¡^¤µ¤Ñ¤½§G¤F2015¦~²Ä¥|©u«×©M¦~²×°]°È·~ÁZ¡A¹üÅã±j«lªº¦¬¤J¼Wªø¥Ñ¤W¤ÉJakafi®¡]ruxolitinib¡^±a°Ê¾P°â¦b¬ü°ê¡A¥H¤Î¶V¨Ó¶V¦hªº«e¤¤¬ü¡C Jakavi®¡]ruxolitinib¡^¿ÕµØ¶O¡C¦¹¥~¡AIncyte¤½¥q2016¦~´£¨Ñªº°]°È«ü¾É¡C Incyte¤½¥q¦bJAK§í¨î»â°ìªº±j¶Õ¦a¦ì¬O¥ÑJakafi¥¿¦b¶i¦æªº°Ó·~¦¨¥\©M³Ìªñªº§e¤å¡A¥Ñ§¨Ó¤½¥q½×ÃÒ¡A´M¨D·Àã©ÊÃö¸`ª¢ªºªvÀøbaricitinibªººÊºÞ³¡ªù§åã¡C Baricitinib³QIncyte¤½¥q±ÂÅvµ¹Â§¨Ó¤½¥q¡A¨Ã¦b¨ä¥þ²y¢»´ÁÁ{§É¬ã¨sªº©Ò¦³¥|Óº¡¨¬ªì¯Å²×ÂIªº¡C¦pªGÀò±o§åã¡A§¨Ó¤½¥q¹wp±N¦b2017¦~¦~ªì±À¥Xbaricitinib¦¹¥~¡Aepacadostat¡AIncyte¤½¥qªº²Ä¤@¤@¬yIDO1§í»s¾¯¡A¹wp±N¦b2016¤@½u¤W¥b¦~¶i¤J²Ä3¶¥¬q±ß´Á©ÎÂಾ©Ê¶Â¦â¯À½Fµ²¦XÀq§J¡®COªºpembrolizumab¡C¦hÓ²Ä2¶¥¬q¡A¦b²Õ¦Xepacadostatªº¸~½F¯S²§©Ê¡A¿±µÈ¶¤¦C»P§ÜPD-1©M§ÜPD-L1ªºÀˬdÂI½Õ¸`¾¯¤]¥¿¦b¶i¦æ¡C ¡§Jakafiªº¶ÕÀY¡A²{¦b¶i¤J°Ó·~¤Æªº²Ä¤Ó¦~ÀY¡A¨ÌµM±j«l¡A¦Ó¥B¡AºÊºÞ³¡ªùªº§å㤧«e¡A§ÚÌ´Á«Ýbaricitinib¦¬¤Jªº²Ä¤GÓ«n¨Ó·½¡A¡¨®Jº¸³¶ø©Y¿Õ¡AIncyte¤½¥qªºÁ`µôݺ®u°õ¦æ©x»¡¡C ¡§¾¨ºÞJANUSµ{§Çªºµ²ªG¡A§Ú̪º¶}µo§ë¸ê¨ÌµM±j«l¡A¥Ñ13¦WÔ¿ï¤H¹ï10ªº¤À¤l¹v¼Ð¡Aªí©úIncyte¤½¥qP¤O©ó³Ð·s¡A§Ú̪ºÃĪ«µo²{©M¶}µoªºµo°Ê¾÷ªº¤u§@®Ä²v¡C¡¨ 2015¦~²Ä¥|©u«×©M¥þ¦~°]°È·~ÁZ ¦¬¤JºI¦Ü2015¦~12¤ë31¤éªº©u«×¡AJakafiªº²£«~²bÀ禬¬°$¦Ê¸U182¬Û¤ñ¡A¦P´Áªº1.06»õ$¡A2014¦~¡A¦û72¢Hªº¼Wªø¡CºI¦Ü2015¦~12¤ë31¤é¡A±q¥þ¦~¨Ó¬Ý¡AJakafiªº²£«~²bÀ禬¬°$¦Ê¸U601¬Û¤ñ¡A¦P´Áªº3.58»õ$¡A2014¦~¡A¦û68¢Hªº¼Wªø¡C¹ï©ó©u«×©M¥þ¦~ºI¦Ü2015¦~12¤ë31¤é¡A¿ÕµØ¤À§O¬°$ 24Ó»õ¤¸©M$ 7500¸U¬ü¤¸¡A¦¬¨ì¨Ó¦Û¬ü°ê¥H¥~ªº¾P°âJakavi²£«~ªº¯S³\Åv¨Ï¥Î¶O¡A«h¤À§O¬°$ 15¦Ê¸U©M$ 4900¸U¬ü¤¸¡A¬°¦P´Á¦b2014¦~ºI¦Ü2015¦~12¤ë31¤éªº©u«×¡A¦X¦P¦¬¤J¬°¦Ê¸U$ 38Ó¬Û¤ñ¡A¦b2014¦~¦P´Áªº$¤T¤d¤¦Ê¸U¼W¥[¨ì¦X¦P¦¬¤JºI¦Ü2015¦~12¤ë31¤éªº©u«×¬Û¤ñ¥h¦~¦P´Áªº$ 3¦Ê¸U¬°2014¦~¯A¤Î¥Ñ¿ÕµØ¤½¥qÀò±o¼W¥[ªº¨½µ{¸O¥I´Ú¡CºI¦Ü2015¦~12¤ë31¤éªº¥þ¦~¡A¦X¦P¦¬¤J¬°»õ$ 78¬Û¤ñ¡A¦b2014¦~ªº»õ$ 27¤é´î¤Ö¦X¦P¦¬¤JºI¦Ü2015¦~12¤ë31¤é¡A¥þ¦~¸û2014¦~¦P´Á¦P´Áªº1.05»õ$¯A¤Î¨½µ{¸O¥I´Ú±q¿ÕµØ¤½¥qűo¤F¤U°¡CºI¦Ü2015¦~12¤ë31¤éªº©u«×¡AÁ`À禬¬°»õ$ 244¬Û¤ñ¡A1.24»õ$¦b2014¦~¦P¤@®É´ÁºI¦Ü2015¦~12¤ë31¤é¡A¥þ¦~Àç·~Á`¦¬¤J¦Ê¸U$ 754¬Û¤ñ¦P´Áªº5.11»õ$¦b2014¦~¡C |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/2/5 ¤U¤È 07:49:28²Ä 60 ½g¦^À³
|
¥Í§Þªï¬K· ¥Á¶iÄÒÁ`²Î·í¿ï¤H½²^¤å¬°¸¨¹ê¤¤j³Ð·s¬ãµo²£·~pµe¡A¹wp¹A¾ä¦~«á®i¶}¡u²£·~¤§®È¡v¡A¨ä¤¤¡A¤S¥H¥Í§Þ²£·~³Ì¨ã«e¤©Ê¡A³Æ¨üÆf¥Ø¡C¦¹¥~¡A¬K¸`¹L«á¡A·s°ê·|¶}ij¡A¥Á¶iÄÒ±Nµo°Ê¥Í§Þ·sÃıø¨Òתk¡A¯Ç¤J«D«I¤J©ÊÂå§÷¡A¦³§U¾ãÅé¥Í§Þ²£·~µo®i§ó¬°½´«k¡C »P¥Í§Þ²£·~²W·½»á²`ªº½²^¤å±N¥Í§Þ·~³]©w¬°¡u¤¤j³Ð·s¬ãµopµe¡v¤@Àô¡A°ÆÁ`²Î·í¿ï¤H³¯«Ø¤¯¤]¬O¡u¥Í§Þ·sÃIJ£·~µo®i±ø¨Ò¡vªº¶Ê¥ÍªÌ¤§¤@¡C¥«³õ¬Ý¦n¡A·s¬F©²¹ï¥Í§Þ²£·~ªº§ß´Ó»P§ë¤J±N¥i½T¥ß¥Í§ÞÂåÃĪø¦hªº§ë¸êÁͶաC¥H2¤ë·s°ê·|¶}ij±N±À°Êªº·sÃıø¨Òתk¨Ó»¡¡A¯Ç¤J«D«I¤J©ÊÂå§÷¡A»â°ì¥]¬A³Ð·sÀË´ú´¹¤ù¡B°ª¶¥¼v¹³Âå§÷¡B«D«I¤J¦¡ÀË´ú§Þ³Nµ¥ºë·ÇÂå¾Ç¡A±N¥i«p¹ê¸ê¥»¥«³õ¹ï¥Í§Þ²£·~ªºÀ°§U¡C ªk¤Hªí¥Ü¡A¥Í§Þ²£·~¦b°ê®a¯Å§ë¸ê°òª÷¡B¤H¤~¶}©ñ¡B§Þ³N²¾Âà¡B¬ãµoÀu´fµ¥§Q¦hµo»Ã¤U¡AÀHµÛ¬ÛÃö¬Fµ¦¸¨¹ê¡A±N¨Ï¥Í§ÞªÑ¨ã·Q¹³ªÅ¶¡¡A¥]¬A·sÃÄ¡Bì®ÆÃÄ¡BÂå§÷¡B«O°·µ¥¦¸±Ú¸s¬Ò¥i±æ¨ü´f¡C°£¤F·s¬F©²¬Fµ¦Å@¯è¡A¤µ¦~¥Í§Þ±ÂÅv®i±æ¨Î¡A·sÃĶ}µo¶i«×¸¨¹ê¡A¤×¨ä·sÃÄÀsÀY¯E¹©¡]4174¡^2¤ë·sÃĸѪ¼¡A¬O¦~«á¥Í§ÞªÑ¦æ±¡¦hªÅÃöÁä¡C¥t¥~¡AÃĵØÃÄ¡]6446¡^ªºÁ{§É¸ÕÅçµ²ªG³Ì§Ö¦b²Ä2©u¤]±N¥XÄl¡A¥ç¥iÃöª`¡C ¦¹¥~¡A¥Íª«¬Û¦üÃĦb¬ü°êFDA¤j¶}¤jªù«á¡A¦¨ªøÁͶէ󬰩ú½T¡C¨ü´fªÑ¥]¬A¥Ã©ý¡]4726¡^¡BªF¥ÍµØ¡]8432¡^¥H¤Î¿³ÂdªºF-³ß±d¡]6540¡^µ¥¡C¦Ó«O°·«O¾i«~¤µ¦~«h¥H¤¤°ê¥«³õ°Ê¯à¦¨ªø³Ì©ú½T¡A¤×¨ä¦b¤¤°ê¤Q¤T¤pµeÅ@¯è¤U¡A¡u°·±d¤¤°ê¡v°Ó¾÷¥i´Á¡A¥]¬Aª½¾P¡B«O°·«~¬Ò¶i¤J§Ö³t¦¨ªø¡A¨ü´fªÑ¥]¬AÄRÂס]4137¡^¡B¸²µå¤ý¡]1707¡^¡B¤j¦¿¡]8436¡^¡B¬ì§°¡]1786¡^µ¥¡C |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/2/5 ¤W¤È 11:37:52²Ä 59 ½g¦^À³
|
§Æ±æP1101»°§Ö®Öã¤W¥«À°§U¤H¡C Áy¬õ¬õ¤£¤@©w¬O®ð¦â¦n ¥i¯à¦³¯f °OªÌªL«Û§Í¡þ¥x¥_³ø¾É 55·³ªº°ª¤p©jÁ`¬OÁyÀU¬õ¼í¡A¦b2014¦~¦]¯Ê¦å©Ê¤¤·¤J°|¡A2015¦~10¤ëµo¥Í¥ª¤âÁu³Â¥B¤G«×¤¤·¤J°|¡A¤J°|¤§«á°µ°©Åè¬ï¨ë¤~½T¶E¬O¡uìµo©Ê¦h¦å¯g¡v¡A²{¦b°ª¤p©j¨C3¶g¨ìÂå°|¡u©ñ¦å¡v250CC¤Î©T©w°lÂÜÀˬd¡C ¼s§i °ª¶¯Âå¾Ç¤j¾Çªþ³]Âå°|¦å²G¸~½F¤º¬ì¥D¥ô¼B¤j´¼«ü¥X¡A¡u¦h¦å¯g¡v¯f±w¥X²{ªº¯gª¬¦³Áy³¡¼é¬õ¡BÀY·w©MÀYµhµ¥¡A¦ý«Ü¦h¯f¤Hª½¨ì¥X²{¤¤·¤~µo²{±w¦³¦h¦å¯g¡C ¦h¦å¯g¥i¤À¬°¡uìµo©Ê¡v»P¡u¦¸µo©Ê¡v¡Aìµo©Ê±wªÌ¤¤¡A¦³95%ªº¯f±w¬O¡uJAK2¿E酶°ò¦]¬ðÅÜ¡v¡A¦nµo©ó50·³¥H¤Wªº¦~ÄÖ¼h¡F¦¸µo©Ê«h¬O¦]±wªÌªø´Á¦í°ª¤s¯Ê®ñ©Î¬O¦³©âµÒ²ßºDªº¤H¡C °¨°ºÂå°|¥DªvÂå®v±i©ú§Ó»¡¡A¥Ø«e¹ï¦h¦å¯g±wªÌ³Ì¦³®ÄªºªvÀø¬O¡u©ñ¦å¡v¡A¦A¨Ó¬Oª`®g¤zÂZ¯À¡B¤ÆÀø©Î¤fªA§í¨î¾¯¡CÀøµ{¨Ì¯f±wÓ§Oª¬ªp¦Ó©w¡A¦ý¶È¥u¬Oªv¼Ð¡A¯f±wÁٻݪø´Á©w´Á°lÂÜÀˬd¡C ¦¹¯fªº±wªÌ«O°·¤§¹D¬On¦h³Ü¤ô¡]¨C¤é¦Ü¤Ö³Ü2000CC¡A¥H«K¹w¨¾¦å²GÂH¸Y¡^¡B¦h¦Y½µæ©M¥Õ¦×¡]Âû©Î³½¡^¡AÁקK°µ¨ë¿Eªº¹B°Ê¡]¨Ò¦p¶]°¨©ÔªQ¡Bªw¤T·Å·xµ¥¡^¡C ¥x¤jÂå°|¦å²G¸~½F¬ì¥DªvÂå®v¥Ð¿·ªâ«ü¥X¡A¥xÆW¡u¦h¦å¯g¡v±wªÌªº¤H¼Æ¨Ã¤£¤Ö¡A¦ý¥Ø«e©|¥¼¦³¡u¦h¦å¯g¡vªºµn¿ý²Îp¼Æ¦r¡C¦h¦å¯g¬O¦]¬°¯f±w¬õ¦å²y¹L¦h¡A¦å²G¹L«×¿@¸Y¦Ó¬y³q½wºC¡AÄY«ªÌ·|¤¤·¡B¤Þµo¤ß¦åºÞ¯e¯f¦p°ª¦åÀ£¡B¤ß¦Ù±ð¶ë©Î¬OµÊŦ¸~¤jµ¥¡F¶È¦³·¥¤Ö¼Æ±wªÌ¦³°©ÅèÅÖºû¤Æ©Î¦åÀù¡C¥Á²³°£¤F¥i±q©úÅ㪺Áy¦â¬õ¼í©Î¥Ö½§¬õÄoÆ[¹î¡A¤]¥i³z¹L©â¦åÀˬd´£¦µo²{¡C |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2016/2/4 ¤U¤È 08:38:02²Ä 58 ½g¦^À³
|
¤£ª¾6446¦³µL¾A¥Î. .......... ¥Í§ÞºÖµ¡I¬F°|¤©¡uÂÂÃÄ·s¥Î¡v·sÃĸê®Æ3-5¦~±MÄÝ«OÅ@ 2016/02/04 13:53 ®É³ø¸ê°T ¡i®É³ø-¥x¥_¹q¡j¦æ¬F°|·|¤µ©çªO¬ü¤èTIFAÃö¤ÁªºÃĨƪk×¥¿®×¡A±N·s¾AÀ³¯g¸ê®Æ±MÄÝ´Á©úq3¦~¡A¦ý¬°¹ªÀy¥Í§Þ·~¦b°ê¤º©Î§l¤Þ°ê¥~»sÃÄ·~¡A¦b¥x±q¨ÆÁ{§É¸ÕÅç¡A¸ê®Æ±MÄÝ«OÅ@±N©µªø«OÅ@¦Ü5¦~¡C ¡@¬°ª§¨ú¬ü¤è¤ä«ù¥xÆW¥[¤JTPP¡A§Ú°ê¥h¦~10¤ë¥x¬üTIFA·|ij®É¡A©Ó¿Õ¬ü¤è¦bTIFAÃö¤Áªº·s¾AÀ³¯g·sÃĸê®Æ±MÄÝ«OÅ@¤©¥H¤Jªk¡C ¡@¯ó®×°Ñ°u°ê»Ú³W½d¡A¥]¬A¬ü°ê¡B·ç¤h¡B°¨¨Ó¦è¨È¦P¼Ë©ú©w3¦~¡A¼Ú·ù1¦~¡B¦Ü©ó¾Fªñªº«nÁú«h¬O4¦~¡C ¡@©Ò¿×¡u·s¾AÀ³¯g¡v¡A²³æ»¡¬O¡uÂÂÃÄ·s¥Î¡v¡A¥H³Ìªñ´¼Àº¬ã¦¨¥\Àò±o§ÚTFDA¤Î¬ü°êFDA·sÃÄÃÒªº¡u¦w¯à±o¡v¬°¨Ò¡A¸ÓÃÄ«~ì¬OªvÀø¤j¸zª½¸zÀù¡AÁ{§É¸ÕÅçµo²{¤]¥iªvÀø¡uµLÃÄ¥iÂå¡vªºÂಾ©Ê¯Ø¸¢Àù¡A§ä¨ì·s¾AÀ³¯g¡A¦P¨B¥Ó½Ð¨ì¥x¬ü¤G¦a·sÃÄÃÒ¡A¥O°ê¤º¥Í§Þ»sÃIJ£·~Àò±o«Ü¤j¹ª»R¡C ¡@¬°¤F¹ªÀy·~ªÌ¬ãµo·sÃÄ¡A¦Ó¤£¥u¬O¥Í²£²{¦¨ÃÄ«~¡Aתk©úq·s¾AÀ³¯g¸ê®Æ±MÄÝ«OÅ@¡A¥¼¨Ó½Ã¥Í¾÷Ãö®Öã·s¼W©ÎÅܧó¾AÀ³¯g¡A¦Û㤧¤é°_¤G¦~¤º¡A¨ä¥LÃÄ°Ó«D¸g¸ÓÃij\¥iÃÒ©Ò¦³¤H¦P·N¡A¤£±o¤Þ¾Ú¨ä¥Ó½Ð¸ê®Æ´N¬Û¦P¾AÀ³¯g¶i¦æ¬dÅçµn°O¡F´Á¶¡©¡º¡²Ý¤é°_¡A¨ä¥LÃÄ°Ó¥i¨Ì¬ÛÃöªk³W¥Ó½Ð¬dÅçµn°O¡A²Å¦X³W©wªÌ½ÃºÖ³¡©ó®Ö·s¼W©ÎÅܧó¾AÀ³¯g©¡º¡¤T¦~¤§²Ý¤é°_¡A¤~¥i¥Hµoµ¹¨ä¥LÃÄ°Ó«~³\¥iÃÒ¡C ¡@¤£¹L¡A¯ó®×¼WqÀò·s¼W©ÎÅܧó¾AÀ³¯g¤§ÃÄ«~³\¥iÃÒ©Ò¦³¤H¡AY¦b°ê¤º°õ¦æÁ{§É¹êÅçªÌ¡AÀò±o¸ê®Æ±MÄÝ«OÅ@¥i©µªø¬°5¦~¡AÂÇ¥H§l¤Þ°ê¥~ÃİӤΰꤺ¥Í§Þ²£·~¡A¦b¥xÆW¶i¦æÁ{§É¸ÕÅçÃÒ©ú·sªºÃĮġA¥H¼W¥[§Ú°êÁ{§É¸ÕÅ窺¯à¶q¡C(·s»D¨Ó·½¡G¤u°Ó§Y®É §f³·±k) |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/2/3 ¤U¤È 06:05:25²Ä 57 ½g¦^À³
|
ÃĵØÃĦ¬Ãö¤é»ùº¦¶q¼W(¶q1400±i)¡A¦¬³Ì°ª174.5¤¸¡C§Æ±æ¦~«á¶}©l°_º¦¡A¥[ªo¡C |
|
|
·|û¡GÁȤ£§¹10137061 µoªí®É¶¡:2016/2/3 ¤U¤È 01:14:02²Ä 56 ½g¦^À³
|
À£¹L©Z§J ¤¤¬ã°|¤h³¯°öõ¦b¬P´Á¤@ªº¸gÀÙ¤é³ø ´N²±ÆgÃĵئbªø®Ä«¬¤zÂZ¯À¶}µo¤è±¤ñ¿ÕµØNovartis, °ò¦]©Z§J(Genentech§Ú½Ķªº)°µ§ó¦n¡C ©Ò¥HP1101¤õ¤Oµ´¹ïÀ£¹L³o¨Ç¬v©Z§J¡C |
|
|
·|û¡GÁȤ£§¹10137061 µoªí®É¶¡:2016/2/3 ¤U¤È 12:42:59²Ä 55 ½g¦^À³
|
¶R±iÃĵئn¹L¦~ ¦~²×¼úª÷¡B¤u§@¼úª÷¡BÁZ®Ä¼úª÷¡B ¦ÒÁZ¼úª÷¡B¤¤¼Ö³z¡B¬Q±ß³Â±N¤âÉa¶¶¡A ´«±iÃĵتѲ¼¡A©ñ¹L¦~¡A¤@©wÁȤ£§¹¡I |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/2/1 ¤W¤È 08:43:37²Ä 54 ½g¦^À³
|
ÃĵطsÃĨƥb¥\¿ Ävª§¤Oup 2016-02-01 04:44 ¸gÀÙ¤é³ø ¥»³ø°T ÃĵØÃĵ¦²¤ªøªL°êÄÁ«ü¥X¡AÃĵØÃĦb¯u©Ê¬õ¦å²y¼W¥Í¯gªºªvÀø¯à¤O¤W¡A¤w¨¬¥H¹ï§Ü¡B¬Æ¦ÜÀu©ó¬ü°ê¤j¼tINCYTE¡A·sÃÄ©é©ú¦~¤U¥b¦~¥Ó½Ð¤W¥«¡C¦Ó§Ü¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^ªº·sÃÄP1101¡]BESREMi¡^¬O¸Ó»â°ìªº¤@½u¥ÎÃÄ¡A¤µ¦~§Y¥i¦V¼Ú¡B¬üÃÄ«~¥DºÞ¾÷Ãö¡A¥]¬A¼Ú¬wEMA¡B¬ü°êFDA»¼¥ó¥Ó½ÐÃÄÃÒ¡C P1101©Ò»EµJªºPV¯e¯f¦b¥þ²y°Ó¾÷¹F¦Ê»õ¬ü¤¸¡AP1101¬°PVªº²Ä¤@½uº¿ï¥ÎÃÄ¡A¥i±æªvÀøPV¯e¯f75%¯f±w¡AÀu©óINCYTE¤w¦b¬ü°ê¤W¥«ªºPV²Ä¤G½u·sÃÄ¡uJakafi¡v¡C¥H¤U¬O±M³X¬ön¡G °Ý¡G¥D¤O²£«~P1101ªº¯S¦â¡H µª¡GP1101¬°ªø®Ä«¬·s¤@¥N¤zÂZ¯À¡A¨S¦³¶Ç²Î¤zÂZ¯À±j¤j°Æ§@¥Î¡A«o¯à°÷©µªø¦bÅ餺µo´§®ÄªGªº®É¶¡¡A¤º³¡§Æ±æ¯à©µªø¦Ü¨â©P¡B¤@Ó¤ë¡A±N¯à¤j´T´£¤É¯f¤H»PÂå¥Í¥ÎÃÄ·NÄ@¡A¬°¥¼¨Ó¤W¥«¾P°â¥[È¡C¤½¥q¥Ø¼Ð¬OÅý³oÓ¾AÀ³¯g쥻µLÃÄ¥i¥Îªº±wªÌ¡A³£¯à¥Î»ù®æ¬Û¹ï¦X²z¡BÃĮĤ]ÅãµÛªº²£«~¡C °Ý¡GP1101¥Ø«e²£«~±ÂÅv·§ªp¡H µª¡GÃĵØÃÄ©ó2009¦~±NP1101¼Ú¬wµ¥¦a°Ïªº°Ó¤ÆÅv§Q±ÂÅvµ¹¶ø¦a§QÃļtAOP¡A¨Ã¥Î©óªvÀø¨u¨£¦å²G¼W¥Í¯e¯f¡A±ÂÅv°Ï°ì¥]§t¼Ú¬w¡B¤¤ªF¡B¿W¥ß°ê¨ó¡A¦ý«O¯d³o¨Ç¦a°Ï¥H¥~ªº»s³y¡B¾P°âÅv§Q¡F¸Ó²£«~¥Ø«e³Q¬ü¡B¼Ú»{©w¬°©t¨àÃÄ¡A¦]¦¹¥¼¨Ó¤W¥««á¡A±N¿W¥e¤C¦Ü¤Q¦~ªº¿W½æÅv»P·¸»ù¡]¸É§U¡^ªÅ¶¡¡A¦³¤@©wªºÄvª§¤O¡C °Ý¡G¥«³õ³ßÅw®³ÃĵØÃÄ©MINCYTE¤ñ¸û¡A¥i§_»¡©ú¨âªÌªº§Q°ò¡H µª¡GINCYTE¤]¬OªvÀø¦å²G¯e¯f»â°ìªº±M·~Ãļt¡A¬Oȱo´L·qªº¹ï¤â¡A¸Ó¤½¥qPV¯e¯fªº¤G½u¥ÎÃĤw¦b¬ü¤W¥«¡A¾AÀ³¯g¬O¥HPV¬°¥D¡B°©ÅèÅÖºû¤Æ¬°»²¡A¥h¦~¤@Ó²£«~´N¦³6»õ¬ü¤¸¾P°â¹ê¤O¡A¤µ¦~¥i¯à½æ¨ì¹O8»õ¬ü¤¸¡B¤W¬Ý10»õ¬ü¤¸¡A¬O«½S«¬ÃÄ«~¡CÃĵØÃÄP1101n¬D¾Ô´N¬O³o¼Ëªº¹ï¤â¡C °Ý¡G¥Ø«ePV¯e¯fªºª¬ªp»P¥«³õ³W¼Ò¡H µª¡GPV¬O¤@ºØ¨u¨£¦å²G¯e¯f¡AP¯fì¦]¬°°©Åè³y¦å²ÓMªø´Á¤£¥¿±`»s³y¹L¦hªº¬õ¦å²y²ÓM¡A³y¦¨¦å²G¹L©óÂH¸Y¡A±`¦ñÀH¥Õ¦å²y»P¦å¤pªO¼Æ¶q¤]¼W¥[¡C´Nµ¥©ó¬O¦åÀùªº«e´Á¡C ¿©±wPVªº±wªÌ¥i¯à·|ÂàÅܦ¨°©ÅèÅÖºû¤Æ©Î¦åÀù¡A±`¨£¯gª¬¥]§tÀYµh¯t·w¡B²´µ²½¤¥R¦å¡Bµø¤O»Ùê¡B¦åÀ£¼W°ª¡B¥Ö½§ªx¬õ¡AÄY«¥i¯à¾ÉP¤£¥¿±`ªº¦å¤pªO¥\¯à¡BµÊ¸~¤j¡B¥þ¨°ÊÀR¯ß®ê¶ë¡B°©ÅèÅÖºû¤Æ¡A©MÂà¤Æ¦¨«æ©Ê°©Åè©Ê¥Õ¦å¯fµ¥¨Öµo¯gª¬¡C ¥Ø«e¬ü°ê¬ù¦³20¸U¦W¯f¤H¡A¼Ú¬w¦³¶W¹L17¸U¤H¡A¥§¡¤@ÓÀøµ{¹F7.5¸U¬ü¤¸¡A¥H20¸U¤Hªº¬ü°ê¼ç¦b¥«³õ¦ôºâ¡A¶W¹L¦Ê»õ¬ü¤¸³W¼Ò¡C¹L¥h¦³¤H»¡¡A©t¨àÃĬJµM¬O¨u¨£¯e¯f¡A¤£¥i¯à¦³¦Ê»õ¬ü¤¸ªº¥«³õ¡F¨ä¹ê³o¬O¤p¬Ý©t¨àÃĪº¹ê¤O¡C¦]¬°©t¨àÃĪvÀø¹ï¶HÁöµM¤£¨ì20¸U¤H¡A¦ý¨CÓÀøµ{³£¦³°ªÃBªºÃÄ»ù¡A¥BÀò±o·í¦a¬F©²ªº¸É§U¡A¦]¦¹¼ç¤O·¥¤j¡C |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/1/29 ¤U¤È 08:15:49²Ä 53 ½g¦^À³
|
³ÌªñÃĵØÃĨSÔ£·s»D,ˬO¦³¤@«h·s»D¡A´£¨Ñºô¤Í°Ñ¦Ò¡A¥i±¤Ó¤Hªº^¤å«Ü¯}(ì¨Ó^¤å¯uªº«Ü«n)¡A©È½Ķ¦³¿ù¡Aª½±µ¤Þ¥Îì¤å¡G Incyte bails on mid-stage study of Jakafi combo in colorectal cancer; shares down 12% premarket Incyte (NASDAQ:INCY) is down 12% premarket on light volume in response to its announcement that it terminated a Phase 2 sub-study, INCB 18424-267, assessing Jakafi (ruxolitinib) or placebo in combination with Bayer¡¦s (OTCPK:BAYRY) Stivarga (regorafenib) in patients with relapsed/refractory metastatic colorectal cancer with high C-reactive protein (CRP), a potential new indication for the drug. An interim analysis of the high CRP group revealed that ruxolitinib plus regorafenib failed to demonstrate a sufficient level of efficacy to justify continuing the study. Ruxolitinib, a JAK1/JAK2 inhibitor, is cleared in the U.S. for the treatment of a type of blood cancer called polycythemia vera and a bone marrow disorder called myelofibrosis. Regorafenib, a kinase inhibitor, is approved for the treatment of colorectal cancer and gastrointestinal stromal tumor. |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/1/28 ¤W¤È 11:27:26²Ä 52 ½g¦^À³
|
http://www.pharmaessentia.com/chinese/partners.html |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/1/28 ¤W¤È 11:24:00²Ä 51 ½g¦^À³
|
ÃĵتºÀu¶Õ 1¡BºØÃþ³Ì¦h:B,C¨x 2¡B¸}¨B³Ì§Ö¡G³£¤w¶i¤J²Ä¤T´Á 3¡B¥d¥q³Ì±j¡G¥]¬A¤T¦ì°|¤h 4¡B¤jÂå°|³Ì¦h:°Ñ»Pªº³£¬O°ê¤ºª¾¦W¤jÂå°| 5¡B°Æ§@¥Î³Ì¤p¡G¤zÂZ¯À¬O¤HÅé¦ÛÅé©Ò¨ã¦³¡A©Ò¥H¬O¤@ºØ§K¬ÌÀøªk 6¡B³Ì¬Ù¨Æ¡G¤G¬P´Á¥´¤@°w¡A¤ñ²{¤µÉ]±¤WªºÃ¹¤ó¤zÂZ¯À§óªø®Ä¡AÃĮħó«A |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2016/1/28 ¤W¤È 08:07:10²Ä 50 ½g¦^À³
|
¬Ý¨ÓC¨xÉ]³õÄvª§ÆZ¿E¯Pªº,¦b¦æ¾P¤è±6446±N¦³W¾Ô |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2016/1/28 ¤W¤È 08:04:32²Ä 49 ½g¦^À³
|
¦N¥ß¼w°ª»ùC¨xÃħð¥x¡A¨xª¢¸t¾Ô¨Ó¤F¡C°ê»Ú§Ü¯f¬r¤j¼tGilead¡]¦N¥ß¼w¡^¶}µoªº§ÜC¨x¯f¬r¤jÃÄSovaldi³Ì§Ö¤µ¦~3¤ë¦b¥x¤W¥«¡A·~¬É»{¬°¡AGilead¨xª¢ÃĨCÁû©w»ù¹O¤d¬ü¤¸¡A¥xÆW·sÃĤ½¥q¦³¬Û¹ï§Q°ò¡A§Ü¯f¬r§Þ³N»â¥ý¥þ²y¡C ·~¬É«ü¥X¡A¥xÆW²{¦³¶}µo¨xª¢ÃÄ«~ªº¤½¥q¥]¬AÃĵØÃÄ¡B¥Í±±¡B´º³Í¡B¤Ó´º¡B¤¤¤Ñµ¥¡A¨C¤@®a§¡¨ã³Æ¯S®íªº§Q°ò¡A²£«~¤W¥««á¡A¦b©w»ùµ¦²¤¤W±N³Ó¹LGilead²£«~¡A¥YÅ㥫³õ°Ï¹j¡C ¨ä¤¤¡AÃĵØÃĤ豫h¬Oªø®Ä«¬¤zÂZ¯À¡A¹L¥h¨xª¢ªvÀø¦h¥H¶Ç²Î¤zÂZ¯À·f°t§Ü¯f¬rÃĪ«¡A¦ý¶Ç²Î¤zÂZ¯À°Æ§@¥Î¤Ó¤j¡A¯f±w±`µLªk§Ô¨ü¦Ó¤¤¤îªvÀø¡AÃĵتº²£«~P1101¥b°I´Áªø¡B°Æ§@¥Î¤p¡A¦P®É¯àµ²¦X¨ä¥L§Ü¨xª¢¯f¬r²£«~¡A²£«~¤w¸g¦b¥xÆW¶i¦æÁ{§É¤T´Á¡C |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/1/21 ¤U¤È 04:46:43²Ä 48 ½g¦^À³
|
¤HÅé§K¬Ì¨t²Î³Ì°ò¥»ªº²Õ¦X¥i°Ï¤À¨â³¡¤À 1 ¥ý¤Ñ§K¬Ì:¥]¬A¥Õ¦å²y²ÓM G»Ä.¥Ö½§ªoà ¦å²G¤¤ªº²ÓM¶¡¯À ¥H¤Î¤zÂZ¯À ¥ý¤Ñ§K¬Ì¯à¦Û°Ê¥´«±³n®zªº¤J«I¼Ä¤H 2 «á¤Ñ§K¬Ì:«h¥]¬A¦hºØ¥Ñ¥Õ¦å²y¶i¤J¯Ý¸¢ ¥Òª¬¸¢ µÊŦ ¨xŦ ¸g¯S§O°V½m¥X¨Óªº¤Q´XºØ¤£¦P¥\¯àªº§K¬Ì²ÓM³æ¦ì ¤Þ¥Î¥X¦Û ¤£¤@¼Ëªº¦ÛµM¾i¥Íªk ¬ü°ê¦ÛµMÀøªk&Àç¾i¾Ç³Õ¤h §d¥Ã´¼ |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/1/21 ¤U¤È 12:54:50²Ä 47 ½g¦^À³
|
http://money.udn.com/money/story/5612/1390678-C¨xÃÄ«~¤§¤÷¨Ó¥x-´ª¦ñ§ð³° |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/1/21 ¤U¤È 12:48:54²Ä 46 ½g¦^À³
|
³oÀ³¸Ó´N¬O¤@ºØ§K¬ÌÀøªk. ¤zÂZ¯À¬O§Ṳ́HÅ饻¨Ó´N¦³ªºªF¦è ¥u¬O¶q¤£¨¬¡AµLªk²£¥Í¨¬°÷¤§§Ü¬r³J¥Õ¡AY¸É¥R¤§¡A ¦Û¯à²£¥Í¨¬°÷§K¬Ì¤O |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/1/21 ¤U¤È 12:39:45²Ä 45 ½g¦^À³
|
ÃĵØp1101 ¤zÂZ¯À¬O¡¨³Ì±µªñ¤W«Òµ¹¤HÅ饻¨¦ÛµM²£¥Íªº¤zÂZ¯À¡¨ §C°Æ§@¥Î¡Bªø®Ä©Ê¡A§ó«A®ÄªG¡A¤G¬P´Á¥´¤@°w¡AB¡BC ¨x³£¤w¶i¤J¤T´Á¡A ¥¼¨Ó¥un»ù®æ¦X²z¡AÀ³¦³«Ü¤jÄvª§¤O |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/1/21 ¤U¤È 12:06:24²Ä 44 ½g¦^À³
|
¡uC¨x¡v¤fªA·sÀøªk«µ®Ä 3Ӥ벬¡ 2016-01-21 °OªÌ§d«G»ö¡þ¥x¥_³ø¾É 59·³ªºªL¥ý¥Í5¦~«eµo²{¿©±w²Ä¤@«¬C«¬¨xª¢«á¡A±µ¨üªAÃÄ©Mª`®g¤zÂZ¯ÀªvÀø¡A¦ýÃĪ«°Æ§@¥ÎÅý¥L«Ü§xÂZ¡A¥B¯f±¡±±¨î®ÄªG¤£¨Î¡A¦]¦¹Å¥Âå®v«Øij¡A§ï´«·sªº¤fªAÀøªk3Ó¤ë¡A¦p¤µ´ú¤£¨ì¯f¬r¥B°·±dª¬ªp¤ñ¥H«e¦n¡C °ª¹Å§»©M¼B®¶÷~¨â¦ìÂå®vªí¥Ü¡AC¨x·sÃĪv¡²v¥i°ª¹F97%¡A±wªÌªL¥ý¥Í¡]¤¤¡^¤]ªí¥Ü¡A·sÃĪº°Æ§@¥Î¤ñ쥻ÃĪ«¤Ö¡C 5¦~«eµo¯f «e2¦¸ªvÀøµL¥\ C«¬¨xª¢¬O¾ÉP¥xÆW¤H¨xµw¤Æ©M¨xÀùªº¥D¦]¤§¤@¡C®Ú¾Ú¬y¦æ¯f¾Ç²Îp¡A¥xÆWC«¬¨xª¢±wªÌ¬ù60¸U¤H¡A¨ä¤¤¬ù¨â¦¨¥i¯àÂàÅܬ°¨xµw¤Æ¡C ªL¥ý¥Í»¡¡A¤§«eªAÃÄ©Mª`®g¤zÂZ¯ÀªvÀø°Æ§@¥Î«Ü¤j¡A¦b¥V¤Ñ®É·|¥X²{¥þ¨«D±`Äo¥B¥þ¨µL¤O¡Bµo¿N¡B±¼ÀY¾v¡B¹¼¤¤£®¶¡BÀYµh¡B¸¡Âm¡Bäú¤ß¡B¹Ã¦R¡AÁÙ¦³¥¢¯v¡BµJ¼{µ¥¯gª¬¡A¨¤ß³Æ¨ü·Î¼õ¡C¨S·Q¨ì§Ô@ªvÀø3Ó¤ë«á¡A©â¦åÀË´úC¨x¯f¬r¶q¤´¶W¹L¤d¸U¡AÅý¥L«Ü³à®ð¡C ª½¨ì«e¦~¤@¤ë±Ä¨ú·sªº¤fªAÀøªk«á¡A¤@¤Ñ¥unªAÃĤ@¦¸¡A¤@¶g«áÀˬd¡A¯f¬r¶q´N°¨ì300¦h¡A²Ä¤G¶g´N¤w´ú¤£¨ì¯f¬r¡C«ùÄòªA¥Î3Ó¤ë«á¡A¥Ø«e¥un©w´Á°lÂÜÀˬd¡A¨Åé¤]«ì´_°·±d¡A¥i¥H¥¿±`¤W¯Z¡B¹L¥Í¬¡¡A¥L¶}¤ß¦a»¡¡G¡u¦n¹³Àò±o·s¥Í¡C¡v ¥x¤jÂå¾Ç°|Á{§ÉÂå¾Ç¬ã¨s©Ò°ê®aÁ¿®y±Ð±Â°ª¹Å§»ªí¥Ü¡AC«¬¨xª¢ªvÀø¤è¦¡¤w¸g¶i¨B«Ü¦h¡A¤£¶·¥´°w¡B°Æ§@¥Î§C¡B¬Æ¦Ü¤@¤Ñ¥unªA¥Î¤@ÁûÃÄ¡Aªv¡²v°ª¹F97%¡C ¥x¤jÂå°|¤º¬ì³¡º[¨xª¢¬ã¨s¤¤¤ßÂå®v¼B®¶÷~¤]«ü¥X¡A·sÃĪvÀø¶g´Á±q24¨ì48Ó¤ëÁYµu¨ì8¨ì12¶g¡A¤]¯à´î¤Ö±wªÌªºt¾á¡C¤£¹L·sÀøªkn»ù¤£µá¡A¼B®¶÷~»¡¡A¾ãÓÀøµ{¬ùn¨â¦Ê¸U¤¸¡A¥Ø«e°·«OÁÙ¥¼µ¹¥I¡C |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/1/21 ¤W¤È 11:57:58²Ä 43 ½g¦^À³
|
§Ú·QÃĮġB»ù®æ¤Î¤W¥«®É¶¡ÂI¬O«ÂI¡A¸ò®É¶¡ÄvÁÉ¡AÄvª§ªÌ«Ü¦h¡C ¤Ó´ºC¨xÃÄ Àò¼Ú·ù±M§Q F*¤Ó´º¡]4157¡^¬Q¡]20¡^¤é«Å¥¬¡A¦Û¥D¬ãµo¤§C«¬¨xª¢¯f¬r¡]HCV¡^³J¥Õ酶§í¨î¾¯¥ñ©Ô·ç³¡]Furaprevir¡A¤S¦WTG-2349¡^Àò¼Ú·ù±M§Q¡A¨É¦³¼Ú·ù¦a°Ï35Ó°ê®a¡]States¡^ªº±M§Q«OÅ@¡C ¤Ó´º»¡¡AºI¦Ü¤µ¦~1¤ë18¤é¬°¤î¡A¤Ó´º¨ú±o¤§¥ñ©Ô·ç³±M§Q¤w¦³94¥ó¡A²[»\¼Ú·ù¡B¬ü°ê¡B¥xÆW¡B¤¤°ê¤j³°¡B¤é¥»¡B«n«D¤Î¿D¬w¡B¯Ã¦èÄõµ¥¥þ²y¥Dn¥«³õ¡C ¤Ó´º¬Q¤éªÑ»ù¦¬28.55¤¸¡A¤U¶^1.35¤¸¡C C«¬¨xª¢¦³¡uµLÁnªº±þ¤â¡v¤§ºÙ¡A¨C¦~±a¨«¤W»õÓC«¬¨xª¢¯f±w¡C®Ú¾Ú¬ü°ê¯e¯fºÞ¨î§½µo¥¬ªº³ø§i¡A¨C¦~¦]·P¬VHCV¡]C¨x¯f¬r¡^¦Ó¦º¤`ªºªº¤H¼Æ¤w¸g¶W¶VHIV¡]·R´þ¯f¡^¡C ¾¨ºÞ¤w¸g¦³¥iª½±µ§í¨îHCV¯f¬r¡]DAA¡^ÃĪ«¦b¼Ú¬ü¤é¥»µ¥¦a¤W¥«¡AµM¦Ó¤Ö¼ÆC¨x·sÃÄ»ù®æ©ù¶Q¡A¤]Åý¯f±wÓ¤H»P°·«O¨t²ÎÃø¥Ht²ü¡C ¥Ø«e¡A¥xÆW¶i¦æ¨xª¢·sÃĶ}µoªº¤½¥q¥]¬A¤Ó´º¦b¤º¡A¥t¦³¥Í±±¡BÃĵءB¤¤¤Ñ¡B®õ©vµ¥¤]§¡¦³¸ó¤J¡A¦U¥H¤£¦P§@¥Î¾÷Âà¡B°w¹ï¤£¦P°ò¦]«¬ªº¨xª¢¯f¬r¡A¤©¥HªvÀø¡C ¨ä¤¤¡A¤Ó´º¬OC¨x¯f¬rªº³J¥Õ酶§í¨î¾¯¡A¥t¥~¡A¥Í±±«h¬O§K¬ÌÀøªk§Ü¯f¬r¬Ì]¡AÂê©w¦P®ÉB¨x¡BC¨xªºªvÀø¡A¨Ã¿n·¥¸Õ±´¤£¦P¾AÀ³¯gªºªvÀø¥i¯à©Ê¡C |
|
|
·|û¡Gphdlhc10136950 µoªí®É¶¡:2016/1/21 ¤W¤È 11:26:37²Ä 42 ½g¦^À³
|
ÃĵØÃÄ C¨xphase3 ¶i¦æ¤¤¡A2018·sÃĹwp¤W¥« ¥«³õ«ç»ò¬Ý¡H ¦n¶QªºÃÄ §ÜC¨xn»ù¦Ê¸U http://health.udn.com/health/story/6012/1456455 2016-01-21 02:51:04 Áp¦X³ø °OªÌ³¯«BøÊ¡þ¥x¥_³ø¾É ¥xÆW¬ù¦³¤»¤Q¦h¸U¦W¢Ñ«¬¨xª¢±wªÌ¡A¶È¤@¦¨¥|±µ¨üªvÀø¡C¥Ø«e¤w¦³Ãļt¬ãµo¤p¤À¤l¤fªA§Ü¢Ñ¨x¯f¬r·sÃÄ¡A¶È»ÝªAÃĤTÓ¤ë¡A´N¦³¾÷·|ªv¡¢Ñ¨x¡A¥B°Æ§@¥Î¤p¡C¤£¹L¡AÂå®v«ü¥X¡A·sÃÄÁö¦³¾÷·|Åý¢Ñ¨x´N¦¹µ´¸ñ¡A¦ýÃĶO©ù¶Q¡A¾ãÓÀøµ{»Ý¤@¦Ê¸U¨ì¤T¦Ê¸U¤¸¡A¥Á²³®£t¾á¤£°_¡C ¶Ç²ÎªvÀø¢Ñ¨x¨Ï¥Î¤zÂZ¯À¥[¹p¤Ú«ÂªL¡A¥x¤jÁ{§ÉÂå¾Ç¬ã¨s©Òº[¤º¬ì¯S¸u±Ð±Â°ª¹Å§»ªí¥Ü¡A°ê¤º¦Ê¤À¤§¤K¤Q¥H¤Wªº¢Ñ¨x±wªÌ¡A±µ¨ü¤@¦¸ªvÀø«á¡A´N¤£Ä@·NÄ~Äò¡A¥Dn¬O¤zÂZ¯À¥i¯à³y¦¨µo¿N¡B±¼¾v¡B¥¢¯v¡B¹Ã¦R¡BµJ¼{µ¥°Æ§@¥Î¡AÅý±wªÌµLªk§Ô¨ü¡C¦ý¢Ñ¨xY¤£ªvÀø¡A¨â¦¨¥i¯àºtÅܬ°¨xµw¤Æ¡A³y¦¨¯fªp´c¤Æ¡C ¥x¤jÂå°|¸zG¨xÁx¬ì¥DªvÂå®v¼B®¶÷~ªí¥Ü¡A¤w¦³Ãļt¬ãµo§Ü¢Ñ¨x·sÃÄ¡A¤£»Ýn¨Ï¥Î¤zÂZ¯À¡A¥B´X¥G¨S¦³°Æ§@¥Î¡A¥Ø«e¦³¤T®aÃļt±À¥X¡A¤À§O¬O¦N¥ß¨È¡B¦ã§Bºû©M¥²ªv§´¡C·sÃĤw¦b¬ü°êµ¥¨ä¥L°ê®a¤W¥«¡A¦]¬°ÃĮĩM°â»ù¤Þµo¸ÜÃD¡A¦b°ê¤º¸ß°Ý«×¤]«Ü°ª¡C ÃÄ»ùÁö©ù¶Q¡A¦ý¦³¾÷·|§¹¥þªv¡¢Ñ¨x¡A¼B®¶÷~«ü¥X¡G¡u¤fªA·sÃĤW¥«¡A¥i±æ«Å§i¥xÆW¢Ñ¨x¥þ±·Àµ´¡C¡v¥Ø«e¤w¦³¦N¥ß¨ÈªºSovaldi¥Ó½Ð¨ú±o½ÃºÖ³¡¹ÃĸpÃÄÃÒ¡A³Ì§Ö¤T¤ë¥i±æ¤W¥«¡A¨ä¾l¨â®aÃļt«h³Ì§Ö¦b¤µ¦~¤»¤ë¨ú±oÃÄÃÒ¡C¾Ú¤F¸Ñ¡A¤T®aÃļt³£§Æ±æ¨ú±o°·«Oµ¹¥I¡C °·«O¸p°Æ¸pªø½²²Q¹aªí¥Ü¡A°·«O¸p±NµøÃļt´£¨Ñ¸ê®Æ¡A´NÃÄ»ù¡BÃĮġB¨ü¯q±wªÌ¦h¤Ö»P°·«O°]°Èºî¦X¦Ò¶q¡A¦A¨M©w¬O§_µ¹¥I¡C |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/1/21 ¤W¤È 09:19:40²Ä 41 ½g¦^À³
|
ºK¦ÛÃĵØÂåÃĤ½¶}»¡©ú®Ñ¤§ªÑ²¼ªì¦¸¤WÂdÃÒ¨é©Ó¾P°Óµû¦ô³ø§ip.41 A. ¯u©Ê¬õ¦å²y¼W¥Í¯g(PV) ¸Ó¤½¥qP1101 ¤w©ó2011 ¦~¤Î2012 ¦~¤À§O³q¹L¼Ú·ùEMA ¤Î¬ü°êFDAªº©t¨àÃÄ»{ÃÒ¡A¨ÃÂǥѸó°ê¬ãµo¦X§@ªº¼Ò¦¡¡A±ÂÅv¶ø¦a§Q±M·~©t¨àÃĶ}µo¤½¥qAOP Orphan ¦b¼Ú¬w¶i¦æªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera¡A¥H¤U²ºÙPV)ªºÁ{§É¸ÕÅç¡A¨ä²Ä¤G´ÁÁ{§É¸ÕÅç¼Æ¾Ú©ó2012¡B2013 ¤Î2014¦~¬ü°ê¦å²G¯e¯f¨ó·|(ASH/AJH)µoªí¡Aµ²ªG¬Û·íÀu²§¡G41 ¦ì¯f±wPV ¯f±wªº¸ê®ÆÅã¥Ü¡A¾ãÅé¯e¯f¤ÏÀ³²v¶W¹L90%¡A45~50%ªº¯f±w¦b¦å²G¾Ç°Ñ¼Æ¥¿±`¤Æ¤UÅã¥Ü§¹¥þ¤ÏÀ³¡A¥BµÊŦ¤j¤p¥ç¦³¥¿±`¤ÆÁͶաA¤@¦~¤§«á©Ò¦³¯f±w§¹¥þµL¶·©ñ¦å¡AªvÀø28 ¬P´Á«á¡AJAK2 °ò¦]¬ðÅܶq¤j´T°§C¡F¨Ì¾Ú°ê»ÚÂåÀø´Á¥Z(Blood/ August 2015)¡A¤À¤l¤ÏÀ³³Qµø¬°¬Oªv¡ªº§ïµ½¼x¥ü¡A¥t¥Ñ¤UªíP1101 »PJakafi ªvÀøPV ¤§Àø®Ä«ü¼Ð¤ñ¸û¥iª¾¡A¥Ñ©óIncyte ¤½¥q¥HJakafiªvÀøPV ªºRelife Á{§É¸ÕÅç¤w½T©wµLªk¹F¨ì³Ì²×Àø®Ä«ü¼Ð¡A¦Ó¨äResponseÁ{§É¸ÕÅ窺³Ì²×Àø®Ä«ü¼Ð¨Ã¤£¨ã²Ä¤@½u¥ÎÃĪº±ø¥ó¡A¬G¸Ó¤½¥qP1101 ¥¼¨Ó¦³¾÷·|¦¨¬°ªvÀøPV ªº²Ä¤@½u¥ÎÃÄ¡CAOP Orphan ¤w©ó2015 ¦~2 ¤ë§¹¦¨²Ä¤T´ÁÁ{§É¸ÕÅç¯f¤HÁ`¼Æ¦¬®×¡A¹wp2016 ¦~²Ä¤T©u¾ã²zÁ{§É¼Æ¾Ú§¹¦¨«á§Y¥i¦VEMA ¥Ó½ÐÃÄÃÒ¡A2017 ¦~²£«~¤W¥«¡C ¦¹¥~¡A¥Ñ©ó¸Ó¤½¥q¤w³W¹º¥HP1101 ©ó¼Ú¬w²Ä¤T´Á¤HÅé¸ÕÅ窺¼Æ¾Ú¦V¬ü°êFDA ´£¥X¥Ó½ÐÃÄÃÒ¡A¦]¦¹2017 ¦~¦³¥i¯à¦P®É¨ú±o¼Ú·ù¤Î¬ü°êFDA ®ÖµoªºÃÄÃÒ¡A¨Ï¥«³õµo®i©Ê§ó¶i¤@¨B±À¤É¡F®Ú¾Ú¿ò¶Ç¯e¯f®a®x¤â¥U(GeneticsHome Reference)»P¼Ú¬wOrphanet ´Á¥Z²Îp¡A¦ôp¬ü°ê¤Î¼Ú·ù¤À§O¬ù¦³19.3¸U¤Î13.3 ¸UPV ¯f±w¡A¦b¥Ø«e¯Ê¥FFDA ®Ö¥iªº¥ÎÃĤU¡A¨C¦~¼ç¦b°Ó¾÷¬Û·íÃe¤j¡A¥H¨C¦ì¯f±w¬üª÷10 ¸U¤¸ªº¥ÎÃÄÂåÀø¶O¥Î¦ôºâ¡A¨C¦~¼ç¦b°Ó¾÷¹F¬üª÷100 »õ¤¸¡C B. C «¬¨xª¢(°ò¦]Åé²Ä¤G«¬) ¥Ø«eªvÀøC «¬¨xª¢¤§¬ãµo¤è¦V¬°ª½±µ§Ü¯f¬rÃĪ«»Pªø®Ä«¬¤zÂZ¯À¤Î¹p¤Ú«ÂªL(Ribavirin)¦X¨ÖªvÀø¡A©Î¥H¤£¦P§Ü¯f¬rÃĪ«ªº²Õ¦XªvÀø¦Ó§¹¥þÁקK¤zÂZ¯À¡F¥Ñ©óP1101 ©ó¼Ú¬w¶i¦æªvÀøPV ªº¤G´ÁÁ{§É¸ÕÅç¼Æ¾ÚÀu²§¡A¬Û¸û©óRoche ªºPegasys ¤ÎMecrk ªºPeg-Intron §ó¨ãÄvª§Àu¶Õ¡A¬G¸Ó¤½¥q¥H¨â¶g¬°ªvÀø©P´Á¡A½Õ°ª¤zÂZ¯À¦b¼Ð·ÇÀøµ{ªº¨Ï¥Î¾¯¶q(Pegasys ªºÀøµ{¥Î¶q¬°¤@©P¤@¦¸¡A180£gg ¤@°w )¡A¦b¥xÆW¶i¦æ¥HP1101 ªvÀøºC©Ê¨xª¢ªº¤HÅéÁ{§É²Ä¤G´Á¸ÕÅç¡A¥Øªº¬°§ä¥X¨â¶g¤@¦¸ªºÀøµ{¡A¥Î©óªvÀøºC©ÊC «¬¨xª¢ªº³Ì¾A¾¯¶q¡]Dose Finding Studies¡^¡C¥Ø«e¸Ó¤½¥q¤wÀò±o¥xÆWTFDA ªº³\¥i¶i¦æ²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç¡A¨Ã¤w¦VÁú°ê¥Ó½ÐÁ{§É¸ÕÅç³\¥i¤¤¡A¥Ñ©óÁ{§É¸ÕÅç³]p¥H6 Ó¤ëÀøµ{¼Æ¾Ú¬°Æ[¹î¡A¬G²Ä¤T´ÁÁ{§É¸ÕÅç´Á¶¡¸ûµu¡C¹wp¦b2017¦~§¹¦¨HCV-GT2 ªº¤HÅé²Ä¤T´ÁÁ{§É¸ÕÅç¡A¨Ã©ó2018 ¦~¦VTFDA ´£¥X¥Íª«»s¾¯(BLA)¥Ó½Ð¤W¥«¡C C. Oraxol ¥Î©óªvÀøÀù¯g Oraxol «Y¥Ñ¬O¥ÑÁú°êHanmi »sÃĤ½¥q©Ò¬ãµo¡A¨Ã±ÂÅvµ¹¬ü°êCC ¤½¥q¶i¦æÃÄ«~¶}µo¡AÄÝ505b(2)·s¾¯«¬·sÃÄ¡AÃĵØÂåÃÄ«Y©ó2013 ¦~12 ¤ë¨ú±o¬ü°êCC ¤½¥q¿W®a±ÂÅv¦b¥xÆW©M·s¥[©Y¶i¦æ¶}µoOraxol® (¤fªAµµ§ü¾J)ªºÅv§Q¡C¥Ñ©óOraxol ¤w¦bÁ{§É¸ÕÅ綥¬qÀò±o¦b¦w¥þ©Ê»P¦³®Ä©Ê¨S¦³ºÃ¼{ªºµ²ªG¡A¬G¥Ø«e¸Ó¤½¥q¤w³W¹º¥Î¸ÓÃÄ«~©óÁú°ê¤Î«n¬ü¬wµ¥°Ï°ìªº¤G´Á/¤T´ÁÁ{§É¼Æ¾Ú¨Ã·f°t¤HÅéÃĪ«°Ê¤OÀËÅç(PK)¼Æ¾Ú¡A¦VTFDA ´£¥X·s¾¯«¬·sÃĪº¶}µop¹º¡A¥HÁYµuÃÄ«~¤W¥«¼f¬dµ{§Ç¤Î¶}µo¦¨¥»¡A¥H30 Ó¤ë®Éµ{¦ôp¡A¹w´Á2018 ¦~¨ú±oTFDA ®ÖãÃÄÃÒ¡A²£«~¤W¥«¾P°â¡C §Ú·Q¡Aµu´Á³æ´N³o¤T¶µ²£«~¦p¹w´Á¤W¥«ªº¸Ü(PV©ó2017¦~¡AC «¬¨xª¢°ò¦]Åé²Ä¤G«¬¤ÎOraxol©ó2018¦~)¡A¤wÄݹê¦b«D±`¤£Â²³æ¡C¤¤´Á2019¦~°_¡A³°Äò±N¦³¥i¯àET¡BB¨x¡BC «¬¨xª¢°ò¦]Åé²Ä¤@«¬¡BKX01µ¥¤W¥«¡Cªø´Áªº¸ÜÁÙ¦³PMF¡BCML¡B(PD-1+PD-L1+P1101)¤Î¦a¤¤®ü³h¦å/ÅI¤M«¬³h¦å·sÃĵ¥¡A¦pªG¤@¤@¹ê²{ªº¸Ü¡A¨ºªÑ»ù·|¦³¦h¤ÖÃzµo¤O? |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/1/20 ¤U¤È 01:36:21²Ä 40 ½g¦^À³
|
§Úªº§ÔªÌÀtÓ©Ê §ë¸êÃĵئh¦~¡AÀHµÛªÑ»ù°_¥ñ¡A§Ú¦Û¼J¬O°¦§ÔªÌÀt¡C ¤µ¤Ñ¬Ý¨ì°ê®õ°ÆÁ`ªL¬L§Êªº¤@¬q¸Ü¡G ¡un¦¨¬°¤j¤º°ª¤â¡E¡E¡E¡E³Ì«nªº¬O¤H®æ¯S½è¡A¹J¨ì¶Â¤ÑÃZ¶Ã¸³o¨Ç¬ðµo¨ÆÅÜ¡A ¤£·|·W¶Ã¡A¥B§ë¸ê®É¤£¯à¤H¤ª¥ç¤ª¡A¸ò§O¤H¤@ºÛ¸Á¶Ã§ë¸ê¡A«OÃÒ¿é銭¡A³Ì¦n¯à°ª§ÜÀ£©Ê¡C ¦W®Õ¡Aª¾¦W¬ì¨t¨Ã¤£ºÞ¥Î¡AµØº¸µó³\¦hª¾¦W¾Þ½L¤â³£¬O¾ú¥v¨t¡A¦Ó«Dª÷¿Ä¬ì¨t¡A ³o¨Ç©À¤å¬ìªº¤Ï¦Ó¨ã¦³§ó°ª«×§ë¸ê±Ó·P«×¡E¡E¡v ³o¨Ç¦~§Ú¬O¥Î¤ß¬ã¨s¡AY»{¦P¥¦¡A³ßÅw¥¦¡Aªø©ê¥¦¡C ¨C¤@ù¸ô³£¦¬Ã¬¬Õ¬Õ¡C |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/1/19 ¤U¤È 05:40:29²Ä 39 ½g¦^À³
|
2016¥þ²y¨î药¤QüL预测¡G¡§辉·ç-¦ãûثء¨¥Ï¨ä¥¦¤½¥q¤L条µó¡H 来·½¡G医药经济报 2016-01-19 ¨î药业ªº¦n时¥ú还¦b©µ续¡A药ª«¬ã发ªº¥X产²v预计将继续维«ù¦b¤@个°ª¤ô¥¡A§Y¨Ï¬ü国ªº¥Íª«类¦ü药热¼é§Y将¨ì来¡A¬Û较¤_预´Á¦Ó¨¥¡A专§Q过´Á对许¦h¤½¥q来说¤´µM¤£È±oü®¤ß¡C EvaluatePharma¤é«e发¥¬¤F医药¦æ业2016¦~«e¤报§i¡C报§i«ü¥X¡A·s药¤W¥««O«ùþÓ2013¦~开©lªº§Ö³t¨B¥ï¡A¤µ¦~预计将¦³¦h达12个畅销药ª«±À¥X¡A这¨Ç药ª«预计¨ì2020¦~会¨ú±o10亿¬ü¤¸ªº¦~销°â额¡CÉO¦¹¦P时¡A¤µ¦~¥u¦³6个¡§«½S¬µ弹¡¨药ª«会±临¥¢¥h¥«场专营权¡A¨ä¤¤¤§¤@ªº×¬ü乐(Humira)¡A预计还¤£会¾D¹Jª½±µªº竞争¡C ¦ý¦b这Ïú±¡§Î¤U¡A§ë资ªÌ对¥Íª«¨î药¦æ业ªº态«×¤´¦b°温¡C这¥Dn¬O¥Ñ¤_¬Fµ¦¨î©wªÌ对药«~©wɲÉOÁ×税¤£断¦a¹G问质ºÃ¡Aªý碍¤F§ë资ªÌªº热±¡¡C继续审¬d©wɲ¥i¯à¬O«d®z§ë资ªÌ«H¤ßªº¤@个¦]¯À¡A¦}导P¨î药¦æ业ªº进¤@¨B°温¡C ¥«场¦ôȪº³v渐°§C¦}¤£¨¬¥H¨Ï¦¬购ªÌ¦Y±¼¤j«¬¨î药¤½¥q¡A尽ºÞ许¦h¤½¥q将³Ì终»Ýn³q过¦¬购来«·s¶ñ补¨ä产«~线¡C2015¦~¡A¥u¦³辉·ç(Pfizer)ªö¨ú¦æ动§¹¦¨¤F¤@笔¤j«¬¦¬购¡C 2016¦~¡A¤j«¬¨î药¤½¥q将会继续¬¡跃¦b较¤p规¼Òªº¦}购®×¤¤¡A¦ý°£«D¦ôÈ«ù续°§C¡A这¨Ç¤½¥qªº¦¬购µ¦²¤将þÓ²´¤_«点业务¡A¦}¤£断¦¨长¥H§K¦Û¨³Q¦¬购¡A¤×¨ä¬O¬Û对较¤pªº¤½¥q¡C ¤£过¡A¹³ªü´µ§Q±d(AstraZeneca)¡B赛诺µá(Sanofi)¡B¦N§Q¼w(Gilead)这Ïú»Ýn¥[³t§¹µ½¦Û¨产«~线ªº¤½¥q¡A¥i¯à会¦b2016¦~¤Ï趋势¦Ó动进¦æ¤j©v¦¬购¡C ¨î药业NO.1¡G ú}击704亿¬ü¤¸¦~销°â额 ³q过对¦U¤j¨î药¤½¥q2016¦~药«~销°â额ªº预测¡AEvaluatePharma¦C¥X¤F¥þ²y¤Q¤j¨î药¤½¥qº]单¡C ¦Û从2011¦~辉·çªº¥ß´¶§´(Lipitor)¥¢¥h专§Q«O护¦Z¡A诺华(Novartis)©M辉·ç¤@ª½¦b争夺销°âº]º]º¡A¦b¦}购¬¡动¯Ê®uªº2016¦~¡A¤ñ«÷¤´将«ù续¡C¤£过¡AY辉·ç对¦ãûثتº¦¬购¯à¦b2016¦~§¹¦¨¡A¨ä将¦bº]单¤W¤@骑绝尘¡C 2016¦~¡A辉·ç-¦ãûثتº组¦X将会¥H704亿¬ü¤¸处¤è药ÉO«D处¤è药ªº销°â额夺±o¥þ²y³Ì¤j¨î药¤½¥qªº头衔¡A将诺华¥H¤Î¨ä¥¦¤j«¬药¥ø远远¥Ï¦b¨¦Z¡C ¦b没¦³¥ô¦ó¨ä¥¦«¤j¦}购ªº±¡úG¤U¡A诺华将稳©~²Ä2¦ì¡A这±o¯q¤_¨ä¤ß脏¯f药ª«Entrestoªº±À¥X¥H¤ÎGilenya¡BTasigna©MAfinitorµ¥专§Q药带来ªº«ù续销°â¦¬¤J¡C这®a·ç¤h¨î药¶°团¥¿¨üªý¤_创·s³¡门ªº¯Ê¥F¡A¤×¨ä¬O爱ûرd(Alcon)²´¬ì业务¥Ø«e¥¿处¤_¤@个¥缓´Á¡C 罗¤ó(Roche)将«O«ù¦b²Ä3¦Wªº¦ì¸m;¦b¿}§¿¯f领°ì¨ü®Àªº赛诺µá±Æ¦b²Ä4¦ì¡A随þÓPraluent©Mdupilumabªº±À¥X¡A¥H¤ÎAubagio©MLemtradaªº¼W长¡A赛诺µá将¦b2016¦~ªí现抢²´;Àq¨F东(Merck & Co)²Ä5ªº¦ì¸m¤]¬O¦w¥þªº;¦ý势§¡¤O敌ªº¸¯兰¯À¥v§J(GlaxoSmithKline)©MüL¥Í(Johnson & Johnson)将¦b²Ä6¦Wªº¦ì¸m¤W®i开争夺¡A§ó¦h来¦ÛGSK©I§l药ª«¥«场专营权ªº§¥®ø®§¡A©ÎªÌ§ó¦h来¦ÛüL¥ÍÉO¦ã§B维¦X§@ªºImbruvicaªº¦n®ø®§¡A³£¥i¯à§ï变这¤@§½±¡C ¦N§Q¼wªí现±o«Ü¦n¡A¨ä¤w经从¤¤«¬ |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/1/19 ¤W¤È 08:43:18²Ä 38 ½g¦^À³
|
ÃĵطsÃĸÕÅç ©ú¦~¹F°} ÃĵØÃÄ¡]6446¡^¬Q¡]18¡^¤é¤½§i¡A¸Ó¤½¥q¥¿¦¡±Ò°Êªø®Ä¤zÂZ¯À·sÃÄP1101C«¬¨xª¢¡]HCV GT2¡^ªvÀøªº²Ä¤T´ÁÁ{§É¸ÕÅç¡AY¶¶§Q¡A¹wp©ú¦~§Y¥i§¹¦¨¸ÕÅç¡A¨Ã¶i¦æ«áÄò·sÃĬdÅçµn°O¤u§@¡C ÃĵØÃĺX¤Uªº·sÃÄP1101©ó¥xÆW¤ÎÁú°ê¦P®É¶i¦æªºHCV GT2²Ä¤T´ÁÁ{§É¸ÕÅç¡A¸g¹Ãĸp¡]TFDA¡^®Öã¦b¥xÆW¶i¦æ¡CÃĵØÃĬQ¤éªÑ»ù¦¬173.6¤¸¡A¤Wº¦4.53¤¸¡C |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/1/18 ¤U¤È 06:16:23²Ä 37 ½g¦^À³
|
²£«~¤§Ävª§±¡§Î ¦å²G¼W¥Í¯e¯f¡]Myeloproliferative Neoplasms¡GMPNs¡^¦b¬ü°ê¤Î¼Ú¬w¬Ò³QÂk類¬° ¨u¨£¯e¯f¡]Rare Disease¡^¡Cµo®iP1101 ¬°¨u¨£¯e¯f¥ÎÃĪºµ¦²¤¡A·|°¾«¦b¥ý¶i°ê®a¦p¼Ú ¬ü¡B¤é¥»¡B¿D¬w¡Kµ¥¡A¦]¦¹P1101 ±N¨ÓªºÃÄ«~q»ù¦³·¥¤jªºªÅ¶¡¡A»Ýn¦A±j½Õªº¬O§Ú Ì©MJakafi ªº¯f±w¤H¤f¬O¨S¦³½Ä¬ðªº¡C ¦å²G¼W¥Í¯e¯f¥]§t¦å¤pªO¼W¥Í¯g¡]Essential Thrombocythemia¡AET¡^¡B°©ÅèÅÖºû¤Æ ¡]Primary Myeloid Fibrosis¡APMF¡^¤Î¯u©Ê¬õ¦å²y¼W¥Í¯g¡]Polycythemia Vera¡APV¡^¡C¯u ©Ê¬õ¦å²y¼W¥Í¯g¥Ø«e°£¤F¾a©w´Á©ñ¦å¨Ó´î§C¦å²G¿@«×¡A©Î¬OªA¥ÎÀù¯g¥ÎÃÄHydroxyurea ¨Ó±±¨î¥~¡A©|µL¦³Àø®ÄªºªvÀø¤è¦¡¡C¦ý¬O©ñ¦å©MHydroxyurea §¡·|¤Þ°_¨ä¥L¨Öµo¯g¡AÄY «ªº§ó·|¾ÉP¦åÀù¡]Leukemia¡^¡C¦b¼Ú¬ü¨â¤j°Ï°ì¡A¯u©Ê¬õ¦å²y¼W¥Í¯g¯f±w¤H¼Æ¦Xp°ª ¹F¼Æ¤Q¸U¤H¡A¦ý¬O¦]¬°ÁÙ¨S¦³¦³®ÄªºªvÀø¤è¦¡¡A©Ò¥H¤@¥¹¦³ªvÀø¥ÎÃÄ¡A¨ä¶O¥Î±N·|¬O ·¥¨ä©ù¶Qªº¡C·sÃÄJakafi ¦b2014 ¦~ªº12 ¤ë¸g¬ü°êFDA ®Ö㬰¯u©Ê¬õ¦å²y¼W¥Í¯gªº²Ä ¤G½u¥ÎÃÄ¡A¥Î©óHydroxyurea ªvÀøµL®Äªº¯f±w¡A¦]¬°P1101 ±N¨Ó¬O²Ä¤@½u¥ÎÃÄ¡A±N¨Óªº ¯f±w¥Ø¼Ð±N¬OJakafi ªº¤TÐù¡C¦]¦¹Jakafi ªº¥ý¦æ¤W¥«¹ïP1101 ªºPV¥«³õ¶}©Ý¬O¥¿±ªº:(1) ¼W¥[¤j²³¤ÎÂå¾Ç¬É¹ï¦¹¯e¯fªº«µø¡A¥[¤j¨D¶Eªº¯f¤H¼Æ¡B(2) Jakafi ÃÄ»ù©ù¶Q¨C¤H¨C¦~ ªvÀø¶O¥Î¬°11 ¸U5 ¥a¬ü¤¸¡C |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/1/18 ¤W¤È 11:50:14²Ä 36 ½g¦^À³
|
¹d¦ëºôªº§Y®É°T®§ ÃĵØÃÄ·sÃÄ©ú¦~¤W¥« Q2¤WÂd ¹w©w²{¼WÄw¸ê7.5»õ¤¸ ¹d¦ëºô°OªÌ±i¦°§» ¥x¥_¡@¡@2016-01-18 11:26¡@ ¦C¦L¥»¤å¡@¡U¡@ Âà±H¦n¤Í¡@¡U¡@ ¤j ¤¤ ¤p ¿³Âd·sÃļtÃĵØÃÄ(6446-TW)·sÃÄP1101¥Î©óªvÀøC«¬¨xª¢(HCV GT2)¤T´ÁÁ{§É¸ÕÅ祿¦¡¦b¥x±Ò°Ê¡A¹wp2017¦~©³¥Ó½Ð¼Ú¡B¬üÃÄÃÒ¡A·m§ð¥þ²y10»õ¤¸°Ó¾÷¡A¥Ø«e¤w»¼¥ó¥Ó½Ð¤WÂd¡A²Ä¤G©u§¹¦¨±¾µP¡A¦P®É¹wpµo¦æ5000±i²{¼W·sªÑ¡Aµo¦æ»ù¼Èq150¤¸¡A±N±oÄw¸ê7.5»õ¤¸¡C ·sÃÄP1101¬O·s¤@¥NPEGªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(PEG-P-IFN-£\ 2b)¡A²{¥¿¶i¦æ¥ÎªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡B¦å¤pªO¼W¥Í¯g¡B¦´Áìµo©Ê°©ÅèÅÖºû¤Æ¤ÎºC©Ê¯f¬r¤Þ°_¨xª¢µ¥Á{§É¸ÕÅç¡A¥Î©óªvÀøºC©Ê¨xª¢(HCV GT2)¡A¥Ø«e¥¿¶i¦æ²Ä¤T´ÁÁ{§É¸ÕÅç¡A¥Ø«e¶}µoªº·sÃÄ«~¶µ°ª¹F15Ó«~¶µ¡A¬ùªñ10Ó«~¶µ¶i¤J¤HÅéÁ{§É¡A5Ó·sÃij£¶i¤J¤T´ÁÁ{§É¸ÕÅç¡C ÃĵØÃÄP1101¬O°ª¯Â«×ªºªø®Ä¤zÂZ¯À¡A²{¦³¾AÀ³¯g¤À§O¬°ºC©Ê¨xª¢¤Î°©Åè³y¦å²ÓM¼W¥Í¯e¯f¡A¥xÆW±M§ðªºB¨x¤w¶i¤J¤T´ÁÁ{§É¡A ¦ÓC¨x¤w¤À§O¦b¥xÆW©MÁú°ê¥Ó½Ð¤T´ÁÁ{§É¤¤¡C ¥Ø«e¼Ú¬wªºPV¯f±w¬ù10¦h¸U¤H¡A¬ü°ê¤]¦³¬ù10¸U¦WªºPV¯f±w¡A¯u©Ê¬õ¦å²y¼W¥Í(PV)·sÃÄ¡A¤w¥¿¦¡©R¦W¡uBESREMi¡v¨Ã¶i¦æ¥þ²yµù¥U¡A¥þ¤O·m§ð¥þ²y10»õ¬ü¤¸°Ó¾÷¥«³õ¡C ÃĵØÃĥثe¤w»¼¥ó¥Ó½Ð¤WÂd¡A²Ä¤G©u§¹¦¨±¾µP¡A¦P®É¹wpµo¦æ5000±i²{¼W·sªÑ¡Aµo¦æ»ù¼Èq150¤¸¡C |
|
|
·|û¡GÁȤ£§¹10137061 µoªí®É¶¡:2016/1/18 ¤W¤È 11:35:59²Ä 35 ½g¦^À³
|
C¨xªvÀøªº²Ä¤@ù¸ô¡A¨º¦ì¤j¤j°Ñ¥[¡A¤º®e¬°¦ó |
|
|
·|û¡Gphdlhc10136950 µoªí®É¶¡:2016/1/18 ¤W¤È 11:34:48²Ä 34 ½g¦^À³
|
ÃĵØÂåÃÄ¡G¤½§i¥»¤½¥q·sÃÄP1101¥Î©óªvÀøC«¬¨xª¢(HCV GT2)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¤w©ó¤µ¤é¥¿¦¡±Ò°Ê ²Ä¤T¤Q¥|±ø¡@²Ä42´Ú 1.¨Æ¹êµo¥Í¤é:105/01/17 2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q·sÃÄP1101©ó¥xÆW¤ÎÁú°ê¦P®É¶i¦æªºHCV GT2²Ä¤T´ÁÁ{§É¸ÕÅç¡A·~¸gTFDA®Öã ¦b¥xÆW¶i¦æ¡A¥»¤½¥q©ó¤µ¤é¦b¤»ºÖ¬Ó®cÁ|¿ìHCV GT2²Ä¤T´ÁÁ{§É¸ÕÅ绡©ú¤j·|¡A¬ù¤ ¤Q¾l¦W¥D«ùÂå¥Í¤ÎÅ@¤h¦@¦P°Ñ¥[¥»¦¸¤j·|¡A¥»»¡©ú¤j·|¤w¶¶§Q§¹¦¨¡C 6.¦]À³±¹¬I:µo¥¬¥»«¤j°T®§ 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¬ãµo·sÃÄ¥N¸¹©Î¦WºÙ¡GP1101 (2)¥Î³~¡GP1101«Y·s¤@¥NPEGªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(PEG-P-IFN-£\ 2b)¡A²{¥¿¶i¦æ¥Î©ó ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡B¦å¤pªO¼W¥Í¯g¡B¦´Áìµo©Ê°©ÅèÅÖºû¤Æ¤ÎºC©Ê¯f¬r¤Þ°_ ¨xª¢µ¥Á{§É¸ÕÅç (3)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡GP1101¥Î©óªvÀøºC©Ê¨xª¢(HCV GT2)¡A¹wp¶i¦æ²Ä¤T´Á Á{§É¸ÕÅç (4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G (¤@)´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G P1101¥Î©óªvÀøC«¬¨xª¢(HCV GT2)²Ä¤T´Á ¤HÅéÁ{§É¸ÕÅç·~¸gTFDA®Öã (¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î (¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î (¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¥»¤½¥q²Ö¿n¤w§ë¤J¸ÓÁ{§É¸ÕÅ礧¬ÛÃö¶O¥Î¬ù46,569 ¤d¤¸ (5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G A.¹wp§¹¦¨®É¶¡¡G¹wp©ó2017¦~§¹¦¨ B.¹wpÀ³t¾á¤§¸q°È¡G¥»¤½¥q±N¤ä¥I°£¨Ò¦æÂåÀø·ÓÅ@(routine clinical care)¥H ¥~¤§Á{§É¸ÕÅç¬ÛÃö¶O¥Î¡C (6)·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A §ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡GÁȤ£§¹10137061 µoªí®É¶¡:2016/1/18 ¤W¤È 11:29:44²Ä 33 ½g¦^À³
|
http://m.cnyes.com/news/article3.aspx?&id=20160117233339783168610 |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2016/1/17 ¤U¤È 10:28:14²Ä 32 ½g¦^À³
|
¤½¶}»¡©ú®Ñ-104¦~²{ª÷¼W¸êµo¦æ·sªÑ½Z¥»--½s»s¤é´Á¬°104/12/23,415¶, ¥t¦³¤@¥÷¤½¶}»¡©ú®Ñ¬°"¥Ó½ÐªÑ²¼ªì¦¸¤WÂd¥Î½Z¥»"--½s»s¤é´Á¬°104/12/30,573¶, ¤ñ¹ï¹L¥Ø¿ý,«áªÌ¸ê®Æ¦h«Ü¦h,«Øij¬Ý«áªÌ§Y¥i. ¹q¤l¸ê®Æ¬d¸ß§@·~ http://doc.twse.com.tw/server-java/t57sb01 |
|
|
·|û¡G¤Óºò±i10135421 µoªí®É¶¡:2016/1/17 ¤U¤È 07:33:59²Ä 31 ½g¦^À³
|
³Ì·s¼W¸ê¤½¶}»¡©ú®Ñ¥X¨Ó¤F,¦³¿³½ìªºªÑªFªB¤Í¥i¥h¤U¸ü¨Ó¬Ý «GÂI 1,P1101(PV)¹wp2016¦~²Ä¤G©u¾ã²zÁ{§É¼Æ¾Ú§¹¦¨«á§Y¥i¦VEMA¥Ó½ÐÃÄÃÒ¡C 2,·sªºpµePEG-INF B(¦Ù¦×µäÁY¯g) Y¿ï«á´XÓ¤ëªÑ»ù¦]¤j½L¯}©³¦Ó¥X²{®£·W©Ê¤j¶^¤£¥¢¬°ªø½u¶RÂI ¥¼¨Ó¬ãµopµe¤Î¹wp§ë¤J¤§¬ãµo¶O¥Î µu¤¤´Á ªø®Ä«¬³J¥Õ½è·sÃÄ¡GP1101(ªø®Ä«¬¤zÂZ¯À)¥Î©óªvÀø¨ä¥L¾AÀ³¯g ¤p¤À¤lÃÄ¡G KX01(¿E酶§í¨î¾¯) Oraxol(¤fªAµµ§ü¾J) Oratecan(¤fªA³ß¾ðÆP) ¤¤ªø´Á «ùÄò¬ãµoªø®Ä«¬³J¥Õ½è·sÃÄ «ùÄòµo®i¤p¤À¤lÃĪ«¬ãµo§Þ³N «Ø¥ß²ÓM®è¶}µo§Þ³N¥¥x¤Î¼W¥[¨äÀ³¥Î Àù¯g§K¬ÌÀøªk·sÃĶ}µo(PD-1/PD-L-1³æ®è§ÜÅé) ÅI¤M¦æ³h¦å¯g¤ÎB«¬¦a¤¤®ü³h¦å¯g·sÃÄ PEG-INF B(¦Ù¦×µäÁY¯g) pµe¶}µo¤§·s°Ó«~(ªA°È)¶µ¥Ø A. ·s¤@¥Nªø®Ä«¬³J¥Õ½èÃĪ«¶}µo (P1101) ¥»¤½¥q±N§Q¥Î¤w«Ø¥ß¤§·sÃĬãµo¥¥x¡AÄ~Äò¶}µo¨ä¥L°ª¦¬益ªºªø®Ä«¬³J¥Õ½èÃĪ«¡C ¯÷´N¥Dn²£«~¶i«×ºKn¦p¤Uªí¡G P1101 (ªø®Ä«¬¤zÂZ¯À) ¼Ú¬w¡GP1101(PV)¡G AOPªºP1101(PV)²Ä¤T´Á¤HÅé¸ÕÅç¡A¤w¦b2015¦~2¤ë§¹¦¨¦¬®×¡A¹wp2016¦~²Ä¤G©u¾ã²zÁ{§É¼Æ¾Ú§¹¦¨«á§Y¥i¦VEMA¥Ó½ÐÃÄÃÒ¡C¥t¥~AOP©ó2015¦~6¤ë»P¼w°êFDA¶}·|¡A©x¤è«Øij±N²Ä¤GªvÀø«ü¼Ð¬ðÅÜ×´_(functional cure)²¾¬°²Ä¤@ªvÀø«ü¼Ð¡C¨u¨£¦å²G¯e¯fÀ³¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g ¬ü°ê¡G P1101(PV)¡G¥»¤½¥q¥H¼Ú¬w§¹¦¨ªº²Ä¤G´ÁÁ{§É¸ÕÅçµ² ªG¡A©ó2014¦~6¤ë¦V¬ü°êFDA¥Ó½Ð¦b¬ü°ê¶i¦æ¥HP1101ªvÀøPVªº²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç¡A¨Ã©ó2014 ¦~7¤ëÀò±o¬ü°êFDA¥¿¦¡¦P·N¡A¥¼¨Ó¥»¤½¥q±o¥H¥Î¼Ú¬w²Ä¤T´ÁÁ{§É¸ÕÅ窺¼Æ¾Ú¦V¬ü°êFDA¥Ó½Ð·sÃĤW¥«¼f¬d¡C ¨u¨£¦å²G¯e¯fÀ³¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g P1101(ET)¡G¹wp©ó2016¦~²Ä¤@©u¦V¬ü°êFDA»¼¥æ²Ä¤T´Á¤HÅéÁ{§É¸ÕÅ窺pµe®Ñ¡A¥»¦¸Á{§É¸ÕÅ窺³W¹º±N¥]¬A¬ü°ê¡B¥xÆW¤Î¼Ú¬w¡A¹wp2016¦~²Ä¤G©u¶}©l¶i¦æÁ{§É¸ÕÅç¬ÛÃö§@·~¡C ¨u¨£¦å²G¯e¯fÀ³¥Î©óªvÀø¦å¤pªO¼W¥Í¯g P1101(PMF)¡G¥Î©óªvÀø°©ÅèÅÖºû¤Æ¤]¤w©ó2014¦~¨ú±o¬ü°êFDA¨u¨£¯e¯f¥ÎÃÄ»{ÃÒ¡C¨u¨£¦å²G¯e¯fÀ³¥Î©ó°©ÅèÅÖºû¤Æ ºC©Ê¨xª¢ ¨È¬w¡G ©ó¥xÆW¦U¤jÂå°|¶i¦æªvÀøºC©ÊC«¬¨xª¢(°ò¦]Åé²Ä¤G«¬)¤§²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç¡C ¦P®É¤]¤w¦VÁú°ê¥Ó½Ð²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç³\¥i¡C B. Àù¯gÃĪ«¶}µo I.¤fªAÀù¯gÃĪ«¡G ¬ü°ê¤ô¤û«°ªºKinex»sÃĤ½¥q¤w©ó102¦~12¤ë¤¤¦¯±Â¤©¥»¤½¥q¿W®a¦b¥xÆW©M·s¥[©Y°õ¦æ¶}µoOraxol® (¤fªAµµ§ü¾J) ©MOratecan® (¤fªA³ß¾ðÆP)ªºÅv§Q¡Cµµ§ü¾J(paclitaxel)©M³ß¾ðÆP(irinotecan) ²{¦b³£³Q¼sªx¥Î©óªvÀøÀù¯g¡F¦p¨ÅÀù¡B§Z±_Àù¡B¤j¸zÀùµ¥¤@½u¥ÎÃÄ¡A¦ý¬O¦]¬°¥HÀR¯ßª`®gªºµ¹ÃĤ覡¡AÀù¯g¯f¤HÅ餺ÃĪ«¿@«×¬ðµM¼W¥[¡A ³y¦¨ÄY«³h¦å¤Î¥Õ¦å²y«ü¼Æ§C¤U¡A¦Ó¤Þµo·P¬Vµ¥¨Öµo¯g¡C Oraxol®©MOratecan®¸g¥Ñ¤fªAªºµ¹ÃĤ覡Åý¤HÅé§l¦¬¡A·~¸g¤HÅé¹êÅçÃÒ©ú¨ä¦bÅ餺¿@«×¥i¥Ã¤W¤É¦Ó¥B¯àºû«ù¸û¤[¡A¦]¦Ó¤j´T´î§C¦b¯f¤H¨¤Wªº°Æ§@¥Î¡C Oraxol® (¤fªAµµ§ü¾J)©MOratecan® (¤fªA³ß¾ðÆP)¬O¥ÑÁú°êHanmi»sÃĤ½¥qªºOrascovery¥¥x§Þ³N¶}µo¥X¨Ó¡Cµµ§ü¾J©Î³ß¾ðÆPª½±µ¸g¥Ñ¤fªA¡A³q¹L¸z¹D®É·|³Q PGP³J¥Õ½è±Æ¥XÅé¥~¦ÓµLªk³Q¸z¹D§l¦¬¡A©Ò¥H»Ýn¥Hª`®g¤è¦¡µ¹ÃÄ¡C Orascovery¨Ï¥Î¤Æ¦Xª«HM30181A¡A¯à±M¤@ªº§í¨îPGP³J¥Õ½è¡A¤¹³\µµ§ü¾J©Î³ß¾ðÆP¶i¤J¦å²G¡A³Q¨Åé§Q¥Î¡C PGP³J¥Õ½è§í¨î¾¯(HM30181A)¤w¸g¦bÁú°ê§¹¦¨²Ä¤G´Á¤HÅé¸ÕÅç¡A¦w¥þ©Ê¤Î¦¨®Ä¨}¦n¡A¦b¬ü°ê¤]¤w¸g¶}©lPhase Ib ªº¤HÅé¸ÕÅç¡Cȱo¤@´£ªº¬OHM30181A¤£³Q¤HÅé¸zG¹D§l¦¬¡A¦]¦¹¨S¦³¬O§_·|³y¦¨¬r©Êªº¦Ò¶q¡C ¥»¤½¥qpµe¹wp¦b105¦~®i¶}¥HOraxol®©MOratecan®ªvÀøÀù¯g¤§²Ä¤G´Á¤HÅé¸ÕÅç¡A´£¨ÑÀù¯g¯f¤H©MÂå¥Í¦bªvÀø¤W§ó¦nªº¿ï¾Ü |
|
|
·|û¡GÁȤ£§¹10137061 µoªí®É¶¡:2016/1/17 ¤U¤È 02:51:22²Ä 30 ½g¦^À³
|
¿ï«á¥Í§ÞÂåÀø§¤¤j¦ì ½Ð»°§Ö¤WÂd¡AÁÈ¡B¤jÁÈ¡BÁȤ£§¹http://appweb.cna.com.tw/webm/menu/afe/201601170133.aspx |
|
|
·|û¡GÁȤ£§¹10137061 µoªí®É¶¡:2016/1/17 ¤U¤È 02:36:17²Ä 29 ½g¦^À³
|
http://udn.com/news/story/7251/1448122-%E7%94%9F%E6%8A%80%E7%94%A2%E6%A5%AD%E5%89%8D%E6%99%AF%E5%85%89%E6%98%8E-%E6%96%B0%E8%97%A5%E8%82%A1%E4%B8%AD%E9%95%B7%E7%B7%9A%E5%8B%95%E8%83%BD%E7%9C%8B%E5%8D%87 |
|
|
·|û¡GÁȤ£§¹10137061 µoªí®É¶¡:2016/1/17 ¤W¤È 10:29:19²Ä 28 ½g¦^À³
|
¤jÅå©_¡I ¤jÅå©_¡I Å¥»¡±Æ©w¤WÂd¼f¬dn¶}©l¤F¡H¡I ¨º´N´£¦¤GÓ¤ë¡A«á±¬yµ{¦A¥[§Ö¡A«Ü§Ö´N·|±¾µP¡A¡§¥Í§Þµo¥ú¡A¥[³t¦³²z¡¨¡C¨ì®Éªk¤H¡B¥~¸ê¡B°òª÷¡A¦@Á¸²±Á|¡AÅý¤j®a¦ÂIÁÈ¡A¤@ª½ÁÈ¡AÁȤ£§¹¡I |
|
|
·|û¡Gphdlhc10136950 µoªí®É¶¡:2016/1/16 ¤U¤È 09:16:51²Ä 27 ½g¦^À³
|
¤p^¤j Incy ªº¤j¶^¡Aì¦]¬OÃĵØÃIJ£«~ªºÄvª§¡H ¤£ºÉµM¬O À³¬O¾ãÅéÀô¹Ò¤£¨Î¡ANBI¾ãÅé¤UשÒP¡A¦P®É¡A¤£ÁÈ¿úªº¤½¥q×¥¿³Ì¤j(ÁöµMJakafy ·~ÁZ¤´°ª¦¨ªø) 2.Incy ²£«~Jakafy ¥Î©óPV(¤G½u)/MF ¥~°êªk¤H¦ô2018¦³10»õ¬ü¤¸¥H¤Wªº·~ÁZ 3.ÃĵØÃÄ P1101 PV ¥Î©ó¤@½u(¤T¿©ójakafy ¾A¥Î¯f±w¼Æ¡A¥B¦³ªv¡¾÷·|) ¥t ³Í°ò¦ô¥«¦û²v 10% ´N¦³11.3»õ¬ü¤¸ ¥t AOP¦Û¦ô¨ä±ÂÅv½d³ò¤ºªº»Ý¨D´N¦³10»õ¬ü¤¸ ¨º ²Î¤@§ëÅU ¥þ²y¥«¦û50% ¥þ²y10»õ¬ü¤¸¡H¡H¡H »Ý§ó¶i¨B¤F¸Ñ¨ä®t²§ |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2016/1/16 ¤W¤È 07:57:48²Ä 26 ½g¦^À³
|
¤Þ¥Î²Î¤@§ëÅU¸ê®Æ¡G ÃĵØPV¡G¥þ²y¥«³õ10»õ¬ü¤¸¡C¨ú±o¥«¥e²v50%¡C ¸ê®Æ¨Ó·½¡G°]°TÂù¶g¥Z494´Á¡C ... INCYTE¬Q¦¬76.95¬ü¤¸,¦p³ø¾É¥¿½T, ¤ÏÀ³¦bªÑ»ù¤W´N¥iª¾,¤v¸I¨ì¥i·q¹ï¤â¤F,±q°ªÂI¤TÓ¤ë¤v¤U¶^1/3 ¨º¨ì¦~©³ªÑ»ù©Î³\·|¸y±Ù.¦]ÃĵØPV¡G¥þ²y¥«³õ10»õ¬ü¤¸¡C¨ú±o¥«¥e²v50%¡C |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/1/15 ¤U¤È 12:54:41²Ä 25 ½g¦^À³
|
http://mpn-japan.org/menu004 |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/1/15 ¤U¤È 12:45:39²Ä 24 ½g¦^À³
|
¤pªQ«h¤Òªº´Â¸t¤§®È ¥t¥~¡A§ÚÌ°Ñ¥[¬ã°Q·|¤§¤H対Norio Komatsu¤@©w¦L¶H²`¨è¡C ¡]§Úªº¤T¸}¿ß¤é»y¬£¤£¤W³õ¡A¤j®aÁ¿^»y¡^¡C ¥L¬OMPN Japan ³Ì³»¦yªº±M®a¡A«ÜÅå³Y¥xÆW¦³³o»ò¦nªºßÓ¡A¥L§Æ±æMPN Asia ¤U¤@©¡¯à¦b ¤é¥»Á|¦æ¡A¦pªGÃĵدà°Ñ¥[¤~¦³·N¸q¡C |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/1/14 ¤U¤È 11:13:03²Ä 23 ½g¦^À³
|
¸É¥R1/9 MPN Asia ¥Áµø³ø¾É ¬ü°êMayo ClinicÂå¾Ç°|±Ð±ÂRuben A.Mesa¡G ³oÓ·|ij¯S§O»EµJ¦b§ä´MºC©Ê°©Åè¼W¥Í¯g¯f¤Hªº·sªvÀø¤èªk»PªvÀøµ²ªG¡A¨ä¤¤¡A¦³¤@Ó»â°ì¬O¦b´M§ä·s¤@¥Nªø®Ä«¬¤zÂZ¯À¡A¹ï©ó¦¹ºC©Ê¯e¯fªºªvÀø¡A¥]¬A¹ï§K¬Ì¨t²Îªº¼vÅT¡C ¼w¦{¤j¾Ç¦w¼w¥ÍÀù¯g¤¤¤ß±Ð±ÂSrdan Veratovsek¡G §Ú«Ü°ª¿³¦³¾÷·|¨Ó¥xÆW°Ñ¥[¥xÆWÁ|¿ìªº²Ä¤@©¡MPN¨È¬w·|ij¡A§Æ±æ¤§«á·|«ùÄòÁ|¿ì¡A¤]Åý§ÚÌ¥i¥H©M¥xÆWªº¤½¥q¦X§@¡A¬ãµo·s¥X·s¤@¥N¤zÂZ¯À¡C ¤Ú¾¤Diderot¤j¾ÇÂå¾Ç°|±Ð±ÂJean Jacques Kiladjian¡G ²{¦b§Ú̦³¥O¤H®¶¾ÄªºªvÀø¥ÎÃÄ¡A¥Dn¥]¬A¤zÂZ¯Àalpha¡A³o¬O¥Ø«e¥DnªºªvÀøÃÄ«~¡A§Ú̦³³\¦hÁ{§É¥H¤Î¥Íª«¹êÅçµ²ªGÅã¥Ü¡A³o¬O¥i¯à¬OªvÀø¯f¤Hªº³Ì¦nÃĪ«¡C |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/1/14 ¤U¤È 01:04:15²Ä 22 ½g¦^À³
|
°]°T³ø¾É¡G ¤Þ¥Î²Î¤@§ëÅU¸ê®Æ¡G ÃĵØPV¡G¥þ²y¥«³õ10»õ¬ü¤¸¡C¨ú±o¥«¥e²v50%¡C ¸ê®Æ¨Ó·½¡G°]°TÂù¶g¥Z494´Á¡C |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/1/13 ¤U¤È 07:40:33²Ä 21 ½g¦^À³
|
^药¥ø¦¬购¬ü¨u见¯e¯f¨î药°Ó 来·½¡G¥_¨Ê°Ó报 2016¦~01¤ë13¤é 2016¦~药¥ø¦¬购²Ä¤@笔¤j«¬¥æ©ö来¦Û^国¨î药¥¨头Shire¡C¬Q¤é¦³®ø®§称¡AShire¤wÉO¬ü国¨u见¯e¯f¨î药°ÓBaxalta达¦¨协议¡A将¥H320亿¬ü¤¸ªºÉ²®æ对Baxalta进¦æ¦¬购¡A这¬O¨³³t¾ã¦Xªº医疗护²z¦æ业¦b·sªº¤@¦~达¦¨ªº²Ä¤@°_¥¨额¦}购¥æ©ö¡C Õu¤F¸Ñ¡AShire¤_¥h¦~7¤ëº¦¸±µ¬¢Baxalta¡A¦}´£¥X¤F¨CªÑ45.23¬ü¤¸¡B总ɲ300亿¬ü¤¸ªº¦¬购n约¡AµM¦ÓBaxalta认为Shireªº报ɲ¦}¥¼¤Ï¬M¥X¨ä§@为¤@®a·s¤W¥«¤½¥qªº潜¤O¡A¦]¦¹¤©¥H©Ú绝¡C¦¹¦Z¡ABaxalta¤@ª½¦b寻¨D§ó°ªªº¦¬购ɲ®æ¡A¦ÓShire¦b过¥h6个¤ë¤¤¤]¤@ª½§V¤O争¨úÉOBaxalta¦X¦}¡C³Ì终¡AShire³q过¦b¦¬购¤è®×¤¤¥[码现ª÷¡A将这®a¥Í产¨u见¦å²G¯f¡BÀù¯g¥H¤Î§K¬Ì¨t统¯¿乱药ª«ªº¨î药°Ó¦¬¤JÅn¤¤¡C®ÚÕu¦¹¦¸¥æ©ö条´Ú¡ABaxaltaªÑ东¤â¤¤¨CªÑªÑ²¼¥i获±o18¬ü¤¸现ª÷¡A¥[¤W0.1482ªÑShire¬ü国¦s¦«ªÑ²¼¡]ADS¡^¡A¥H¤W©P¤¦¬盘ɲ计ºâ¡A¬Û当¤_¨CªÑ45.57¬ü¤¸¡C©MShire¦¬购Baxaltaªº¥æ©ö¬Û¤ñ¡A过¥h12个¤ë¤¤¡A¨î药¦æ业¥u¦³两笔¦}购¥æ©öªºª÷额§ó¤j¡A§Y¬ü国¨î药¥¨头辉·ç¡]Pfizer¡^1600亿¬ü¤¸¦¬购¦ã尔«Ø¡]Allergan¡^¡A¥H¤Î±è¥Ë¡]Teva¡^405亿¬ü¤¸¦¬购¦ã尔«Øªº¥é¨î药业务¡C ¤½开资®Æ显¥Ü¡AShire总³¡¦ì¤_爱尔兰³£¬fªL¡A¥Í产¥Î¤_¦hÏú¯e¯f¡]¥]¬A¦h动¯g©M¤z²´¯f¡^ªº药ª«¡A专ª`¬ã发¥Î¤_ªv疗¨u见¯e¯fªº药ª«¡CShireªí¥Ü¡A预计¦b¥¼来¤¦~¤¤将±À¥X30Ïú·s药¡CY¦¹¦¸对Baxaltaªº¥æ©ö顺§Q进¦æ¡ABaxalta©Î将总³¡迁©¹爱尔兰¡A从¦ÓÓì¥Î较§Cªº税²v¡C业内认为¡A该¥æ©ö标§Ó着2016¦~医疗«O°·领°ìªº¦}购¬¡动将¥H强势开§½¡C¥h¦~¡A这¤@领°ìªº¦}购¥æ©ö屡创历¥v纪录¡A®ÚÕu汤´Ë¸ô³z数Õu¡A¥þ²y医疗«O°·领°ì¥æ©ö总规¼Ò¥h¦~达¨ì¤F6730亿¬ü¤¸¡C该¥æ©ö还¥Y显¥X¡A针对¤p¸sÊ^¯f¤Hªº¨u见¯f药ª«¬O¤@项«Ü¦³§l¤Þ¤Oªº业务¡A¨C¦~¥i¥H为¨î药°Ó´£¨Ñ数¤QÉE¬ü¤¸ªº¦¬¤J¡C ¬Û关阅读 |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2016/1/13 ¤U¤È 04:09:50²Ä 20 ½g¦^À³
|
1/9 MPN Asia ¥Áµø³ø¾É is good news! ²{ÀR«Ý¬O§_¦³Ãѳfªº°ê»Ú¤j¼t¨Ó¥x¦X§@©ÎÁp·ù,·íµM¥~¸ê¨é°Óªº±ÀÂˤ]§Y±N®i¶}. |
|
|
·|û¡GÁȤ£§¹10137061 µoªí®É¶¡:2016/1/13 ¤W¤È 10:21:59²Ä 19 ½g¦^À³
|
¨ä¤¤³Ì§Öªº¬õ¦å²y¼W¥Í¯gPv,¼Ú¬w¢°¢³°êªº¹êÅç¡A¤UÓ¤ë´N¥þ³¡µ²§ô¡A§¹¦¨²Ä¤T´Á¡AÀµ¨D¥~°ê©M¥xÆWªº¬ì¾Ç®a»°§Ö´£¥XßÓµý¥Ó¿ì¡A¤µ¦~·d©w¡Acash in¡A ¤j®aÁȤ£§¹ |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/1/12 ¤U¤È 10:15:21²Ä 18 ½g¦^À³
|
·PÁ·Ƥj´£¨Ñ1/9 MPN Asia ¥Áµø³ø¾É ¨u¨£¦å²G¯e¯f¡A±`±`¥O±wªÌ®a®x¡A¬Æ¦ÜÂå®v±¹¤âµLµ¦¡I¦ý²{¦b¡A¥xÆWÂå¬É¬ãµo¥X·sÃÄ¡A±N¥i¯àÀ°§U±wªÌ¹ï§Ü¯fÅ]¡AÁöµMÁÙ¦bÁ{§É¶¥¬q¡A¦Ü¤Ö1¨ì2¦~¤~·|¤W¥«¡C¿ï¦b¤µ¤Ñ¡]1¤ë9¤é¡^Á|¿ìªº¡u¨È¬w°Ï¦å²G¼W¥Í¯e¯f·|ij¡v¤W¡Aµoªí¬ã¨s¦¨ªG¡A¨ä¤¤ÁÙ¦³¤£¤Ö°ê»Ú«¶q¯ÅÂå®v»P·|¡C ºtÁ¿ªÌ¥XÃDÀH°ó´úÅç¡A¥x¤UÆ[²³°¨¤W§@µª¡C³o¥i¤£¬O¯q´¼¹CÀ¸¡A¦Ó¬OÂå¾Ç¬ã°Q·|¡A¤£¤Ö°ê»Úª¾¦WÂå®v»ô»E¤@°ó¡C »P°ê»Ú±µy¡A¥xÆWº«×Á|¿ì¡u¨È¬w°Ï¦å²G¼W¥Í¯e¯f·|ij¡v¡AÁܽХxÆWÁÙ¦³¼Ú¬ü¡B¤é¡BÁú¡B¤¤°êªº³»¦yÂå®v¡A¦@¦P¬ã°Q¥æ´«·N¨£¡C¥Ø«e¤¤j¨u¨£¦å²G¯e¯f¡A¥]¬A¯u©Ê¬õ¦å²y¼W¥Í¯g¡B°©ÅèÅÖºû¤Æ¡B¦å¤pªO¡B¥Õ¦å²y¼W¥Í¯g¡AÁÙ¦³¦hµo©Êµw¤Æ¯g¡AÄY«¬Æ¦Ü·|¤Þµo¦åÀù¡AÅý¤£¤Ö¨u¯f®a®x±¹¤âµLµ¦¡A¦p¤µ¥xÆWÁ{§É¬ã¨s¡A¦³¤F·s¬ð¯}¡C ¬ã¨sµ²ªG¤w¸gµoªí¦b¦h½g°ê»Ú´Á¥Z¡A±M®a¦ôp¦A¹L2¦~¬ãµo´N¯à¤W¥«¡AÃĪ«¬ã¨s·s¬ð¯}¡A¤£¥u¬°¨u¯f®a®x±a¨ÓºÖµ¡A§óÅý¥xÆWÂå¾Ç»â°ìÁÚ¶i¤@¤j¨B¡C¡]¥Áµø·s»D³¯Ã¢¶v¡BJ§Æõ¥x¥_³ø¾É¡^ |
|
|
·|û¡GDesert10136931 µoªí®É¶¡:2016/1/12 ¤U¤È 10:01:53²Ä 17 ½g¦^À³
|
«Ü¦¨¥\¡A¥O¤H·P°Êªº¬ã°Q·|¡A²Ä¤@¦¸ÁܽХ@¬É¤@¬y¦å²G±M®a¡A¥xÆW¯à¯¸¤W¥@¬É»R¥x¡A ¾aªº¬O³o¨ÇÀqÀq¦bÃĪ«¬ãµoªº¬ì¾Ç®aÌ¡CÃĵإ[ªo¡I |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/1/12 ¤U¤È 03:44:43²Ä 16 ½g¦^À³
|
1/9 MPN Asia ¥Áµø³ø¾É https://m.youtube.com/watch?feature=youtu.be&v=0a9x9jkCT58 |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/1/11 ¤U¤È 05:13:42²Ä 15 ½g¦^À³
|
辉·ç105个药«~齐涨ɲ¡A闹þ样¡H 来·½¡G医药Å]¤è数Õu 2016-01-09 Õu¥þ²y«H®§±¡报ªA务°Ó«Â¬ì³zÅS¡A辉·ç¤½¥q¦Û2016¦~1¤ë1¤é°_调¼W¤F100¦h个药«~ªºÉ²®æ¡A³¡¤À药«~ªº涨´T°ª达20%¡A¨ä¤¤¯«经¯f²z©Ê¯kµh药ª«Lyrica¡]´¶·ç¤ÚªL¡^ªºÉ²®æ调¼W¤F9.4%¡A伟ôViagra¡]¦è¦a¨º«D¡^ªºÉ²®æ调¼W¤F12.9%¡A¨Å¸¢Àù·s药Ibrance¡]palbociclib¡^ªºÉ²®æ调¼W¤F5%¡A辉·ç随¦Z对¦¹®ø®§¤©¥HÚÌ认¡C Lyrica¦b2014¦~ªº¬ü国¦a区销°â额¬O23亿¬ü¤¸¡AViagraªº2014¦~¬ü国销°â额¬O11亿¬ü¤¸¡AIbrance¦b2015¦~2¤ë刚获±oFDAªº¥[³t§åã¡A当时©wɲ为9850¬ü¤¸/¤ë¡]11.82ÉE¬ü¤¸/¦~¡^¡C ·ç银证¨é¦b¤@¥÷报§i¤¤´©¤Þ¤F«Â¬ìªº数Õu¡C·ç银证¨é称¡A辉·ç将§ÜÕa³Ö药Dilantin¡B»Û¿E¯À药ª«Menest¡B¤ß绞µh药ª«Nitrostat¡B¤ß«ß¤£齐药ª«Tykosyn¥H¤Î§Ü¥Íª«¯ÀTygacilªºÉ²®æ³£调¼W¤F20%¡C辉·ç¦¹¦¸涨ɲªº药«~为105个¡A没¦³¥ô¦ó药«~°É²¡C辉·ç¤½¥q发¨¥¤HSteven Danehy©|¥¼对¦¹进¦æÚÌ认¡C 辉·ç¦}¤£¬O°ß¤@涨ɲªº药¥ø¡C数Õu¬ã¨s¤½¥qTruveris发现¡A¬ü国处¤è药ªºÉ²®æ¦b2014¦~¼W长¤F10.9%¡A¨ä¤¤专§Q药ª«ªºÉ²®æ¼W长¤F15%¡C 辉·çÉOAllergan¦X¦}¥H¦Z将诞¥Í¥þ²y³Ì¤jªº药¥ø¡A辉·çªº总³¡¤]将·h©¹爱尔兰¡A这¤]¬O¬ü国历¥v¤W³q过¦}购°§C税¦¬¤ä¥Xªº³Ì¤j¤½¥q¡C奥¤Ú马¬F©²将¦¹类税¦¬Ë¸m¥æ©ö视为¤@Ïú¤£爱国ªº¦æ为¡A¦}尝试¥ßªk¥[¤j¦¹类¥æ©öªº难«×¡C ¥Á¥DÐÞÔ选¤H§Æ©Ô¨½¡P§JªL顿¤]©I©Iªö¨úªý¤î类¦ü¥æ©öªº±¹¬I¡C§Æ©Ô¨½ªº竞选对¤âBernie Sanders议员©M¦@©MÐÞÔ选¤HDonald Trump¤]发¨¥©á击¤F辉·ç©MAllerganªº¦}购¥æ©ö¡C 辉·ç¦b2014¦~ªº¥þ²y¥Íª«¨î药销°â¦¬¤J为457亿¬ü¤¸¡A¦b¬ü国¦a区ªº销°â¦¬¤J为172亿¬ü¤¸¡CÉO¦¹¬Û应¡A辉·ç2014¦~ªº¬ã发¤ä¥X为84亿¬ü¤¸¡A销°âºÞ²z¦¨¥»为141亿¬ü¤¸¡]§t广§i费¥Î¡^¡A¦^购ªÑ²¼¤ÎªÑ东红§Q¦X计120亿¬ü¤¸¡C辉·ç将¦b2016¦~2¤ë2¤é报§i2015¦~ªº业绩¡C ¬Û关阅读 2016-01-11 |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/1/11 ¤U¤È 12:46:37²Ä 14 ½g¦^À³
|
§i§O2015¡A¥xÆW¥Í§Þ¬É¦b¥h¦~ú¥XªºÀu¨q¦¨ÁZ¡A©Î³\¥i¥Ñ¬ü°ê¥Í§Þ»sÃÄÁͶմM§ä¥xÆW·s¥D¬y¡C ¤@¡B¥ÑÀø®Ä§ä¥D¬y¡G»P°ê»Ú²{¦³ÃĪ«¤ñ¸û«Ü¦h¤H¥H¬°Á{§É¤¤ªº·sÃÄ«ÜÃøµû¦ô»ùÈ¡A¥u¬Oª£¹Ú¦Ó¤w¡A¨ä¹ê¤£ºÉ¨äµM¡C¦³¨ÇÃĪ«¦b»P¹ï·Ó²Õ¬Û¤ñ®É¡A¤w¥i²¤ª¾Àø®Ä¡F¦pªG¹ï·ÓÃĪ«¤S¬O°ª»ùÃÄ¡A«h¥¼¨ÓÀ禬§ó¦³°Ñ¦ÒÈ¥i¨Ñ²{®É±À¦ô¡C µû¦ô¤èªk¦³«Ü¦h¡A¨Ò¦p²{¦bÁ¿¨sÃĪ«ªºªvÀø¾÷¨î¡]Mechanism of Action¡^¡A§Y¸ÓÃĦp¦óªvÀø¯e¯fªºì²z¡A¥Ø«e«Ü¦h³£¬O§Q¥Î¡u¤À¤l°T¸¹¶Ç¾É Molecular Pathway¡v¨Ó¸ÑÄÀÃĪ«¤À¤l¹ï²ÓMªºªv¯fì²z¡A¤×¨ä¦bÀù¯gÃĪ«¤èªk¡A¯à¹ïFDAÁ¿¥X²M·¡ªºªvÀø¾÷¨î¡A¤ñ¸û¦³¾÷·|Àò±o»{¦P¡C ¥xÆW¦b¤À¤l°T®§¶Ç¾É¤W¡A²`¤J¶}µo·sªv¯f¾÷Â઺¤½¥q«Ü¦h¡A¨Ò¦p¡A¥Í±±°ò¦]ªº¡uT²ÓM§K¬ÌªvÀø¥¥x¡v¡B¥xºÍªº¡uÀù¯g·F²ÓM¥h°£¡v¡B¥ÍµØªº¡uDNA×´_¡vµ¥¡C ¦³¨Ç¤½¥q«h¬O§Q¥Î¤wª¾¾÷¨î¡A¦ý¤ñ¹ï¤â¤½¥q§ó¶i¤@¨B´x´¤¤W´åÃö¥d¡A¬G¤ñ°ê¥~¤½¥q§ó¨ã¼ç¤O¡A¨Ò¦pÃĵتºªø®Ä¤zÂZ¯À¤ñ¹ï¤âÃĪ«JakafiªºJak 1/Jak2§í¨î¾¯§ó¤W´å¡A¦Ó¥B¤zÂZ¯À¨ã¦³¼W¥[§K¬Ì¯à¤O¡A¥i²M°£Àù²ÓMµ¥¤wª¾¥\¯à¡A¦ýJakafi¤@¦¸Àøµ{©w»ù11¸U¬ü¤¸¡A³o¤]ÅýÃĵز£«~§ó²KÄvª§¤O¡C ¸gÀÙ¤é³ø1¤ë11¤é |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/1/10 ¤W¤È 07:41:47²Ä 13 ½g¦^À³
|
¤µ¤Ñ¡]9¤é¡^¡A¥Ñ¤¤µØ¥Á°ê¦å²G¯f¾Ç·|¤ÎÃĵØÂåÃĦ@¦P¥D¿ìªº¡uMPN Asia¡v¡A¬O¬°²Ä¤@©¡°ê»Ú°©Åè¼W¥Í©Ê¸~½F¬ã°Q·|¡A©ó¥x¥_´HªÙ¦ãÄR°s©±¶©«µn³õ¡C²{³õ°£ÁܽЦh¦ì«¶q¯Å°ê»Ú¾Ç³N±M®a¶i¦æ±MÃDºtÁ¿¡A¥ç´£¨Ñ¨C¦ì»P·|ªÌ¥ªO¹q¸£§Y®É³s½u¤¬°Ê¡A¹ïÃöÁäijÃD¶i¦æ§ë²¼¤Î°Q½× ¡C⋯⋯¹Ï¬°¤¤µØ¥Á°ê¦å²G¯f¾Ç·|²z¨ÆªøªLªFÀé¡A¥H¤Î»P·|Á¿ªÌ¤§¤@¡A¬ü°ê¼w¦{¤j¾ÇM.D.¦w¼w´ËÀù¯g¬ã¨s¤¤¤ßÂå®vSrdan Verstovsek¡C -Àô²y¥Í§Þ¤ë¥Z- |
|
|
·|û¡G¤p¥¿¥¿10141351 µoªí®É¶¡:2016/1/8 ¤W¤È 12:49:20²Ä 12 ½g¦^À³
|
ÃĵØÃÄ6446 쥻¹w´Á¥Ó½Ð¤WÂd«á¡AªÑ»ù¯à©¹200¤¸ÁÚ¶i¡A¦ý105¦~¶}½L¤j½L³s¶^4¤Ñ¡AªÑ»ù¥ç·Æ¸¨¦Ü168¤¸¡A¯u¬O¤£¯à¤@´[±¡Ä@¦¡ªº¹L«×¼ÖÆ[¡CÁÙ¬On«O«ù§Ù·V®£Äߪº¤ß¡C²{¦b¡A¤£¾å±onÄò©êÁÙ¬On¥X²æ¡A¯u¬O³´¤J±Ã¤ã¡C¤£ºÞ¤F¡AÃĵØÃÄ6446¥h¦~©³·s»D¨£³ø®ø®§¤@°ï¡A¤µ¦~ªì¶}©l§Y³´¤J·s»D°±º¢¡A¨ÓÓ·s»D¨g·Q¦±¡A¹w´ú¥»¦~«×ÃĵØÃÄ·í¤ë·s»D¤½¥¬¡C (¦U¦ìºô¤Í¡A¤U¦C·s»D¯ÂÄÝ·Q¹³¡AÄÝÓ¤H¥DÆ[§ù¼¶¡A¤Á¤Å·í¯u)¡G 105¦~1¤ë¥÷¡G²Ä¤@©¡¨È¬w°Ï¦å²G¼W¥Í¯e¯f·|ij¡A¤½¥¬PV§Q¦h¡C 105¦~2¤ë¥÷¡GC¨x¯«ÃÄSovaldi¤§¤÷¡BAtea»sÃĸ³¨ÆªøJean Pierre Sommadossi¡]Åý¡D¥Ö®Jº¸¡AÄâ¤âÃĵØÃÄ¡Aµ²¦XÂù¤èªvÀø B «¬¨xª¢¡]¤j³°ºÙ¤A¨x¡^ªº±M§Q§Þ³N¡A¶ix¥þ²yB¨x¤j¥»Àç-¤j³°¥«³õ¡C(Jean Pierre¨Ó¥x¤Þ°_°ê¤º·sÃĬɤ@°}°Q ½×¡Aªñ´Á¸Ó¤½¥q±N©ó1¤ë¶¡¦A¬£¹Î¶¤¨Ó¥x¡A¶i¤@¨B»PÄÝ·N¹ï¶H½Í¦X§@¡C) 105¦~3¤ë¥÷¡GÃĵØÃļW¸êªÑ¤½¥¬»{Áʤé¡C(¼W¸ê»ù150¤¸¡B¨C¥aªÑ»{ÁÊ23.6ªÑ)¡C 105¦~6¤ë¥÷¡GÃĵØÃĤWÂd¡C(¤WÂd»ùq150¤¸¡B¿³Âd³Ì«á¥æ©ö¤é¬°220¤¸¡A¨Ï¥ÓÁʤᦳ»ù®t¡B¤§«e¤W¿³Âdq206¤¸)¡C 105¦~9¤ë¥÷¡GPV¥Ó½Ð¼Ú·ùÃÄÃÒ¡C(ÃĵتºBESREMi¡A¤w©ó104¦~2¤ë©³§¹¦¨¦¬®×¡A¥¿µ¥«Ý¨ü¸ÕªÌªvÀø1¦~ªº¹êÅç¼Æ¾Ú¡A§¹¦¨¸ê®Æ¾ã ²z´N¥i¦V¼Ú·ù¡B¬ü°êFDA»¼¥æ·sÃĤW¥«³\¥i¡C) 105¦~10¤ë¥÷¡GB¨x¡BC¨x¬ÛÃöÁ{§É´Áµ{»P®ÄªG¡C(¥xÆW±M§ðªºB¨x¤w¶i¤J¤T´ÁÁ{§É¡A ¦ÓC¨x¤w¤À§O¦b¥xÆW©MÁú°ê¥Ó½Ð¤T´ÁÁ{§É ¤¤¡CC«¬¨xª¢¸ÕÅç¥ý¦b¥xÆW§¹¦¨¥Ó½Ð¤§«á¡A¤]±N¦VÁú°ê¹«~ÃĪ«ºÊ·þºÞ²z§½¡]KFDA¡^»¼¥æ¤T´ÁÁ{§É¸ÕÅç¥Ó½Ð¡A ¤@¥¹Àòã¡A±N¤À§O¦b¥xÆW¡BÁú°ê¤G¦aªº¦U¤jÂå¾Ç¤¤¤ß±Ò°Ê¤T´Á¦h°ê¦h¤¤¤ß¤HÅéÁ{§É¸ÕÅç¡A¦Xp30-35ÓÂå¾Ç¤¤ ¤ß¶i¦æ¡A¨Ãpµe©Û¦¬240¦W¯f±w¡A¥H¤G¶g¬I¥´¤@¾¯¡BªvÀø24¶g¡AµM«á¦A°lÂÜÆ[¹î12¶g¨Ã¶i¦æ¼Æ¾Ú¤ÀªR»P¸ê®Æ¾ã ²z¡C¦¹Á{§É¸ÕÅç¥u»Ý9Ó¤ë´N¯à§¹¦¨¡AY®ÄªG²Å¦X¹w´Á¡A´N·|°e¥ó¥Ó½Ð·sÃĦæ¾P³\¥iÃÒ¡C) 105¦~11¤ë¥÷¡GÃĵØÃijQ¯Ç¤JMSCI¦¨¥÷ªÑ(¯Ç¤J±ø¥ó¡GÁ`¥«È¡B²£·~¥Nªí©Ê¡B¬y°Ê©Ê¥ó)¡C 105¦~12¤ë¥÷¡GASH¤Wµoªí¬ãµo¡uÅI¤M«¬¦å²y³h¦å¯g¡v»P¡u£]«¬¦a¤¤®ü«¬³h¦å¯g¡v·sÃĽפå¡B§e³ø¬ãµo¸ê®Æ¡C(57©¡¬ü°ê¦å²G¾Ç ·|¦~·|¡]ASH¡^¤w±NÅI¤M«¬¦å²y³h¦å¯gªºªvÀø»P·ÓÅ@¦C¬°¥¼¨Ó5¦~Àu¥ý¬ã¨s¶µ¥Ø)¡C 105¦~12¤ë¡GET¤T´Á§¹¦¨(¦å¤pªO¼W¦h¯gET¡Aªñ¤G¤Q¦~¨ÓFDA©|¥¼®Öã¹L¥ô¦óªvÀøET·sÃĪº¤W¥«¡B¥Ø«e¬ü°êªºET¯f±w¬ù¦³15¸U ¤H¡BETªº¤T´ÁÁ{§É¹êÅç¡A¤½¥q±N©e°U¬ü°êÁ{§ÉªA°È¤½¥q¨Ó¶i¦æ¡A¹w¦ô¨C¦¬®×1¤H1¦~ªºªá¶O¬ù10¸U¬ü¤¸¡A¤½¥q105 ±N³Wµe¶Ò¸ê¡A¹wp2017¦~¨ú±o¬ü°êÃÄÃÒ) ¡C ¡°¡°¦A¦¸±j½Õ¡A¤Wz·s»D¡B¯ÂÄÝÁr´ú»Pµêºc¡A¤Á¤Å¬Û«H»P°Ñ¦Ò¡A¥Øªº¬O³Õ§g¤@¯º¡C¤£¹L¡A¤º¤ß²`³B¡A¦h»ò§Æ±æÃĵØÃĪº PV¡BET¡BB¨x¡BC¨xµ¥ÃĬүন¥\¡A¦¤é¥Ó½ÐÃÄÃÒ¡B¨Ã¯à¶¶§Q¤WÂd¡B¯Ç¤JMSCI¦¨¥÷ªÑ¡C©¡®É¡AÃĵØÃĪºªÑ»ù¨ì©³¥i¥H º¦¨ì¦h¤Ö¡A¯u¬O¥Rº¡·Q¹³¡H¡°¡° |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/1/7 ¤U¤È 06:42:25²Ä 11 ½g¦^À³
|
¡i预¨¥¡j2015获§å¤W¥«·s药þ¨Ç会¦¨¡§«½S¬µ弹¡¨¡H 来·½¡G汤´Ë¸ô³z 2016-01-07 2015¦~¦¨Ç时Ô¡A汤´Ë¸ô³zCortellis竞争±¡报对¡§È±o´Á«Ýªº药ª«¡¨(Drugs To Watch)°µ¥X预测¡A预计2015¦~进¤J¥«场¡B¦³±æ¦¨为¡§«½S¬µ弹¡¨ªº药ª«¶W过2014¦~¡C2015¦~获§å/¤W¥«药ª«¤¤¡A2019¦~销°â额预计¶W过10亿¬ü¤¸ªº¦@11Ïú(2014¦~仅¦³3Ïú)¡C¦Ó´N¥Ø«e±¡况¬Ý¡A°£¤F预´Á©Ò¦C药ª«¥~¡A还¦³¨ä¥L¤LÏú2015¦~获§å©M(©Î)进¤J¥«场ªº药ª«¦³±æ¦b¤µ¦Z5¦~内跻¨¡§«½S¬µ弹¡¨药ª«¦æ¦C¡C 2015¦~获§åªº¥¼来¡§«½S¬µ弹¡¨药ª« ¦Ê时¬ü¬I贵宝¤½¥qªv疗¶Â¦â¯À½F¡B«D¤p细MªÍÀù(NSCLC)¡B肾细MÀù(RCC)ªºOpdivo(nivolumab)¤´¦Cº]º¡A¨ä2019¦~预´Á销°â额达78.78亿¬ü¤¸¡A对¨ä¥L¡§«½S¬µ弹¡¨药ª«ªº预测µy¦³ªi动¡C2015¦~¦¨Ç时Ô¡A对Repatha©M赛诺µá/RegeneronªºPraluent(alirocumab¡A¥Î¤_°ª胆©T¾J¦å¯gªv疗)ªº销°â额预计¶W过40亿¬ü¤¸¡A仅¦¸¤_Opdivo¦ì©~²Ä2¦ì¡C¦Ó现¦b对该药ªº销°â额预测¤U调¨ì22.54亿¬ü¤¸(±Æ²Ä5¦ì)¡C辉·ç获§åªºªv疗¨Å¸¢Àùªº药ª«Ibrance(palbociclib)¡A销°â额预测从27.56亿¬ü¤¸¤W¤É¨ì45.71亿¬ü¤¸(±Æ¦W从²Ä4¤W¤É¨ì²Ä2¦ì)¡C诺华(Novartis)¤½¥q¥Î¤_ºC©Ê¤ß°Iªv疗ªºSacubitril and Valsartan(°Ó«~¦W:Entresto)¡A销°â额预测从37.31亿¬ü¤¸¤W¤É¨ì40.44亿¬ü¤¸(±Æ¦W«O«ù²Ä3¦ì)¡AVertex¥Î¤_Ån©Ê纤维¤ÆªºOrkambi(lumacaftor+ivacaftor)紧随¨ä¦Z¡A销°â额预测¤W¤É¨ì39.36亿¬ü¤¸(±Æ¦W从²Ä5¤W¤É¨ì²Ä4¦ì)¡C ¡§«½S¬µ弹¡¨药ª«预测º]单¤¤ªº¨ä¥L药ª«还¦³¡G¦ã§B维(AbbVie)¥þ¤fªA¤þ¨x鸡§À°sViekira Pak (ombitasvir/paritaprevir/ritonavir©Mdasabuvir)(预测销°â额22.18亿¬ü¤¸¡A±Æ¦W维«ù²Ä6¦ì¤£变)¡AAmgen©MAstella¨î药¬ã发ªº§Ü°ª胆©T¾J¦å¯g药ª«Repatha(evolocumab)(预计销°â额18.36亿¬ü¤¸¡A维«ù²Ä7¦ì)¡A诺华¨î药¤û¥Ö癣©M银®h¯f关节ª¢单§Ü药ª«Cosentyx(secukinumab)(预计销°â额15.87亿¬ü¤¸¡A±Æ¦W从11¦ì¤É¦Ü²Ä8¦ì)¡A赛诺µáªv疗¿}§¿¯fªºToujeo(·s¤@¥N¥Ìºë¯Ø岛¯À)(预测销°â额14.53亿¬ü¤¸¡A±Æ¦W从²Ä10¤W¤É¦Ü²Ä9¦ì)¡A¤jà¨î药¦³¤½¥q©MH. Lundbeck开发§Üºë¯«¤Àµõ©M§í§¯g药ª«Rexulti (brexpiprazole)(预测销°â额14.03亿¬ü¤¸¡A从²Ä9¦ì°¦Ü²Ä10¦ì)¡AÀq¨F东(Merck & Co)§Ü¤H¨Å头½F¯f¬r·P¬VGardasil 9(9ɲHPV¬Ì])ªº³Ì·s预测将¦b¤µ¦~12¤ë¥÷©ÜÅS¡Aì预测±Æ¦W为²Ä9¦ì¡C °£¤F¡§Drugs To Watch¡¨预测ªº药ª«¡A¥t¥~3Ïú预计¦b2019¦~销¶q¶W过10亿¬ü¤¸ªºªv疗¦h发©Ê°©Åè½Fªº·s药为¡GJanssen Biotech¤½¥q¬ã发ªºDarzalex¡AªZ¥Ð药«~¤u业®è¦¡会ªÀ开发ªºNinlaro¡A¦Ê时¬ü¬I贵宝(BMS)ÉO¦ã§B维(AbbVie)¦X§@开发ªºEmpliciti¡C¦¹¥~¡A«kªL®æ®ï®æ¿«&礼来¿}§¿¯f联¦X¨î剂Glyxambi预计销¶q¤]进¤J¡§«½S¬µ弹¡¨º]单¡C ©Ò¦³这¨Ç药ª«ªº预测销¶q将¦b2020¦~«ù续Ãk¤É(°£Viekira Pak)¡C OPDIVO获§å¥Î¤_NSCLC©MRCCªv疗 Opdivo继续领¶]肿½F§K¬Ìªv疗领°ì¡A继§åã¥Î¤_¶Â¦â¯À½Fªv疗¦Z¡A¦A获§å¥Î¤_NSCLC©MRCCªv疗¡C2015¦~10¤ë¡AOpdivo¦b¬ü国获ã¥Î¤_ÉOYervoy(ipilimumab)联¥Î©Î单药ªv疗ªìªvBRAF V600³¥¥Í«¬¤£¥i¤Á°£©Î转²¾©Ê¶Â¦â¯À½F±wªÌ¡C°ò¤_ÉO |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2016/1/7 ¤U¤È 03:18:11²Ä 10 ½g¦^À³
|
¤p¦Ó¬ü¡v±Ú¸s ªk¤H·sÃd ªk¤H°éªñ´Á±N¥Ø¥úÂà¦Üè±¾µP·sªÑ¡A¥H¤Î¿³Âd¥«³õ¤¤ªº¼ç¤O·s¨q¡C¨½©ù¡B·ç«HÃÒ¨éªñ´Á±µ³s¶}±Ò¹ï¯«¬Þ¡]6462¡^¬ã¨s¡Aµ¹¤©¡u¶R¶i¡v¡B¡uÀu©ó¤j½L¡v§ë¸êµûµ¥¡F¥»¤g¤j«¬¬ã¨s¾÷ºcªº¤¸¤j¡B³Í°ò§ëÅU¡A¥h¦~©³®É«h¤À§O³Û¦hF-³ß±d»PÃĵØÃīᥫ¡C ¥xªÑ2016¦~¶}¬K¤£¦p·N¡Aµuµu¤TÓ¥æ©ö¤é¡A¥[Åv«ü¼Æ±q8,338ÂI¶^¯}8,000ÂI¤jÃö¡C¥«³õ´Á¬ß·sÃD§÷±a¨Ó·s§ë¸ê«´¾÷¡A¦]¦¹¬ã¨s¾÷ºcÂ੹µo±¸¡u¤p¦Ó¬ü¡v¼Ðªº·¼é³vº¥½«¬°¼é¬y¡C ·ç«HÃÒ¨é¬ì§Þ²£·~¤ÀªR®vĬ«p¦X«ü¥X¡A«ü¯¾¿ëÃѪº¶W¯Å²£·~´`Àô¥¿¦b±Ò°Ê¡A¯«¬Þ¬O«DÄ«°}À礤°ß¤@¸Ñ¨M¤è®×¨ÑÀ³°Ó¡A¨ä¦b¦æ°Ê¤ä¥I¤Wªººtºâªk±M§Q³q¹L¤T¬P»{ÃÒ¡A¥[¤W¾Ö¦³¸`¬Ù¦¨¥»Àu¶Õ¡A¦³§Q·m¤U§ó¦h¥«¥e¡A±À´ú¥¼¨Ó12Ó¤ë¦X²zªÑ»ù¬°220¤¸¡C ¨½©ùÃÒ¨é¥b¾ÉÅé²£·~¤ÀªR®v«J©ú§µ§ó¬O¦b¯«¬Þ±¾µPº¤é¡A´N¶}±Ò¡u¶R¶i¡vµûµ¥¡C¥L«ü¥X¡A«ü¯¾¿ëÃѪï¨ÓÃzµo©Ê¦¨ªø¡A«DÄ«´¼¼z¾÷·f¸ü«ü¯¾¿ëÃÑ¥\¯àªº¤ñ¨Ò±N±q2015¦~ªº16%¡A¤@¸ô´£¤É¦Ü¤µ¡B©ú¦~ªº28%»P37%¡A¦b¥X³f¶q¤è±¡A·f¸ü«ü¯¾¿ëÃÑ¥\¯àªº«DÄ«´¼¼z¾÷¤]±N±q2015¦~ªº1.9»õ¤ä¡A¿¼W¦Ü4»õ¤ä¡C ¥Í§Þ±Ú¸sªñ´ÁÁöÀH¤j½L¶i¤J¦^ÀÉ×¥¿¡A¤¸¤j§ëÅU¡B³Í°ò§ëÅUÂùÂù±NIJ¨¤©µ¦ù¦Ü¿³Âd¥«³õ¡A²v¥ý¦VºX¤U°ê»Ú«È¤á¤¶²Ð²£·~·s¬P¡C ³Í°ò§ëÅU¥Í§Þ²£·~¤ÀªR®v§f«³¹F«ü¥X¡A³J¥Õ½èÃĪ«¼tÃĵØÃĶ}µoªºP1101¤ñ¬J¦³Ã¹¤óPegasys¡B²ö§JªºPeg-Intron§ó¨ãÄvª§Àu¶Õ¡A¥¼¨Ó¨ú±o¼Ú¬üÃÄÃÒ¥i´Á¡A¬O¥xªÑ¥Í§Þ±Ú¸sªº©ú¬P³J¥Õ½èÃĪ«¶}µo°Ó¡Aµ¹¤©¡u¶R¶i¡v§ë¸êµûµ¥¡C ¤¸¤j§ëÅU¥Í§Þ²£·~¤ÀªR®v§õ¯\µ×¬Ý¦nF-³ß±d¡A¦o«ü¥X¡A¥þ²y³J¥Õ½è¬Û¦üÃÄ¥«³õ2014¦Ü2020¦~´Á¶¡¦~½Æ¦X¦¨ªø²v¥i±æ¹F60%¡A¥Ñ©ó²£·~µ²ºc¥¼¦¨¼ô¡AF-³ß±d¦b³J¥Õ½è¬Û¦üÃÄ»sµ{¶}µo¤è±¹ê¤O¶¯«p¡A¥i´x´¤¦¨¥\¾÷·|¡C |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2016/1/7 ¤W¤È 08:09:41²Ä 9 ½g¦^À³
|
¥xÆWªº§ë¸ê²ß©Ê§Y±NºCºC§ïÅÜ ¸Õ·Q ¤d¤¸ªº§»¹F¹q¶^¦^2¦ì¼Æ,¬Q¤é¤j§Q¥úªº¶^°±... ¤@¦Aªº§i¶D§ÚÌ, ¹q¤lªÑÁöµMÁÈ¿úªº®ÉÔ«ÜÉq,¦ý¤@¦ýq³æ¨S¤F,´N¶^ºG¤F ¦Ó¥B¤p´²¤á¥Ã»·¬O³Ì«á¤@Óª¾¹Dªº ¥Í§ÞªÑ¥i´N¤j¤jªº¤£¦P¤F ¸Õ·Q,ßÓÃÒ¨ì¤â«á ¦³¦n´X¦~ªº¿W¥e®É¶¡ ¥B´N¦pß «á±±µµÛ¤S¦³4ÓßÓ¦b3´Á,¦³xÓ¦b2´Á,¦³yÓ¦b1´Á... ³oºØ°Ê¯à¬O«ùÄò¤£Â_ªº Áo©úªº§A ¬Ý¨£¤F¶Ü? |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2016/1/6 ¤U¤È 11:40:29²Ä 8 ½g¦^À³
|
Dear §õÁ`²Î¤j~ ±z²×©ó¦^¨Ó¤F~ ÅwªïÅwªï! ³Ìªñ¤@ª½¯Ç´e±z«ç»ò¤£¨£¤F«¨ ? |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2016/1/6 ¤U¤È 04:15:56²Ä 7 ½g¦^À³
|
FDA©x员¡Gɬ¥ý审评¨é¬O错误ªº¨î«×¡I 来·½¡G医药Å]¤è数Õu 2016-01-05 为¤F¹ª励¨î药¥ø业开发¡§©ö³Q©¿²¤热带¯e¯f¡¨©M¡§¨u见¤I¬ì¯e¯f¡¨药ª«¡AFDA¥ý¦Z«Ø¥ß¤F¡§热带¯e¯fɬ¥ý审评¨é¡¨©M¡§¨u见¤I¬ì¯e¯fɬ¥ý审评¨é¡¨ªº奖励Éó¨î¡A¦}¥B¦b2014¦~©³调¾ã¤F两ªÌªº®tÉÝ¡A¥Ø«e获±o这两Ïúɬ¥ý审评¨éªº¥ø业³£¥i¥H¤£¦¸数进¦æ¥æ©ö¡A¦Ó¥B决©w®ø费ɬ¥ý审评¨é时³£¥un´£«e90¤Ñ§iª¾FDA§Y¥i¡]FDAɬ¥ý审评¨é¤j´¦¯µ¡G诺华³Ì´d剧¡A赛诺µá³Ì会ª±¡I¡^¡C ¥Ñ¤_¥æ©ö§ó¥[¦Û¥Ñ¡A¨Ï¥Î§ó¥[«K§Q¡Aɬ¥ý审评¨é¦b2015¦~¦¨¤F»饽饽¡Aɲ®æ¦ÛµM¤]¬O¤ô涨²î°ª¡A¹³Alexion这Ïú连®³两张ɬ¥ý审评¨éªº®£©È¬On§y货©~©_¤F¡A赛诺µá¥ÜS¤§¤U¡A¨ä¥L¥¨头们¦ü¥G¤]难¥H¹K¨î¥æ©öªº冲动¡A储备¤@张¥H备¤£时¤§»Ý显µM¬O¤Wµ¦¡C 还¦³¤j®a¤w经¤ñ较¼ô±xªº«e图灵¨î药CEO Martin Shkreli¡A这个§ëÉóªÌ¦b11¤ë获±o¤F濒临¯}产ªº¥Íª«¨î药¤½¥qKaloBios 70%ªºªÑ权¡A扬¨¥会寻¨DFDA§åã¨äChagas¯f药ª«¦}¦¬获¤@张ɬ¥ý审评¨é¡AµM¦Z择Éó¥X°â¡C当µM¡A随着Martin Shkreli¦b12¤ë³QFBI¶e®·¡AKaloBios¤½¥qªÑɲ¦A¦¸«æ¶^¦}¥Ó请¯}产¡C¬Ý¤j®aª±±o这¤\high¡A规则¨î©wªÌFDA§@¦ó·P·Q©O¡H ¬ü国PharmExec杂§Ó发ªíªº¤@½g¤å³¹称¡A¶V来¶V¦hªºFDA©x¤è¤H员开©l¤Ï对ɬ¥ý审评¨é¨î«×¡A¦]为药ª«¬O§_¥i¥H获±o6个¤ëªºÉ¬¥ý审评资®æ쥻应该¥ÑFDA®ÚÕu这个药ª«¬O§_¬O©t¤I药¡B¬ð¯}©Ê药ª«¡B©ÎªÌ¤Ç°t¥¼满¨¬医疗»Ý¨D来综¦X评ɲ¦Z¤©¥HÚÌ©w¡A¦ýɬ¥ý审评¨é¥i赋¤©¥ô¦óNDAɬ¥ý审评资®æ¡A§¹¥þ¯}§¥¤FFDAªº评ɲÊ^¨t¡A为¨ä监ºÞ¬yµ{²K¥[¤F负担¡C ¤]¦³FDA©x员认为¡A颁发ɬ¥ý审评¨éÚÌ实¨ë¿E¤F¤@¨Ç热带¯e¯f药ª«ªº¬ã发¡A¦ý这¨Ç药ª«¤¤¦³¨Ç¬Æ¦Ü¥Ã远¤£会¦b¬ü国¤W¥«¡A¦]¦¹É¬¥ý审评¨é¦}没¦³达¨ì«P进药ª«¬ã发ªº¥Øªº¡C 错误ªº¨î«×¡H ɬ¥ý审评¨é¥i¥H赋¤©¤@¨Ç¤£²Å¦X条¥óªº药«~¥Ó请ɬ¥ý审评资®æ¡A这¤@°µªk¥¿©ÛPFDA©x员ªº强¯P©á击¡C¦b2015¦~12¤ë举¦æªºFDA/CMS°ª层会议¤W¡AFDA药«~评ɲÉO¬ã¨s¤¤¤ß¡]CDER¡^·s药办¤½«Ç¥D¥ôJohn Jenkins抛¥X¤F¡§É¬¥ý审评¨é¨î«×§¹¥þ«Ø¥ß¦b错误ªº经济规则¤§¤W¡¨这¤@观点¡C John Jenkins强调¡G¡§§Ú¤ä«ù¹ª励¥Í产ÉD®a开发ªv疗热带¯e¯f©M¨u见¤Iµ£¯e¯fªº药ª«¡A¦ý§Ú¤Ï对¤£¥[鉴别¦a±Â¤©¥ô¦ó¤@个¥Ó请ɬ¥ý审评资®æ¡A这¨½±¦s¦b«¤j¦w¥þ©Ê风险¡C对¤_¤@个«ö·Ó标ã审评µ{§Ç处²zªº¥Ó请¡A§A¤£¯à变Å]ªk¯ë随«Kn¨DFDA进¦æɬ¥ý审评¡C¦]为评审员³q±`n¦Ò虑诸¦hÎ`杂ªº问题¡A仓«P审评¥i¯à会导P错误¡Aɬ¥ý审评¨é¨î«×«Ø¥ßªº«e´£´N¬O错误ªº¡A§Ú们¨C¤Ñ¦b办¤½«Ç¨½¥i¤£¬O°µ©Ü萨ªº¡I¡§ John Jenkinsª½¨¥¹D¡G¡¨FDAªº审评资·½¦³¡A¥Xɲ°ªªÌ±oɬ¥ý审评Éó会¡A这会导P¤½众产¥ÍFDA³Q¦æ业绑¬[ªº错觉¡I¡§ ¬Û关阅读 |
|
|
·|û¡G¤ÑY¦³Àº10141343 µoªí®É¶¡:2016/1/4 ¤U¤È 09:35:13²Ä 6 ½g¦^À³
|
³¯«Ø¤¯¡G±À¥Í§Þ²£·~ ±a»â¥xÆW¸gÀÙ°_¸ ¤À¨É¤À¨É¤À¨É¯d¨¥ 2016-01-04 21:03Áp¦X³ø °OªÌ§õ¬L¦w¢¬§Y®É³ø¾É ¤¤¿ï·|¤µÁ|¿ì°ÆÁ`²ÎÔ¿ï¤H¹qµø¬F¨£µoªí·|¡A¥Á¶iÄÒ°ÆÁ`²ÎÔ¿ï¤H³¯«Ø¤¯²Ä¤G½üµo¨¥¥D¥´¥Í§ÞÂåÀø¬Fµ¦¡A¥L©Ó¿Õ·í¿ï·|¥ß§Y±À°Ê¡u¬ì¾Ç§Þ³N°ò¥»ªk¡v¡B¡u¥Í§Þ·sÃIJ£·~µo®i±ø¨Ò¡vתk¡A±À°Ê¥Í§Þ¤H¤~¡B¬ãµo¡B§ë¸ê¡A¦Ó¥B¤£¥²µ¥¨ì5¤ë20¤é¡A2¤ë1¤é·s°ê·|¤W¥ô´N·|°¨¤W±À°Ê¡AnÅý¥Í§ÞÂåÃĹ³¥b¾ÉÅé²£·~¤@¼Ë¡A±a»â¥xÆW¸gÀÙ°_¸¡C ³¯«Ø¤¯«ü¥X¡A¦ôp¥¼¨Ó10¦~¡A¥Í§Þ°·±d²£·~±N·|¹F¨ì5¥ü¦Ü6¥ü¬ü¤¸³W¼Ò¡A¥xÆW¥i¥H§V¤Oµo®i±Mªù¥Î¨Ó¶EÂ_¨È¬w¤H¯e¯fªº·s¸Õ¾¯¡A¹³·ç¤h¡B¤ñ§Q®É¡B·ç¨å¡B²üÄõµ¥°ê¤@¼Ë¡A¦¨¬°¤@¬y¥Í§Þ°ê®a¡A ³¯«Ø¤¯ªí¥Ü¡A½²^¤å¾á¥ô¦æ¬F°|°Æ°|ªø®É¡A»P¥ßªk°|ªø¤ýª÷¥¦X§@±À°Ê¡u¥Í§Þ·sÃIJ£·~µo®i±ø¨Ò¡v¥ßªk¡A¥i±¤2012¦~¤j¿ï´Á¶¡¥Í§Þ²£·~µo®i³Q¦¾¦W¤Æ¡A¥O¤H«D±`µh¤ß¡C |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2016/1/4 ¤W¤È 07:38:47²Ä 5 ½g¦^À³
|
¤ß®® ¤Uӥͧ޷s¬P 2016-01-04 05:47 ¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É ¥Í§Þ¤j®i¨¤â¡Aªk¤H°é±Ò°Ê¤p¯E¹©·j¯Ápµe¡C2016³ø¨ì¡A¥Í§ÞªÑ´§§O¥h¦~ªºªwªj³±¼v¡A§i§OÃÒ©Òµ|ªºÀ£¤O¡A¦b§ë¸êÁͶժº®ö¼é¤U¡Aªk¤H°é¿n·¥·j¯Á¤U¤@Ó¯E¹©¡]4174¡^¡B¤¤¸Îµ¥¨ã¦³¼ç¤Oªº·sÃħë¸ê¼Ðªº¡C ªk¤H°é»{¬°¡A¥Ø«e¥¼¤W¥«ªº·sÃĤ½¥q¤¤¡A¥]¬A¤ß®®¡B¥Í±±³Ì¨ã³Æ§Þ³N»P¥«³õ«GÂI¡A¦Ó¤w¸g¿³Âdªº«h¦³ÃĵØÃÄ¡B·çÄ_¡B¦]µØµ¥¦³§Q°ò»P¯S¦âªº·sÃĤ½¥q¡C ªk¤H«ü¥X¡A¯E¹©¡B¤¤¸Î³o¥S§ÌÀÉ¡AÂù¤è¦³¼í®õ¶°¹Î¡A¯E¹©¦³¤¤¬ã°|°|ªø¯Î±Ò´f¹Î¶¤¡B¤¤¸Î«hÀò·R´þ¯f±M®a¦ó¤j¤@ªº¥úÀô¥[«ù¡A¦ý³o¨Ç¤½¥qªÑ»ùÀHµÛ¥«³õÁL¾Ö¦Ó¤ôº¦²î°ª¡A¹ï§ë¸êªÌ¦Ó¨¥¤w¸g³vº¥¨B¤J¦¨¼ô¶¥¬q¡C¦]¦¹§ë¸ê¤H³£¦b°Ý¡A¤UÓ¯E¹©¡B¤¤¸Î¦bþ¸Ì¡H ¤@¯ë»{¬°¡A¤ß®®±M§ðºë¯«¯e¯f¦³Ãö¥ÎÃÄ¡A§ó¤Á¤J«C¤Ö¦~ºë¯«¤Àµõµ¥§Q°ò¥«³õ¡A¨äÀu¶Õ«ê»P¤¤¸Î¤ñªÓ¡A¥[¤W¨âªÌ³£¾Ö¦³¬ü°êFDA¬ð¯}©ÊÀøªkªº¥úÀô¡A³o¤]Åý¤ß®®ªñ´Áªº¥¼¤W¥«½L»ùª½¹G200¤¸¤jÃö¡C ¦Ü©ó¥Í±±¡A»P¯E¹©¦PÄݧK¬ÌÀøªk§ÜÀù§Þ³N¡BªvÀø©Ê¬Ì]¡A¥Í±±¬O¥ÍÄ_¶°¹ÎºX¤Uªº§Ü¯f¬r¡]Àù¡^·sÃĤ½¥q¡A¸Ó¤½¥q¶}µo¥X¥þ·s¤@¥N¡u¦¸³æ¦ì¿Ä¦X³J¥Õ§ÜÀùªvÀø©Ê¬Ì]¡v¡A²£«~½u¾î¸ó¤l®cÀVÀù¡B¨xÀùµ¥¦hºØÀù¯g¡AB«¬¨xª¢¡B·R´þ¯f¡B§xÃø¬y·Pµ¥¡AÄvª§¼s«×¤j¡C §ó¯S§Oªº¬OÃĵØÃÄ¡AºX¤U·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101¥¿¦¡©R¦WBESREMi¡A¹wp©ú¦~¤U¥b¦~¦V¼Ú·ù¡B¬ü°ê¥Ó½ÐÃÄÃÒ¡F¸Ó²£«~¥[p¬ü°ê¥«³õ¦³¾÷·|¬ð¯}¦Ê»õ¬ü¤¸»ùÈ¡A¾P°âÃB«h¥i¯à¬ð¯}10»õ¬ü¤¸¡A¼ç¤OÅå¤H¡C |
|
|
·|û¡G¤ÑY¦³Àº10141343 µoªí®É¶¡:2015/12/31 ¤U¤È 08:54:21²Ä 4 ½g¦^À³
|
¦pªG¥«È200e¬üª÷¡A¥Ø«e¤~12e¬üª÷¥«È¡A¨ºÃĵØÃĪѻù¦h¤Ö¤~¦X²z?200»õ¬üª÷¥«È¡AÃĵØÃĦh¤Ö»ù¤~¯à¨ì |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2015/12/31 ¤U¤È 05:06:35²Ä 3 ½g¦^À³
|
¯Ç¤JMSCI¦¨¤ÀªÑ¤~¬O«ÂI¡]¥þ²y¤j«¬¸êª÷¥Dnbenchmark¦¹«ü¼Æ), ¤p«¬ªÑ«ü¼Æ¦¨¤ÀªÑ´N¨SÔ£·N¸q. ÃĵإH¨ä¥«È, ÃD§÷, ¯Ç¤JMSCI¦¨¤ÀªÑÀ³¸Ó¬O¥²µMªº. Ó¤H»{¬°¥¦¾Ö¦³¤ñ¨ä¥L¥xÆW·sÃÄÃþªÑ¨ü¥~¸ê«C·ýªº±ø¥ó: - ¾Ö¦³IP (¤£³Q©â¦¨¡^ - ¾Ö¦³»s³y ¡]ÃĪ«¬ãµo³t«×§Ö, °£¤F¦hÁȤ@¬q¥~¡^ - ¾Ö¦³«~µP, ¦Û¦æ¥Ó½ÐÃÄÃÒ, ¨ú±o°ê»Ú»{¦P (·íµM¤]¥i¯à»P°ê»Ú¤j¼t¦@¦P¦æ¾P, ¦ý¥çÃĵت¾¦W¨ú±oÃÄÃÒ¡^ - ¾Ö¦³¿W½æÅv. - ¥B´XÓ«½S¼ç¤OÃÄ(PV,ET)¤w¦b¶}µo¥½´Á. - ¥~¸ê¸û©ö»{¦P¦]¬°¹p¦P¤½¥q INCYTE (INCY US) ¥«È¤w¹FUS$200»õ,¦ÓÃĵضÈUS$12»õ ³o¼Ëªº¤½¥q, ¥[¤W¥xÆW¬ì§Þ·~¤wº¥¥¢Ävª§¤O¤U, ¥H§Ú¹L¥h¦b§ë¦æ15¦~¸gÅç, ¤@¥¹¯Ç¤JMSCI, 3~5¦~¥ª¥k, ¥~¸ê«Ü®e©ö´N«ù¦³50%¥H¤Wªº«ùªÑ, ¥unÃĪ«¶}µo¦p¹w´Á¹F¦¨. - |
|
|
·|û¡G¤Óºò±i10135421 µoªí®É¶¡:2015/12/30 ¤U¤È 06:21:46²Ä 2 ½g¦^À³
|
¤§«e¤Ó´º¸ò¯E¹©³£¦bipo«á¤£¤[´N³Q¯Ç¬°MSCI ¦¨¤ÀªÑ. F*¤Ó´ºÀò¿ï¯Ç¤JMSCI©úÑÔ¥þ²y¤p«¬ªÑ«ü¼Æ¦¨¤ÀªÑ. 2014¦~5¤ë16¤é ¯E¹©¯ÇMSCI¦¨¤ÀªÑªÑ»ù³Ð¾ú¥v·s°ª¡I 2015¦~11¤ë13¤é 2016 /6 ¤ëÃĵØIPO «á, ¥HÃĵتºÅé½èÀò¿ï¯Ç¤J2016 MSCI¦¨¤ÀªÑ¾÷·|«D±`¤j , ¤¤¸Î¾÷·|¤]«Ü¤j. ¯E¹©¥~¸ê15.83% ¥Ø«eÃĵع´¥~¸ê«ù¦³¤ñ²v¶È5.92% . ¥¼¨Ó«ØܶR½L¥i´Á, ¬O§_·|½Æ»s¤¤¸Î¸ò¯E¹© IPO «á¦æ±¡È±o´Á«Ý. |
|
|
·|û¡G¤ÑY¦³Àº10141343 µoªí®É¶¡:2015/12/30 ¤U¤È 05:58:21²Ä 1 ½g¦^À³
|
¯u¬O¥O¤H¿³¾Ä¤@¨è¡A¦U¦ìÃĵØÂåÃĤpªÑªFÌ®¥³ßµo°]¡A2016½Ä^_^ |
|
|
|